INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D - 3 FEB 2004
WIPO   PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed   *Stephen Horchley*

Dated   20 November 2003

An Executive Agency of the Department of Trade and Industry

Form 1/77

Patents Act 1977
(Rule 16)

5 NOV 2002

Request for grant of a patent
(See the notes on the back of this form. You can also
get an explanatory leaflet from the Patent Office to
help you fill in this form)

The
Patent
Office

18NOV02 E764026-2 D00019
P01/7700 0.00-0226734.2

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1.	Your reference	P032364GB	
2.	Patent application number *(The Patent Office will fill in this part)*	**0226734.2**	**15 NOV 2002**

3. Full name, address and postcode of the or of
each applicant *(underline all surnames)*

CHIRON SpA
VIA FIORENTINA 1
53100 SIENA
ITALY

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the
country/state of its incorporation

ITALY   85073740 01

4. Title of the invention

UNEXPECTED MENINGOCOCCUS SURFACE PROTEINS

5. Name of your agent *(if you have one)*

Carpmaels & Ransford

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

**43 Bloomsbury Square
London
WC1A 2RA**

Patents ADP number *(if you know it)*

83001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number	Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:* a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body *See note (d))*	Yes		

9. Enter the number of sheets for any of the
following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	-
Description	48
Claim(s)	- ƆML
Abstract	- **Sequence-listing: 20**
Drawing(s)	3-1 3

10. If you are also filing any of the following,
state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	-
Request for preliminary examination and search *(Patents Form 9/77)*	-
Request for substantive examination *(Patents Form 10/77)*	-
Any other documents *(please specify)*	Sequence listing: 20

11.   I/We request the grant of a patent on the basis of this application.

Signature   Date

Carpmaels & Ransford   15th November 2002

12. Name and daytime telephone number of person to contact in the United Kingdom   **CAMERON MARSHALL**   **020-7242 8692**

Warning
After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes
a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
b) *Write your answers in capital letters using black ink or you may type them.*
c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
e) *Once you have filled in the form you must remember to sign and date it.*
f) *For details of the fee and ways to pay please contact the Patent Office.*

UNEXPECTED MENINGOCOCCUS SURFACE PROTEINS

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention is in the field of meningococcal biochemistry, in particular the trafficking and localisation of meningococcal proteins.

BACKGROUND ART

The complete genome sequence of serogroup B *N.meningitidis* has been published [1] and has been subjected to analysis in order to identify candidate vaccine antigens [2].The complete genome sequence of serogroup A *N.meningitidis* is also known [3].

Footnote 12 of reference 2 describes the authors' approach to antigen selection. Briefly, a first screening for coding capacity of the genome sequence was performed using computer programs included in the Wisconsin package version 10.0, Genetics Computer Group (GCG). BLASTX was used to classify ORFs as coding either for known cytoplasmic functions or for other functions. The cytoplasmic ORFs were "not further investigated" as candidate antigens.

A second screening step aimed at identifying putative proteins with a cellular localization spanning from the inner membrane to outside the bacterium was also used. This screening involved F-BLAST, FASTA, MOTIFS, FINDPATTERNS, and PSORT, as well as the ProDom, Pfam, and Blocks databases. ORFs were thus selected on the basis of features typical of surface-associated proteins such as transmembrane domains, leader peptides, homologies to known surface proteins, lipoprotein signature, outer membrane anchoring motifs, and host cell binding domains such as RGD.

In total, reference 2 identified 570 ORFs within the genome as candidate vaccine antigens. 98.8% of these selected serogroup B ORFs were also found and conserved in serogroup A, and 95.3% were found and conserved in *N. gonorrhoeae*.

This "reverse genomics" approach to vaccine candidate selection is undoubtedly powerful, and has been copied for other organisms [e.g. 4, 5, 6, 7, 8, 9, 10], but it does not identify all surface-exposed proteins and vaccine candidates [11]. It is therefore an object of the invention to identify surface-exposed meningococcal proteins which are not identified by computer prediction methods.

DISCLOSURE OF THE INVENTION

The invention is based on the discovery of 205 proteins which, contrary to expectations, are found in the membrane of *Neisseria meningitidis*. Of these 205, 76 in particular evade all algorithmic methods for predicting membrane localisation. Existing knowledge of protein trafficking pathways in meningococcus does not explain how or why these proteins are located in the bacterial membrane *e.g.* there is no apparent biochemical reason for a DNA helicase or a chromosomal replication initiator protein to be found in the membrane.

The 205 proteins are listed in Table I according to their 'NMB' numbering, which corresponds to the standardised nomenclature from reference 1. The NMB numbering can be used directly to query online databases e.g. a protein query of thje NCBI Entrez system [12] using the term 'NMB1506' unequivocally identifies the Arginyl-tRNA synthetase of *N.meningitidis* (see Figure 5), leading to a

5   single amino acid sequence. Details of the DNA sequences which encode these proteins are similarly accessible from the online databases.

Although the online databases are the most convenient source of information concerning the 205 proteins of the invention, and the most likely to be consulted by the skilled person, for formal reasons the amino acid sequences are also provided in a sequence listing (SEQ ID NO^s: 1 to 205).

10   **Proteins of the invention**

The invention provides a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 205.

It also provides a protein comprising an amino acid sequence which shares at least $x\%$ sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 205.

15   Depending on the particular sequence, x is preferably 50% or more (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more). These proteins include allelic variants, homologs, orthologs, paralogs, mutants *etc.* of SEQ ID NO^s: 1 to 205. Typically, 50% identity or more between two proteins is considered to be an indication of functional equivalence. Identity between proteins is preferably determined by the Smith-Waterman homology search algorithm as implemented in the MPSRCH program (Oxford

20   Molecular), using an affine gap search with parameters *gap open penalty=12* and *gap extension penalty=1*.

It is preferred that one or more of the differences these proteins compared to SEQ ID NO^s: 1 to 205 involves a conservative amino acid replacement *i.e.* replacement of one amino acid with another which has a related side chain. Genetically-encoded amino acids are generally divided into four

25   families: (1) acidic *i.e.* aspartate, glutamate; (2) basic *i.e.* lysine, arginine, histidine; (3) non-polar *i.e.* alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar *i.e.* glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In general, substitution of single amino acids within these families does not have a major effect on the

30   biological activity. Proteins of the invention may contain 1 or more (*e.g.* 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) conservative mutations.

The invention further provides a protein comprising a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 205. The fragment should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n is 7 or more

35   (*e.g.* 8, 10, 12, 14, 16, 18, 20, 30, 40, 50, 75, 100, 150, 200 or more). Preferred fragments include: (a) fragments which comprise an epitope; (b) fragments common to two or more of SEQ IDs 1 to

205; (c) SEQ IDs 1 to 205 with 1 or more (*e.g.* 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, *etc.*) N-terminal residues deleted; (d) SEQ IDs 1 to 205 with 1 or more (*e.g.* 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, *etc.*) C-terminal residues deleted; (e) SEQ IDs 1 to 205 without their signal peptides; and (f) SEQ IDs 1 to 205 with the N-terminal deleted up to and including a poly-glycine sequence (*i.e.* Gly_g, where $g \geq 3$ *e.g.* 4, 5, 6, 7, 8, 9 or more), referred to as 'ΔG' proteins. These preferred fragments are not mutually exclusive *e.g.* a fragment could fall into category (a) and (b), or category (c) and (d), *etc.*

Proteins can be prepared by various means *e.g.* by chemical synthesis (at least in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture (*e.g.* from recombinant expression or from *N.meningitidis* culture). *etc.* Heterologous expression in *E.coli* is a preferred preparative route.

Proteins can take various forms (*e.g.* native, fusions, glycosylated, non-glycosylated, lipidated, disulfide bridges, *etc.*).

Proteins are preferably prepared in substantially pure form (*i.e.* substantially free from other Neisserial or host cell proteins) or substantially isolated form.

Proteins are preferably meningococcal proteins.

Proteins of the invention may be attached to a solid support. They may comprise a detectable label (*e.g.* a radioactive or fluorescent label, or a biotin label).

Proteins of the invention may be located within a lipid bilayer. The invention thus provides a lipid bilayer (*e.g.* a cell membrane, a liposome, a bacterial ghost, an OMV, a bleb, *etc.*) including a protein of the invention. The bilayer preferably does not include native membrane components such as porins (PorA in particular, class I outer membrane proteins (OMPs), class III OMPs, *etc.*), LOS, LPS, PilC, Omp85, opacity proteins (*e.g.* Opa & Opc), pilins (*e.g.* PilC, PilT, *etc.*), P64k, *etc.*

Preferred fusion proteins follow the approach set out in references 13 to 15 in which two or more (*e.g.* 3, 4, 5, 6 or more) Neisserial proteins are joined such that they are translated as a single polypeptide chain. In general, such hybrid proteins can be represented by the formula:

$$NH_2\text{-}A\text{-}[\text{-}X\text{-}L\text{-}]_n\text{-}B\text{-}COOH$$

wherein X is an amino acid sequence as defined above, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. The value of n is between 2 and x, and the value of x is typically 3, 4, 5, 6, 7, 8, 9 or 10. Preferably n is 2, 3 or 4; it is more preferably 2 or 3; most preferably, $n = 2$.

In some hybrid proteins, referred to as 'tandem' proteins, a -X- moiety has sequence identity to at least one of the other X moieties, as defined above *e.g.* X_1 is SEQ ID 1 and X_2 is a variant of X_1.

For X moieties other than X_1, it is preferred that the native leader peptide should be omitted. In one embodiment, the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein *i.e.* the leader peptide of X_1 will be retained, but the leader peptides of X_2 ... X_n will be omitted. This is equivalent to deleting all leader peptides and using the leader

5   peptide of X_1 as moiety -A-.

For each n instances of [-X-L-], linker amino acid sequence -L- may be present or absent. For instance, when n=2 the hybrid may be $NH_2\text{-}X_1\text{-}L_1\text{-}X_2\text{-}L_2\text{-}COOH$, $NH_2\text{-}X_1\text{-}X_2\text{-}COOH$, $NH_2\text{-}X_1\text{-}L_1\text{-}X_2\text{-}COOH$, $NH_2\text{-}X_1\text{-}X_2\text{-}L_2\text{-}COOH$, *etc.* Linker amino acid sequence(s) -L- will typically be short (*e.g.* 20 or fewer amino acids *i.e.* 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples

10   include short peptide sequences which facilitate cloning, poly-glycine linkers (*i.e.* Gly_n where n = 2, 3, 4, 5, 6, 7, 8, 9, 10 or more), and histidine tags (*i.e.* His_n where n = 3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG, with the Gly-Ser dipeptide being formed from a *Bam*HI restriction site, thus aiding cloning and manipulation, and the Gly_4 tetrapeptide being a typical poly-glycine linker.

15   -A- is an optional N-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (*e.g.* histidine tags *i.e.* His_n where n = 3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable N-terminal amino acid

20   sequences will be apparent to those skilled in the art. If X_1 lacks its own N-terminus methionine, -A- may be a methionine residue.

-B- is an optional C-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein

25   trafficking, short peptide sequences which facilitate cloning or purification (*e.g.* comprising histidine tags *i.e.* His_n where n = 3, 4, 5, 6, 7, 8, 9, 10 or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

Within SEQ ID NO^s 1 to 205, those marked with a '*' in Table 1 are preferred, and the 76 marked '**' are particularly preferred,

30   *Nucleic acids of the invention*

The invention provides nucleic acid encoding the proteins of the invention.

The invention also provides nucleic acid comprising sequences which share at least x% sequence identity with nucleic acid encoding a protein of the invention. Depending on the particular sequence, x is preferably 50% or more (*e.g.* 60%, 70%, 80%, 90%, 95%, 99% or more).

Furthermore, the invention provides nucleic acid which can hybridise to nucleic acid encoding a protein of the invention. Hybridisation reactions can be performed under conditions of different "stringency". Conditions that increase stringency of a hybridisation reaction of widely known and published in the art. Examples of relevant conditions include (in order of increasing stringency):

5   incubation temperatures of 25°C, 37°C, 50°C, 55°C and 68°C; buffer concentrations of 10 X SSC, 6 X SSC, 1 X SSC, 0.1 X SSC and their equivalents using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or de-ionized water. In some embodiments, the isolated nucleic acid of the

10   invention selectively hybridises under low stringency conditions; in other embodiments it selectively hybridises under intermediate stringency conditions; in other embodiments, it selectively hybridises under high stringency conditions. An exemplary set of low stringency hybridisation conditions is 50°C and 10xSSC. An exemplary set of intermediate stringency hybridisation conditions is 55°C and 1xSSC. An exemplary set of high stringent hybridisation conditions is 68°C and 0.1 x SSC.

15   Nucleic acid comprising fragments of nucleic acid encoding a protein of the invention are also provided. These should comprise at least n consecutive nucleotides from the coding sequences and, depending on the particular sequence, n is 10 or more (e.g. 12, 14, 15, 18, 20, 25, 30, 35, 40, 50, 75, 100, 200, 300 or more).

The invention provides nucleic acid comprising sequences complementary to those described above
20   (e.g. for antisense or probing purposes).

Nucleic acid of the invention can, of course, be prepared in many ways e.g. by chemical synthesis (at least in part), by digesting longer polynucleotides using restriction enzymes, from genomic or cDNA libraries, from the organism itself etc.

Nucleic acid of the invention can take various forms (e.g. single-stranded, double-stranded, linear,
25   circular, vectors, primers, probes etc.).

Nucleic acids of the invention may be attached to a solid support (e.g. a bead, plate, filter, film, slide, resin, etc.). Nucleic acids of the invention may include a detectable label (e.g. a radioactive or fluorescent label, or a biotin label). This is particularly useful where the polynucleotide is to be used in nucleic acid detection techniques e.g. where the nucleic acid is a primer or as a probe for use in
30   techniques such as PCR, LCR, TMA, NASBA, bDNA etc.

Nucleic acids of the invention are preferably meningococcal nucleic acids.

The term "nucleic acid" includes DNA, RNA, DNA/RNA hybrids, and DNA or RNA analogs, such as those containing modified backbones or bases, and also peptide nucleic acids (PNA) etc..

Nucleic acids of the invention may be isolated and obtained in substantial purity, generally as other
35   than an intact chromosome. Usually, the polynucleotides will be obtained substantially free of other

naturally-occurring nucleic acid sequences, generally being at least about 50% (by weight) pure, usually at least about 90% pure.

Nucleic acids can be used, for example: to produce polypeptides; as probes for the detection of nucleic acid in biological samples; to generate additional copies of the polynucleotides; to generate
5   ribozymes or antisense oligonucleotides; and as single-stranded DNA probes or as triple-strand forming oligonucleotides *etc.*

The invention provides vectors comprising nucleotide sequences of the invention (*e.g.* cloning or expression vectors) and host cells transformed therewith.

Compositions

10   According to a further aspect, the invention provides compositions comprising protein and/or nucleic acid according to the invention. These compositions are preferably immunogenic compositions, such as vaccines, and are suitable for immunisation and vaccination purposes. Vaccines of the invention may be prophylactic or therapeutic, and will typically comprise an antigen which can induce antibodies which are (a) capable of binding to a meningococcal membrane component and/or
15   (b) bactericidal against meningococcus.

Compositions of the invention will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection (*e.g.* subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, or pulmonary or other mucosal administration. Electrical
20   methods may be used to for delivery *e.g.* delivery via electroporation.

The invention may be used to elicit systemic and/or mucosal immunity.

Dosage treatment can be a single dose schedule or a multiple dose schedule.

The immunogenic composition of the invention will generally include a pharmaceutically acceptable carrier, which can be any substance that does not itself induce the production of antibodies harmful
25   to the patient receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly-metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers can include liquids such as water, saline, glycerol and ethanol. Auxiliary
30   substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Liposomes are suitable carriers. A thorough discussion of pharmaceutical carriers is available in ref. 16.

Neisserial infections affect various areas of the body and so the compositions of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as
35   liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles

prior to injection can also be prepared. The composition may be prepared for topical administration *e.g.* as an ointment, cream or powder. The composition be prepared for oral administration *e.g.* as a tablet or capsule, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration *e.g.* as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration *e.g.* as drops.

The composition is preferably sterile. It is preferably pyrogen-free. It is preferably buffered *e.g.* at between pH 6 and pH 8, generally around pH 7.

Further components of compositions

Immunogenic compositions comprise an immunologically effective amount of immunogen, as well as any other of other specified components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (*e.g.* non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule (*e.g.* including booster doses). The composition may be administered in conjunction with other immunoregulatory agents.

The composition will generally comprise an adjuvant. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (A) MF59 (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer) [see Chapter 10 of ref. 17; see also ref. 18]; (B) microparticles (*i.e.* a particle of ~100nm to ~150µm in diameter, more preferably ~200nm to ~30µm in diameter, and most preferably ~500nm to ~10µm in diameter) formed from materials that are biodegradable and non-toxic (*e.g.* a poly(α-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone *etc.*), with poly(lactide-co-glycolide) being preferred ('PLG'), optionally being charged surface (*e.g.* by adding a cationic, anionic, or nonionic detergent such as SDS (negative) or CTAB (positive) [*e.g.* refs. 19 & 20]); (C) liposomes [see Chapters 13 and 14 of ref. 17]; (D) ISCOMs [see Chapter 23 of ref. 17] , which may be devoid of additional detergent [21]; (E) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion [see Chapter 12 of ref. 17]; (F) Ribi™ adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (G)

saponin adjuvants, such as QuilA or QS21 [see Chapter 22 of ref. 17], also known as Stimulon™; (H) chitosan [e.g. 22]; (I) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (J) cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g. interferon-γ), macrophage colony stimulating factor, tumor necrosis factor, etc. [see

5   Chapters 27 & 28 of ref. 17], RC529; (K) a saponin (e.g. QS21) + 3dMPL + IL-12 (optionally + a sterol) [23]; (L) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) [e.g. chapter 21 of ref. 17]; (M) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions [24]; (N) oligonucleotides comprising CpG motifs [25] i.e. containing at least one CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (O) a polyoxyethylene ether or a

10   polyoxyethylene ester [26]; (P) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol [27] or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol [28]; (Q) an immunostimulatory oligonucleotide (e.g. a CpG oligonucleotide) and a saponin [29]; (R) an immunostimulant and a particle of metal salt [30]; (S) a saponin and an oil-in-water emulsion [31]; (T) E.coli heat-labile enterotoxin ("LT"), or

15   detoxified mutants thereof, such as the K63 or R72 mutants [e.g. Chapter 5 of ref. 32]; (U) cholera toxin ("CT"), or detoxified mutants thereof [e.g. Chapter 5 of ref. 32]; (V) double-stranded RNA; (W) aluminium salts, such as aluminium hydroxides (including oxyhydroxides), aluminium phosphates (including hydroxyphosphates), aluminium sulfate, etc [Chapters 8 & 9 in ref. 33]; and (X) other substances that act as immunostimulating agents to enhance the effectiveness of the

20   composition [e.g. see Chapter 7 of ref. 17]. Aluminium salts (aluminium phosphates and particularly hydroxyphosphates, and/or hydroxides and particularly oxyhydroxide) and MF59 are preferred adjuvants for parenteral immunisation. Toxin mutants are preferred mucosal adjuvants.

Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-

25   alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.

Compositions of the invention may comprise antigens (e.g. protective antigens against N.meningitidis or against other organisms) in addition to the proteins mentioned above e.g. DTP antigens, Hib antigen etc. The composition may comprise one or more of the following further antigens:

−   antigens from Helicobacter pylori such as CagA [34 to 37], VacA [38, 39], NAP [40, 41, 42],
30   HopX [e.g. 43], HopY [e.g. 43] and/or urease.

−   a saccharide antigen from N.meningitidis serogroup A, C, W135 and/or Y, such as the oligosaccharide disclosed in ref. 44 from serogroup C [see also ref. 45] or the oligosaccharides of ref. 46.

−   a saccharide antigen from Streptococcus pneumoniae [e.g. 47, 48, 49].

35   −   an antigen from hepatitis A virus, such as inactivated virus [e.g. 50, 51].

−   an antigen from hepatitis B virus, such as the surface and/or core antigens [e.g. 51, 52].

- an antigen from *Bordetella pertussis*, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B.pertussis*, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [*e.g.* refs. 53 & 54].

- a diphtheria antigen, such as a diphtheria toxoid [*e.g.* chapter 3 of ref. 55] *e.g.* the CRM_{197} mutant [*e.g.* 56].

- a tetanus antigen, such as a tetanus toxoid [*e.g.* chapter 4 of ref. 75].

- a saccharide antigen from *Haemophilus influenzae* B [*e.g.* 45].

- an antigen from hepatitis C virus [*e.g.* 57].

- an antigen from *N.gonorrhoeae* [*e.g.* 58, 59, 60, 61].

- an antigen from *Chlamydia pneumoniae* [*e.g.* refs. 62 to 68].

- an antigen from *Chlamydia trachomatis* [*e.g.* 69].

- an antigen from *Porphyromonas gingivalis* [*e.g.* 70].

- polio antigen(s) [*e.g.* 71, 72] such as IPV.

- rabies antigen(s) [*e.g.* 73] such as lyophilised inactivated virus [*e.g.* 74, RabAvert™].

- measles, mumps and/or rubella antigens [*e.g.* chapters 9, 10 & 11 of ref. 75].

- influenza antigen(s) [*e.g.* chapter 19 of ref. 75], such as the haemagglutinin and/or neuraminidase surface proteins.

- an antigen from *Moraxella catarrhalis* [*e.g.* 76].

- an protein antigen from *Streptococcus agalactiae* (group B streptococcus) [*e.g.* 77, 78].

- a saccharide antigen from *Streptococcus agalactiae* (group B streptococcus).

- an antigen from *Streptococcus pyogenes* (group A streptococcus) [*e.g.* 78, 79, 80].

- an antigen from *Staphylococcus aureus* [*e.g.* 81].

- an antigen from *Bacillus anthracis* [*e.g.* 82, 83, 84].

- an antigen from a virus in the flaviviridae family (genus flavivirus), such as from yellow fever virus, Japanese encephalitis virus, four serotypes of Dengue viruses, tick-borne encephalitis virus, West Nile virus.

- a pestivirus antigen, such as from classical porcine fever virus, bovine viral diarrhoea virus, and/or border disease virus.

- a parvovirus antigen *e.g.* from parvovirus B19.

- a prion protein (*e.g.* the CJD prion protein)

- an amyloid protein, such as a beta peptide [85]

- a cancer antigen, such as those listed in Table 1 of ref. 86 or in tables 3 & 4 of ref. 87.

The composition may comprise one or more of these further antigens.

Toxic protein antigens may be detoxified where necessary (*e.g.* detoxification of pertussis toxin by chemical and/or genetic means [54]).

Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. DTP combinations are thus preferred.

Saccharide antigens are preferably in the form of conjugates. Carrier proteins for the conjugates include the *N.meningitidis* outer membrane protein [88], synthetic peptides [89,90], heat shock proteins [91,92], pertussis proteins [93,94], protein D from *H.influenzae* [95], cytokines [96], lymphokines [96], streptococcal proteins, hormones [96], growth factors [96], toxin A or B from *C.difficile* [97], iron-uptake proteins [98], *etc*. A preferred carrier protein is the CRM197 diphtheria toxoid [99].

Antigens in the composition will typically be present at a concentration of at least 1 μg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

Immunogenic compositions of the invention may be used therapeutically (*i.e.* to treat an existing infection) or prophylactically (*i.e.* to prevent future infection).

As an alternative to using proteins antigens in the immunogenic compositions of the invention, nucleic acid (preferably DNA *e.g.* in the form of a plasmid) encoding the antigen may be used.

Medical methods etc.

The invention also provides nucleic acids or proteins of the invention, or antibodies which bind to proteins of the invention, for use as medicaments (*e.g.* as vaccines). It also provides the use of nucleic acid or protein according to the invention in the manufacture of a medicament (*e.g.* a vaccine or an immunogenic composition) for treating or preventing infection due to a *Neisseria*. This will generally be *N.meningitidis* but, due to inter-species cross-reactivity, it may also be *N.gonorrhoeae*.

The invention also provides a method of treating (*e.g.* immunising) a patient (*e.g.* a human), comprising administering to the patient a therapeutically effective amount of nucleic acid or protein according to the invention.

The invention also provides a method of raising antibodies in an animal, comprising administering to the patient an immunologically effective amount of nucleic acid or protein according to the invention.

The invention also provides a method of detecting *N.meningitidis* bacteria in a sample, comprising the steps of: (a) contacting an antibody (*e.g.* monoclonal or polyclonal) which binds to a protein of the invention with a biological sample under conditions suitable for the formation of an antibody-

antigen complexes; and (b) detecting said complexes. The method is particularly suitable for detecting intact bacteria because the proteins of the invention are present in the membrane.

The invention also provides nucleic acids or proteins of the invention, or antibodies which bind to proteins of the invention, for use as diagnostic reagents. It also provides the use of nucleic acid or protein according to the invention, or antibodies which bind to proteins of the invention, in the manufacture of a reagent for diagnosing infection due to a *Neisseria*.

The invention also provides a method for investigating *N.meningitidis*, wherein the method includes a step of performing 2D electrophoresis on a membrane fraction from the bacterium.

Techniques

A summary of standard techniques and procedures which may be employed in order to perform the invention (*e.g.* to utilise the disclosed sequences for immunisation or diagnosis) follows. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.

General

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature *e.g.* Sambrook *Molecular Cloning; A Laboratory Manual, Second Edition* (1989) and *Third Edition* (2001); *DNA Cloning, Volumes 1 and ii* (D.N Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed, 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Transcription and Translation* (B.D. Hames & S.J. Higgins eds. 1984); *Animal Cell Culture* (R.I. Freshney ed. 1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide to Molecular Cloning* (1984); the *Methods in Enzymology* series (Academic Press, Inc.), especially volumes 154 & 155; *Gene Transfer Vectors for Mammalian Cells* (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), *Immunochemical Methods in Cell and Molecular Biology* (Academic Press, London); Scopes, (1987) *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.), and *Handbook of Experimental Immunology, Volumes I-IV* (D.M. Weir and C. C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are used in this specification.

Definitions

A composition containing X is "substantially free of" Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.

The term "comprising" means "including" as well as "consisting" *e.g.* a composition "comprising" X may consist exclusively of X or may include something additional to X, such as X+Y.

The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a

gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell. A further examples would be two epitopes from the same or different proteins which have been assembled in a single protein in an arrangement not found in nature.

5   An "origin of replication" is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen,

10   effective in COS-7 cells.

A "mutant" sequence is defined as DNA, RNA or amino acid sequence differing from but having sequence identity with the native or disclosed sequence. Depending on the particular sequence, the degree of sequence identity between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (*e.g.* 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the Smith-Waterman algorithm as described above).

15   As used herein, an "allelic variant" of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs essentially at the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic

20   variant can also comprise an alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions (*e.g.* see US patent 5,753,235).

Expression systems

The Neisserial nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, plants, bacteria, and yeast.

25   i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (*e.g.* structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream

30   of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In *Molecular Cloning: A Laboratory Manual, 2nd ed.].*

35   Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or

regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) *Science 236:*1237; Alberts et al. (1989) *Molecular Biology of the Cell*, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) *EMBO J. 4:*761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982) *PNAS USA 79:*6777] and from human cytomegalovirus [Boshart et al. (1985) *Cell 41:*521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) *Trends Genet. 2:*215; Maniatis et al. (1987) *Science* 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus triparite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) *Cell 41:*349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) *Trends Biochem. Sci. 14:*105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminater/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*].

Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (*e.g.* plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing

the replication systems of papovaviruses, such as SV40 [Gluzman (1981) *Cell 23*:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian

5   cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) *Mol. Cell. Biol. 9*:946] and pHEBO [Shimizu et al. (1986) *Mol. Cell. Biol. 6*:1074].

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated

10   transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of polynucleotide(s) in liposomes, direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human

15   hepatocellular carcinoma cells (*e.g.* Hep G2), and a number of other cell lines.

ii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a

20   bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

25   After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and

30   fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This

35   construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (*e.g.* plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and

40   amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, *Virology* (1989) *17*:31.

5 The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, *42*:177) and a prokaryotic ampicillin-resistance (*amp*) gene and origin of replication for selection and propagation in *E. coli.*

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription

10 of a coding sequence (*e.g.* structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

15 Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), *J. Gen. Virol. 69*:765.

20 DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) *Gene, 73*:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-

25 insect origin, such as those derived from genes encoding human α-interferon, Maeda et al., (1985), *Nature 315*:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), *Molec. Cell. Biol. 8*:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA, 82*:8404; mouse IL-3, (Miyajima et al., (1987) *Gene 58*:273; and human glucocerebrosidase, Martin et al. (1988) *DNA, 7*:99, can also be used to provide for secretion in insects.

30 A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.

35 Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing
5   heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.* (1983) *3*:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays 4*:91.The DNA sequence, when cloned in place of the polyhedrin gene in the
10   expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between ~1% and ~5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify
15   recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15μm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with
20   recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers & Smith, *supra*; Miller et al. (1989).

25   Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: *Aedes aegypti* , *Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda*, and *Trichoplusia ni* (WO 89/046699; Carbonell et al., (1985) *J. Virol. 56*:153; Wright (1986) *Nature 321*:718; Smith et al., (1983) *Mol. Cell. Biol. 3*:2156; and see generally, Fraser, *et al.* (1989) *In Vitro Cell. Dev. Biol. 25*:225).

30   Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. *See, e.g.* Summers and Smith *supra*.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under
35   inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g. HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like.
40   As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins

which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g. proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary,
5 dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

iii. Plant Systems

There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: US 5,693,506; US 5,659,122;
10 and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to the references described above in Vaulcombe et al., *Mol. Gen. Genet.* 209:33-40 (1987); Chandler et al., *Plant Molecular Biology* 3:407-418 (1984); Rogers, *J. Biol. Chem.* 260:3731-3738 (1985); Rothstein et al., *Gene* 55:353-356 (1987); Whittier et al., Nucleic Acids Research 15:2515-2535 (1987); Wirsel et al., *Molecular*
15 *Microbiology* 3:3-14 (1989); Yu et al., *Gene* 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R.L. Jones and J. MacMillin, Gibberellins: in: *Advanced Plant Physiology*,. Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, *Plant Cell*, 2:1027-1038(1990); Maas et al., *EMBO J.* 9:3447-3452 (1990); Benkel and Hickey, *Proc.*
20 *Natl. Acad. Sci.* 84:1337-1339 (1987)

Typically, using techniques known in the art, a desired polynucleotide sequence is inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral
25 origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker; and, for Agrobacterium transformations, T DNA sequences for Agrobacterium-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable
30 marker gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, *Plant Mol. Biol. Reptr*, 11(2):165-185.

Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like for homologous recombination as well as
35 Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.

The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only one expression cassette, although two or more are
40 feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding

sequence the following elements, a promoter region, plant 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5' and 3' ends of the cassette allow for easy insertion into a pre-existing vector.

5   A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for

10   translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed. While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.

15   Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the "intron" region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, *Cell* 41:95-105, 1985.

The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the

20   recombinant DNA. Crossway, *Mol. Gen. Genet*, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., *Nature*, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., *Nature*, 327, 70-73, 1987 and Knudsen and Muller, 1991, *Planta*, 185:330-336 teaching particle bombardment of barley

25   endosperm to create transgenic barley. Yet another method of introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79, 1859-1863, 1982.

The vector may also be introduced into the plant cells by electroporation. (Fromm et al., *Proc. Natl Acad. Sci. USA* 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids

30   containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is

35   known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersion*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*,

40   *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Hererocallis*, *Nemesia*, *Pelargonium*,

Panicum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum, and *Datura.*

5

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

10

In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected. Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.

15

iv. Bacterial Systems

20

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (*e.g.* structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli) [Raibaud *et al.* (1984) *Annu. Rev. Genet. 18*:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

25

30

35

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) [Chang *et al.* (1977) *Nature 198*:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) [Goeddel *et al.* (1980) *Nuc. Acids Res. 8*:4057; Yelverton *et al.* (1981) *Nucl. Acids Res. 9*:731; US patent 4,738,921; EP-A-0036776 and EP-A-0121775]. The g-laotamase (*bla*) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I.

Gresser)], bacteriophage lambda PL [Shimatake *et al.* (1981) *Nature 292*:128] and T5 [US patent 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon

5 sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [US patent 4,551,433]. For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and *lac* operon sequences that is regulated by the *lac* repressor [Amann *et al.* (1983) *Gene 25*:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci. 80*:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate

10 transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier *et al.* (1986) *J. Mol. Biol. 189*:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci. 82*:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO-A-0 267 851).

15 In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine *et al.* (1975) *Nature 254*:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' and of *E.*

20 *coli* 16S rRNA [Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook *et al.* (1989) "Expression of cloned genes in Escherichia coli." In *Molecular Cloning: A Laboratory Manual*].

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA

25 molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* on *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO-A-0 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal

30 portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai *et al.* (1984) *Nature 309*:810]. Fusion proteins can also be

35 made with sequences from the *lacZ* [Jia *et al.* (1987) *Gene 60*:197], *trpE* [Allen et al. (1987) J. Biotechnol. 5:93; Makoff *et al.* (1989) *J. Gen. Microbiol. 135*:11], and *Chey* [EP-A-0 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (*e.g.* ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign

40 protein. Through this method, native foreign protein can be isolated [Miller *et al.* (1989) *Bio/Technology 7*:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [US patent 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is

5   either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) [Masui *et al.* (1983), in: *Experimental Manipulation of Gene*

10   *Expression*; Ghrayeb *et al.* (1984) *EMBO J. 3*:2437] and the *E. coli* alkaline phosphatase signal sequence (*phoA*) [Oka *et al.* (1985) *Proc. Natl. Acad. Sci. 82*:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from *B. subtilis* [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA 79*:5582; EP-A-0 244 042].

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the

15   translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

20   Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (*e.g.* plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon

25   may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

30   Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EP-A- 0 127 328). Integrating vectors may also be

35   comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies *et al.* (1978) *Annu. Rev. Microbiol. 32*:469].

Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or
5   developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: Bacillus subtilis [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA 79*:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541], Escherichia coli [Shimatake *et al.* (1981) *Nature 292*:128; Amann
10   *et al.* (1985) *Gene 40*:183; Studier *et al.* (1986) *J. Mol. Biol. 189*:113; EP-A-0 036 776, EP-A-0 136 829 and EP-A-0 136 907], Streptococcus cremoris [Powell *et al.* (1988) *Appl. Environ. Microbiol. 54*:655]; Streptococcus lividans [Powell *et al.* (1988) *Appl. Environ. Microbiol. 54*:655], Streptomyces lividans [US patent 4,745,056].

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl$_2$ or other agents, such as divalent cations and DMSO.
15   DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See *e.g.* [Masson *et al.* (1989) *FEMS Microbiol. Lett. 60*:273; Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA 79*:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541, Bacillus], [Miller *et al.* (1988) *Proc. Natl. Acad. Sci. 85*:856; Wang *et al.* (1990) *J. Bacteriol. 172*:949, Campylobacter], [Cohen *et al.* (1973) *Proc. Natl. Acad. Sci. 69*:2110; Dower *et al.* (1988) *Nucleic Acids Res. 16*:6127; Kushner
20   (1978) "An improved method for transformation of Escherichia coli with ColE1-derived plasmids. In *Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering* (eds. H.W. Boyer and S. Nicosia); Mandel *et al.* (1970) *J. Mol. Biol. 53*:159; Taketo (1988) *Biochim. Biophys. Acta 949*:318; Escherichia], [Chassy *et al.* (1987) *FEMS Microbiol. Lett. 44*:173 Lactobacillus]; [Fiedler *et al.* (1988) *Anal. Biochem 170*:38, Pseudomonas]; [Augustin *et al.* (1990) *FEMS Microbiol. Lett. 66*:203, Staphylococcus],
25   [Barany *et al.* (1980) *J. Bacteriol. 144*:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation, in: *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss III); Perry *et al.* (1981) *Infect. Immun. 32*:1295; Powell *et al.* (1988) *Appl. Environ. Microbiol. 54*:655; Somkuti *et al.* (1987) *Proc. 4th Evr. Cong. Biotechnology 1*:412, Streptococcus].

<u>v. Yeast Expression</u>

30   Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (*e.g.* structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may
35   also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the
40   metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase

(ADH) (EP-A-0 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO-A-0 329 203). The yeast *PHO5* gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara *et al.* (1983) *Proc. Natl. Acad. Sci. USA 80*:1].

5   In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (US Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the *ADH2*,

10   *GAL4, GAL10,* OR *PHO5* genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EP-A-0 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, *inter alia*, [Cohen *et al.* (1980) *Proc. Natl. Acad. Sci. USA 77*:1078; Henikoff *et al.* (1981) *Nature 283*:835; Hollenberg *et al.* (1981) *Curr. Topics Microbiol. Immunol. 96*:119;

15   Hollenberg *et al.* (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae," in: *Plasmids of Medical, Environmental and Commercial Importance* (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon *et al.* (1980) *Gene 11*:163; Panthier *et al.* (1980) *Curr. Genet. 2*:109;].

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always

20   be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this

25   construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See *e.g.* EP-A-0 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (*e.g.* ubiquitin-specific processing protease) to

30   cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (*e.g.* WO88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and

35   the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the genes for invertase (EP-A-0012873; JPO 62,096,086) and A-factor (US patent 4,588,684). Alternatively, leaders of non-yeast origin exit, such as an interferon leader, that also provide for secretion in yeast (EP-A-0060057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (US Patents 4,546,083 and 4,870,008;

5   EP-A-0 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (e.g. see WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct

10   the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression

15   constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein et al. (1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982)

20   J. Mol. Biol. 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g. Brake et al., supra.

25   Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245]. An integrating vector may be

30   directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al., supra. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the

35   expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable

40   marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For

example, the presence of *CUP1* allows yeast to grow in the presence of copper ions [Butt *et al.* (1987) *Microbiol, Rev. 51*:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, *inter alia*, the following yeasts:Candida albicans [Kurtz, *et al.* (1986) *Mol. Cell. Biol. 6*:142], Candida maltosa [Kunze, *et al.* (1985) *J. Basic Microbiol. 25*:141]. Hansenula polymorpha [Gleeson, *et al.* (1986) *J. Gen. Microbiol. 132*:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet. 202*:302], Kluyveromyces fragilis [Das, *et al.* (1984) *J. Bacteriol. 158*:1165], Kluyveromyces lactis [De Louvencourt *et al.* (1983) *J. Bacteriol. 154*:737; Van den Berg *et al.* (1990) *Bio/Technology 8*:135], Pichia guillerimondii [Kunze *et al.* (1985) *J. Basic Microbiol. 25*:141], Pichia pastoris [Cregg, *et al.* (1985) *Mol. Cell. Biol. 5*:3376; US Patent Nos. 4,837,148 and 4,929,555], Saccharomyces cerevisiae [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA 75*:1929; Ito *et al.* (1983) *J. Bacteriol. 153*:163], Schizosaccharomyces pombe [Beach and Nurse (1981) *Nature 300*:706], and Yarrowia lipolytica [Davidow, *et al.* (1985) *Curr. Genet. 10*:380471 Gaillardin, *et al.* (1985) *Curr. Genet. 10*:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See *e.g.* [Kurtz *et al.* (1986) *Mol. Cell. Biol. 6*:142; Kunze *et al.* (1985) *J. Basic Microbiol. 25*:141; Candida]; [Gleeson *et al.* (1986) *J. Gen. Microbiol. 132*:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet. 202*:302; Hansenula]; [Das *et al.* (1984) *J. Bacteriol. 158*:1165; De Louvencourt *et al.* (1983) *J. Bacteriol. 154*:1165; Van den Berg *et al.* (1990) *Bio/Technology 8*:135; Kluyveromyces]; [Cregg *et al.* (1985) *Mol. Cell. Biol. 5*:3376; Kunze *et al.* (1985) *J. Basic Microbiol. 25*:141; US Patents 4,837,148 & 4,929,555; Pichia]; [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA 75*;1929; Ito *et al.* (1983) *J. Bacteriol. 153*:163 Saccharomyces]; [Beach & Nurse (1981) *Nature 300*:706; Schizosaccharomyces]; [Davidow *et al.* (1985) *Curr. Genet. 10*:39; Gaillardin *et al.* (1985) *Curr. Genet. 10*:49; Yarrowia].

Pharmaceutical Compositions

Pharmaceutical compositions can comprise polypeptides and/or nucleic acid of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.

For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and

5   which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides,

10   hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering

15   substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods

20   Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary

25   administration, suppositories, and transdermal or transcutaneous applications (*e.g.* see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Vaccines

Vaccines according to the invention may either be prophylactic (*ie.* to prevent infection) or therapeutic (*ie.* to treat disease after infection).

30   Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with "pharmaceutically acceptable carriers," which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or

35   liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, *etc.* pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO 90/14837; Chapter 10 in

5   *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to

10   generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating

15   complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, *etc.*), interferons (*e.g.* gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ are preferred.

20   As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), *etc.*

The immunogenic compositions (*e.g.* the immunising antigen/immunogen/polypeptide/protein/ nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol,

25   ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed

30   above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon

35   the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (*e.g.* nonhuman primate, primate, *etc.*), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

The immunogenic compositions are conventionally administered parenterally, *e.g.* by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (*e.g.* WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be
5   administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination may be employed [*e.g.* Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648; see later herein].

Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to
10   be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constitutive or regulated.

The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences.
15   The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) *Cancer Gene Therapy* 1:51-64; Kimura (1994) *Human Gene Therapy* 5:845-852; Connelly (1995) *Human Gene Therapy* 6:185-193; and Kaplitt (1994) *Nature Genetics* 6:148-153.

20   These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US patent 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.

25   Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (*e.g.* HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

30   Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia, Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) *J Virol* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC Nol VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No.
35   VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

The gene therapy vectors of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a sequence encoding a thymidine kinase polypeptide such as those

disclosed in US 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar), pHSVlac described in Geller (1988) *Science* 241:1667-1669 and in WO90/09441 & WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) *Human Gene Therapy* 3:11-19 and HSV 7134, 2 RH 105 and GAL4 described in EP 0453242 (Breakefield), and those

5   deposited with ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in

10   US patents 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in US Serial No. 08/405,627, filed March 15, 1995,WO94/21792, WO92/10578, WO95/07994, US 5,091,309 and US 5,217,879 are employable. Such alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see USSN 08/679640).

15   DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.

Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example

20   ATCC VR-58 and those described in Evans, Nature 339 (1989) 385 and Sabin (1973) *J. Biol. Standardization* 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) *J Cell Biochem* L401; pox viruses such as canary pox virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) *Proc Natl Acad Sci* 86:317; Flexner (1989) *Ann NY Acad Sci* 569:86, Flexner (1990) *Vaccine* 8:17; in US 4,603,112 and US 4,769,330 and WO89/01973; SV40 virus, for example ATCC

25   VR-305 and those described in Mulligan (1979) *Nature* 277:108 and Madzak (1992) *J Gen Virol* 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in US 5,166,057 and in Enami (1990) *Proc Natl Acad Sci* 87:3802-3805; Enami & Palese (1991) *J Virol* 65:2711-2713 and Luytjes (1989) *Cell* 59:110, (see also McMichael (1983) *NEJ Med* 309:13, and Yap (1978) *Nature* 273:238 and *Nature* (1979) 277:108); human immunodeficiency virus as

30   described in EP-0386882 and in Buchschacher (1992) *J. Virol.* 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach virus, for example ATCC VR-927; Mayaro

35   virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Triniti virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus,

40   for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) *Proc Soc Exp Biol Med* 121:190.

Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see US Serial No. 08/366,787, filed December 30, 1994 and Curiel (1992) *Hum Gene Ther* 3:147-154 ligand linked DNA, for

5 example see Wu (1989) *J Biol Chem* 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see US Serial No.08/240,030, filed May 9, 1994, and US Serial No. 08/404,796, deposition of photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in US Patent 5,149,655, ionizing radiation as described in US5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) *Mol Cell Biol* 14:2411-2418 and in Woffendin (1994) *Proc*

10 *Natl Acad Sci* 91:1581-1585.

Particle mediated gene transfer may be employed, for example see US Serial No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described

15 in Wu & Wu (1987) *J. Biol. Chem.* 262:4429-4432, insulin as described in Hucked (1990) *Biochem Pharmacol* 40:253-263, galactose as described in Plank (1992) *Bioconjugate Chem* 3:533-539, lactose or transferrin.

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO90/11092 and US 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA-coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be

20 improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in US 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in USSN. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control

25 sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems

30 such as the approach described in Woffendin *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in US 5,149,655; use of ionizing radiation for activating transferred gene, as described in US 5,206,152 and

35 WO92/11033

Exemplary liposome and polycationic gene delivery vehicles are those described in US 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697; and WO91/14445; in EP-0524968; and in Stryer, Biochemistry, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) *Biochem Biophys Acta* 600:1; Bayer (1979) *Biochem Biophys Acta* 550:464; Rivnay (1987) *Meth Enzymol* 149:119; Wang (1987) *Proc Natl Acad Sci*

40 84:7851; Plant (1989) *Anal Biochem* 176:420.

A polynucleotide composition can comprises therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

Delivery Methods

5   Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered *ex vivo*, to cells derived from the subject; or (3) *in vitro* for recombinant protein expression. The subjects to be treated can be mammals or birds. Also, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The
10   compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (*e.g.* see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in *e.g.* WO93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells,
15   particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells.

Generally, delivery of nucleic acids for both *ex vivo* and *in vitro* applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

20   *Polynucleotide and polypeptide pharmaceutical compositions*

In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide compositions.

A.Polypeptides

One example are polypeptides which include, without limitation: asioloorosomucoid (ASOR); transferrin;
25   asialoglycoproteins; antibodies; antibody fragments; ferritin; interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.

30   B.Hormones, Vitamins, *etc.*

Other groups that can be included are, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.

C.Polyalkylenes, Polysaccharides, *etc.*

Also, polyalkylene glycol can be included with the desired polynucleotides/polypeptides. In a preferred
35   embodiment, the polyalkylene glycol is polyethlylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also, chitosan and poly(lactide-co-glycolide)

D.Lipids, and Liposomes

The desired polynucleotide/polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.

5   Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) *Biochim. Biophys. Acta.* 1097:1-17; Straubinger (1983) *Meth. Enzymol.* 101:512-527.

10   Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7416); mRNA (Malone (1989) *Proc. Natl. Acad. Sci. USA* 86:6077-6081); and purified transcription factors (Debs (1990) *J. Biol. Chem.* 265:10189-10192), in functional form.

15   Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY. (See, also, Felgner *supra*). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, *e.g.* Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) 20   liposomes.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the 25   DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

The liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See *e.g.* Straubinger (1983) *Meth. Immunol.* 101:512-527; Szoka (1978) *Proc. Natl. Acad. Sci. USA* 30   75:4194-4198; Papahadjopoulos (1975) *Biochim. Biophys. Acta* 394:483; Wilson (1979) *Cell* 17:77); Deamer & Bangham (1976) *Biochim. Biophys. Acta* 443:629; Ostro (1977) *Biochem. Biophys. Res. Commun.* 76:836; Fraley (1979) *Proc. Natl. Acad. Sci. USA* 76:3348); Enoch & Strittmatter (1979) *Proc. Natl. Acad. Sci. USA* 76:145; Fraley (1980) *J. Biol. Chem.* (1980) 255:10431; Szoka & Papahadjopoulos (1978) *Proc. Natl. Acad. Sci. USA* 75:145; and Schaefer-Ridder (1982) *Science* 215:166.

35   ## E.Lipoproteins

In addition, lipoproteins can be included with the polynucleotide/polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, IDL, LDL, and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein

receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.

Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.

A lipoprotein can comprise more than one apoprotein. For example, naturally occurring chylomicrons comprises of A, B, C, & E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, & E apoproteins, LDL comprises apoprotein B; HDL comprises apoproteins A, C, & E.

The amino acid of these apoproteins are known and are described in, for example, Breslow (1985) Annu Rev. Biochem 54:699; Law (1986) Adv. Exp Med. Biol. 151:162; Chen (1986) J Biol Chem 261:12918; Kane (1980) Proc Natl Acad Sci USA 77:2465; and Utermann (1984) Hum Genet 65:232.

Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in Meth. Enzymol. 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.

Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in Meth. Enzymol. (supra); Pitas (1980) J. Biochem. 255:5454-5460 and Mahey (1979) J Clin. Invest 64:743-750. Lipoproteins can also be produced by in vitro or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) Annu Rev Biophys Chem 15:403 and Radding (1958) Biochim Biophys Acta 30: 443. Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Techniologies, Inc., Stoughton, Massachusetts, USA. Further description of lipoproteins can be found in Zuckermann et al. PCT/US97/14465.

F.Polycationic Agents

Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide/polypeptide to be delivered.

Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both in vitro, ex vivo, and in vivo applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.

The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as (X174, transcriptional factors also contain domains that bind DNA and therefore may be useful as nucleic aid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.

Organic polycationic agents include: spermine, spermidine, and purtrescine.

The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.

Synthetic polycationic agents which are useful include, for example, DEAE-dextran, polybrene. Lipofectin™, and lipofectAMINE™ are monomers that form polycationic complexes when combined with
5   polynucleotides/polypeptides.

Nucleic Acid Hybridisation

"Hybridization" refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that
10   affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook *et al.* [*supra*] vol.2, chapt.9, pp.9.47 to 9.57.

15   "Stringency" refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200°C below the calculated Tm of the hybrid under study. The temperature and salt conditions can often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different
20   stringencies. See Sambrook *et al.* at page 9.50.

Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1μg for a plasmid or phage digest to 10^{-9} to 10^{-8} g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides,
25   substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 μg of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 10^8 cpm/μg. For a single-copy mammalian gene a conservative approach would start with 10 μg of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of
30   greater than 10^8 cpm/μg, resulting in an exposure time of ~24 hours.

Several factors can affect the melting temperature (Tm) of a DNA-DNA hybrid between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the
35   hybridization buffer. The effects of all of these factors can be approximated by a single equation:

$$Tm = 81 + 16.6(\log_{10}Ci) + 0.4[\%(G + C)] - 0.6(\%formamide) - 600/n - 1.5(\%mismatch).$$

where Ci is the salt concentration (monovalent ions) and *n* is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) *Anal. Biochem.* 138: 267-284).

In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (*ie.* stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabelled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.

In general, convenient hybridization temperatures in the presence of 50% formamide are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

Nucleic Acid Probe Assays

Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA. A probe is said to "hybridize" with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.

The nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells. mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding sequence.

The probe sequence need not be identical to the Neisserial sequence (or its complement) — some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected. Also, the nucleic acid probe can include additional nucleotides to stabilize the formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex. For example, a non-complementary nucleotide sequence may be attached to the 5' end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.

The exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like. For example, for diagnostic applications, depending on the complexity of the analyte sequence, the nucleic acid probe typically contains at least 10-20 nucleotides, preferably 15-25, and more

preferably ≥30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.

Probes may be produced by synthetic procedures, such as the triester method of Matteucci *et al.* [*J. Am. Chem. Soc.* (1981) 103:3185], or according to Urdea *et al.* [*Proc. Natl. Acad. Sci. USA* (1983) 80: 7461], or using
5   commercially available automated oligonucleotide synthesizers.

The chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated e.g. backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase *in vivo* half-life, alter RNA affinity, increase nuclease resistance *etc.* [*e.g.* see Agrawal & Iyer (1995) *Curr Opin Biotechnol* 6:12-19; Agrawal (1996)
10   *TIBTECH* 14:376-387]; analogues such as peptide nucleic acids may also be used [*e.g.* see Corey (1997) *TIBTECH* 15:224-229; Buchardt *et al.* (1993) *TIBTECH* 11:384-386].

Alternatively, the polymerase chain reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in: Mullis *et al.* [*Meth. Enzymol.* (1987) 155: 335-350]; US patents 4,683,195 & 4,683,202. Two 'primers' hybridize with the target nucleic acids and are used to prime the reaction.
15   The primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.

A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase,
20   they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labelled probe will hybridize to the Neisserial sequence (or its complement).

Also, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook *et al* [*supra*]. mRNA, or cDNA generated from mRNA using a polymerase enzyme, can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The
25   solid support is exposed to a labelled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labelled probe are detected. Typically, the probe is labelled with a radioactive moiety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the overall strategy for 2D-PAGE. The individual gels are shown as Figures 2 to 4.
Figure 5 shows the results of a protein query of the NCBI Entrez system using the term 'NMB1506'.

30   **MODES FOR CARRYING OUT THE INVENTION**

The overall strategy for identifying membrane proteins was to use two dimensional electrophoresis to separate the proteins in a *N.meningitidis* membrane preparation, followed by identification of proteins found in the electrophoretic gel. This experiment was not straightforward because, as is well known, preparing a membrane fraction which is not contaminated with cytoplasmic proteins is
35   extremely difficult.

Some of the proteins identified by electrophoresis were expected to be there, but many were not. Furthermore, several proteins which were annotated as "hypothetical" have now been shown to exist

in vivo — they are not artefacts. A further point to note is that proteins visible on a 2D gel must be expressed at least at a moderate level, thus making them useful targets for binding.

Preparation of membrane fraction

To prepare the membrane fraction, *N.meningitidis* strain MC58 was growth in liquid "base for the isolation of pathogenic Neisseria" (GC, Difco), supplemented with 4g/l glucose, 0.1 g/l glutamine, and 2.2 mg/l cocarboxylase, at 37°C in a humidified atmosphere containing 5% CO_2. Bacteria were harvested at OD_{600nm}=0.5 by centrifugation at 10,000 g for 20 minutes. The pellet was resuspended with 10 ml Tris-base containing the EDTA-free protease inhibitor cocktail used according to the manufacturer (Roche Diagnostic Mannhein, Germany). The bacteria were inactivated 45 minutes at 56°C, cooled in ice in presence of 1,000 U benzonase, and were disrupted with a French Press at 18000 psi (4 passages). The lysate was centrifuged at 70,000 g overnight at 5°C. The pellet was washed twice with 40mM Tris-base and resuspended in 10 ml of 5M urea, 2M thiourea, 2% (w/v) CHAPS, 2% (w/v) ASB 14, 0.5% (v/v) C.A., 2mM TBP and centrifuged at 100,000 g at 10°C for 3 hours. Supernatant containing solubilised membrane proteins was aliquoted and stored at –80°C.

This process is quick, easy to use, and results in a membrane preparation with little or no contamination from cytosolic proteins [*e.g.* refs. 100 to 103]. It was improved by using new techniques for the solubilisation of bacterial membrane proteins prior and during to isoelectric focusing, in order to optimise the separation of outer membrane proteins by two-dimensional electrophoresis (2DE). Thirourea was thus used with the urea as chaotropic agents [100], the zwitterionic detergent ASB-14 was used in association with CHAPS [104], and tributyl phosphine was added prior to 2DE [105].

2D electrophoresis

200µg of the membrane proteins were brought to a final volume of 125 µl with reswelling solution (7M urea, 2M thiourea, 2% (w/v) CHAPS, 2% (w/v) ASB 14, 2% (v/v) adequate ampholine (Amersham Pharmacia Biotech (Piscataway, NJ), 2 mM thiobutyl phosphine). The proteins were absorbed overnight onto an Immobiline DryStrip (7 cm; pH-gradient 3-10 non linear, pH-gradient, 4-7 or 6-11 linear) using the Immobiline Dry-Strip Reswelling Tray (Amersham Pharmacia Biotech (Piscataway, NJ). Proteins were then separated by 2D electrophoresis. The first dimension was run on an IPGphor Isoelectric Focusing Unit (Amersham Pharmacia Biotech, Piscataway, NJ), The proteins were separated applying sequentially 150 V for 35 min., 500 V for 35 min., 1000 V for 30 min, 2600 V for 10 min., 3500 V for 15 min., 4200 V for 15 min., and then 5000 V to reach 10kVh. For the second dimension, the strips were equilibrated as described in ref. 105 and the proteins were separated on a linear 9-16% acrylamide SDS-PAGE (1.5 mm thick, 6 cm high) using the Mini Proten II Cell from BioRad. The 2D gel was stained with colloidal Coomassie [106]. Gels were scanned with a Personal densitometer SI (Molecular Dynamics) at 12 bits and 50 µm per pixel.

The initial 2D IPG gradient gel is shown in Figure 2. 325 protein spots were visualised by colloidal Coomassie blue. In order to increase the spot number, 200µg of the same protein fraction was separated on 2D gels with a pH gradients of 4-7 (Figure 3) and 6-11 (Figure 4). 498 and 187 spots were visualised by colloidal Coomassie blue in these gels, respectively. Each gel was performed and analysed in duplicate, with no major differences observed between duplicates.

Spot excision

A total of 1,867 protein spots were excised from the three gels, plus the duplicated gels, in-gel digested with trypsin, and the generated peptides were analysed by MALDI-TOF mass spectrometry. Proteins were identified by interpreting their peptide mass fingerprint using the software Mascot.

The protocol used for in-gel digestion was a modification of reference 107. Protein spots were excised from the gel, washed sequentially with Milli-Q water and acetonitrile (1/1, v/v), and dried by a Speed Vac vacuum centrifuge apparatus (Savant, Holbrook, NY). The pieces of gel were re-hydrated by adding 7-10 µl of a solution of 50 mM ammonium bicarbonate, 5 mM $CaCl_2$ containing 12 mg/l trypsin sequencing grade (Roche Diagnostic Corporation, Indianapolis, IN). The tryptic digestion was allowed to run for 18 hours at 37°C. Following digestion, the peptides were extracted by sonication in a sonicator bath with 50 µl 50% acetonitrile, 5% TFA for 30 min. The extraction was repeated, extract solutions were pooled together and the volume was reduced to 10 µl in a Speed Vac vacuum centrifuge apparatus. The samples were automatically prepared for mass spectrometry using the MAP II (Bruker, Bremen, Germany). The instrument was programmed to perform a desalting of the sample with ZIP-TIP (C18, Millipore). The peptides were eluted from the ZIP TIP with a solution of 5 g/l of 2,5-dihydroxybenzoic acid in 50% acetonitrile/0,1% TFA and directly loaded onto the Anchorchip (400 µm, Bruker, Bremen, Germany), The samples were allowed to air dry at room temperature.

Excised spot analysis

MALDI-TOF spectra were acquired on a Bruker Biflex II MALDI-TOF (Bremen, Germany) equipped with the SCOUT 381 multiprobe ion source in a positive-ion reflector mode. The acceleration voltage was set to 19 kV and the reflector voltage was set to 20 kV. Typically about 100 laser shots were average per spectrum from a 337 nm N2 laser. Spectra were externally calibrated using a combination of angiotensin II (1,046.54 Da), substance P (1,347.74 Da), Bombensin (1,619.82 Da) and ACTH18-39 (Clip human, 2,465.20 Da). Peptides were selected in the mass range of 700-3000 Da. Resulting values for monoisotopic peaks were used for search using the software Mascot run on a database containing the genome information of *N.meningitidis* and *C.pneumoniae*. All the searches were performed using a window of 500 ppm as constraint, allowing one missed cleavage, and considering propiamide cysteines as fixed modification, and oxidized methionine as variable modification. Signals generated from keratin digestion or trypsin autolysis were not considered for the search in the database. Proteins were successfully identified when the MOWSE

score was superior to 47. When proteins were identified with an inferior Mowse score, Post Source Decay (PSD) experiments were performed to confirm the identification. PSD spectra of the parent ions were built by pasting the spectra obtain with successive reflector voltage from 20 to 0.59 V.

Within the Figure 2 gel, 261/325 spots were identified by peptide mass fingerprint. When the same protein was identified in two or more samples from a train of spots clearly arising from isoforms of the same protein, the identification was extended to cover all spots in this row. When needed, the identification of the proteins were confirmed by PSD experiments, mainly for protein with a Mr inferior to 15 kDa. The remaining 64/325 spots contained too little protein material to give an unambiguous identification. The identified 261 spots were encoded by 138 separate genes, of which 11 were confirmed by PSD experiments. An additional 18 proteins were identified from the duplicated gel.

The Figure 3 gel allowed the identification of 194 unique proteins, of which 72 were not identified from the Figure 2 gel. Similarly, the Figure 4 gel allowed the identification of 87 unique proteins of which 26 were not identified from the Figure 2 gel.

The identified proteins are listed in Table 1, with columns indicating which gel they were found in. In summary, among the 1,867 proteins spots processed, 1,433 proteins were identified. The identified spots represent 250 unique proteins. Only 8.8% of the proteins were identified from the pH 6–11 gels which confirms the difficulty of separating very basic proteins by 2DE. The identified proteins cover 11.58% of the predicted ORFs encoded by the genome [1].

Within the 250 proteins, 45 acted as positive controls, as they had previously been identified as useful vaccine/diagnostic antigens in references 108 to 110. These 45 proteins are indicated with a '+' in Table 1. The remaining 215 proteins are listed as SEQ ID NO^s 1 to 215.

Within the remaining 205 proteins, 138 completely elude the PSORT subcellular localisation algorithm [111, 112]. These 138 are marked with a '*' in Table 1, and it is particularly surprising to find these proteins in the membrane. Of these 138, 76 elude various algorithmic predictions, and this subset is marked '**'.

It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

TABLE 1

	NMB	ID (gi722xxxx): name / MW / pl	Gel (Fig.)			Note
			2	3	4	
1	0010	5235: phosphoglycerate kinase / 41902 / 5.12		X		
2	0018	5244: pilin PilE / 15 246 / 9.21	X		X	
3	0030	5249: methionyl-tRNA synthetase / 76 853 / 5.44		X		
4	0035	5255: conserved hypothetical protein / 40 218 / 4.74	X	X		+
5	0038	5258: UDP-N-acetylglucosamine pyrophosphorylase / 49 013 / 6.48	X		X	
6	0045	5266: signal recognition particle protein / 45 142 / 4.85		X		*
7	0051	5271: twitching motility protein / 45 675 / 6.51	X		X	*
8	0052	5272: twitching motility protein PilT / 38 050 /6.61	X		X	**
9	0068	5288: polysialic acid capsule biosynthesis protein SiaC / 38821 / 5.35		X		*
10	0088	5306. outer membrane protein P1, putative / 45 902 / 9.35	X		X	+
11	0089	5307: pyruvate kinase II / 52 435 / 5;27	X	X		*
12	0109	5324: conserved hypothetical protein / 43 188 / 6.77	X		X	*
13	0115	5331: nitrogen assimilation regulatory protein NtrX / 46373 / 4.98	X			**
14	0124/0139	5341-5357: translation elongation factor TU / 42 909 – 42 925/ 5.07	X	X	X	**
15	0126	5343: transcription antitermination protein NusG / 20 550 / 6.03	X	X		**
16	0128	5345: 50S ribosomal protein L1 / 24 102 / 9.59	X	X	X	*
17	0130	5347: 50S ribosomal protein L10 / 17 594 / 7.91	X	X	X	**
18	0131	5348 : 50S ribosomal protein L7/L12 / 12623 / 4.60		X		
19	0132	5349: DNA-directed RNA polymerase, beta subunit / 155 945 / 5.34	X	X	X	
20	0133	5351: DNA-directed RNA polymerase, beta' subunit / 154660 / 6.86			X	*
21	0137	5355: 30S ribosomal protein S7 / 10646 / 10.33			X	*
22	0138	5356: elongation factor G (EF-G) / 77 244 / 5.08	X	X	X	**
23	0140	5358: 30S ribosomal protein S10 / 11799 / 7.57			X	**
24	0142	5360: 50S ribosomal protein L3 / 22664 / 10.03			X	**
25	0143	5361: 50S ribosomal protein L4 / 23248 / 9.92			X	**
26	0144	5362: 50S ribosomal protein L23 / 11268 / 9.85			X	
27	0154	5372: 50S ribosomal protein L5 / 20 323/ 9.49	X	X	X	**
28	0156	5374: 30S ribosomal protein S8 / 14257 / 9.73			X	*
29	0157	5375: 50S ribosomal protein L6 / 18 892 / 9.63		X	X	*
30	0159	5377: 30s ribosomal protein S5 / 18235 / 10.04			X	*
31	0168	5386: DNA-directed RNA polymerase, alpha subunit / 36 076 / 4.94	X	X	X	**
32	0171	5389: septum site-determining protein MinD / 29 559 / 5.70	X	X		**
33	0173	5391: transcriptional regulator, LysR family /34 071 /5.74	X	X		
34	0181	5400: outer membrane protein OmpH, putative / 19261 / 9.23		X		+
35	0182	5401: outer membrane protein Omp85 / 86 254 / 8.37	X		X	+
36	0191	5411. ParA family protein / 27 150 / 5.53	X			+
37	0193	5413: glucose inhibited division protein A / 69 808 / 6.57	X		X	*
38	0196	5417: ribonuclease E / 102087 / 5.97		X	X	*
39	0212	5433: DNA gyrase subunit B / 88 188 / 5.46	X	X		*

#	ID	Description				
40	0214	5436: oligopeptidase A / 76 054 / 5.16	X	X		+
41	0219	5441: 3-oxoacyl-(acyl-carrier-protein) synthase II / 43 221 / 5.36		X		
42	0246	5468: NADH dehydrogenase I, F subunit / 48007 / 5.66		X		*
43	0278	5503. thiol:disulfide interchange protein DsbA / 23 228 / 5.16 /18	X	X	X	+
44	0286	5510: conserved hypothetical protein / 22120 / 5.04		X		*
45	0292	5516: conserved hypothetical protein / 22080 / 5.37		X		+
46	0294	5518: thiol:disulfide interchange protein DsbA / 23 566 / 5.09 lipo	X	X	X	
47	0329	5549: type IV pilus assembly protein / 61 965 / 5.42	X	X		*
48	0335	5555: 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase / 29 410 / 5.42	X	X		**
49	0336	5556: enoyl-(acyl-carrier-protein) reductase / 25 252 / 5.45 / 22		X		
50	0337	5557: branched-chain amino acid aminotransferase, putative / 36421 / 5.80		X		
51	0345	5566: cell-binding factor, putative / 31507 / 9.23			X	+
52	0351	5572: transaldolase / 37 578 / 5.09		X	.	**
53	0359	5581: glutamate--ammonia ligase / 52137 / 5.20	X	X	X	*
54	0382	5603: outer membrane protein class 4 / 23 969 / 6.26	X	X	X	
55	0387	5608:ABC transporter, ATP-binding protein /62 073 / 5.23		X	X	+
56	0390	5612: maltose phosphorylase / 85 490 / 5.36	X	X		*
57	0391	5613: beta-phosphoglucomutase / 23728 / 5.08		X		
58	0426	5649: cell division protein FtsA / 44 061 / 5,33	X	X		
59	0427	5651: cell division protein FtsZ / 41 487 / 4.94	X			
60	0446	5671: chorismate mutase/prephenate dehydratase / 39778 / 5.65		X		
61	0462	5689: spermidine/putrescine ABC transporter, periplasmic ... / 50 556 / 6.92	X	X		
62	0466	5693. aspartyl-tRNA synthetase / 68 125 / 5.28	X	X	X	**
63	0477	5705: conserved hypothetical protein / 19758 / 5.19		X		**
64	0530	5755: glycosyl hydrolase, family 3 / 39554 / 5.39		X		**
65	0537	5762: conserved hypothetical protein / 31 150 / 4.77		X		+
66	0540	5765: aspartate aminotransferase / 43 929 / 6.52	X	X	X	**
67	0546	5772: alcohol dehydrogenase, propanol-preferring /36 548 / 5.65	X	X		*
68	0550	5777: thiol:disulfide interchange protein DsbC / 26 451 / 6.93	X			+
69	0554	5780: dnaK protein / 68 792 / 4.85	X	X	X	+
70	0564	5791: Na(+)-translocating NADH-quinone reductase, subunit F / 42 303 / 4.95	X	X		
71	0569	5796: Na(+)-translocating NADH-quinone reductase, subunit A /48 636 /6.20	X	X	X	+
72	0589	5819: 50s ribosomal protein L19 / 13760 / 10.45			X	**
73	0595	5825: DNA-binding response regulator / 24 780 / 5.44	X	X		**
74	0604	5834: alcohol dehydrogenase, zinc-containing / 38394 / 5.47		X		
75	0610	5840: spermidine/putrescine ABC transporter, ATP-binding protein / 47 425 / 6.03	X	X		*
76	0617	5847: transcription termination factor Rho / 47 306 / 6.23	X		X	**
77	0618	5848:phosphoenolpyruvate synthase / 87 170 / 5.01	X	X	X	**
78	0623	5854: spermidine/putrescine ABC transporter, periplasmic ... / 39 511 / 5.38	X	X		
79	0626	5856: peptide chain release factor 3 / 59 589 / 5.43		X		+
80	0631	5861: phosphate acetyltransferase Pta, putative / 50306 / 4.83	X	X		
81	0634	5862: iron(III) ABC transporter, periplasmic binding protein / 35806 / 9.60			X	
82	0637	5866: argininosuccinate lyase /51 245 / 5,22	X	X		**

83	0641	5870: inorganic pyrophosphatase / 19 812 / 4.71		X		**
84	0663	5888: outer membrane protein NsgA / 18386 / 9.64			X	
85	0667	5893: hypothetical protein / 45 292 / 5,97 / 16	X	X		+
86	0697	5925: dimethyladenosine transferase / 29269 / 7.11			X	**
87	0703	5932 : competence lipoprotein ComL / 29 273 / 8.72	X		X	
88	0711	5938: conserved hypothetical protein / 33516 / 6.11		X		**
89	0720	5946: threonyl-tRNA synthetase / 72 692 / 5,86	X	X		*
90	0724	5951: phenylalanyl-tRNA synthetase, alpha chain / 37 334 / 5.46	X	X	X	**
91	0728	5955: phenylalanyl-tRNA synthetase, beta chain / 86 050 / 5.19	X	X		*
92	0743	5972: ubiquinone/menaquinone biosynthesis methyltransferase UbiE / 27 366 / 7.14	X		X	**
93	0757	5987: phosphoribosylaminoimidazole-succinocarboxamide synthase / 32476 / 5.26		X		**
94	0758	5988: polyribonucleotide nucleotidyltransferase / 76 422 / 5.35	X	X	X	
95	0763	5993: cysteine synthase / 32 821 / 6.06	X	X		*
96	0768	5999: twitching motility protein PilT / 41 508 / 7.64	X	X	X	+
97	0778	6009: uroporphyrin-III C-methyltransferase HemX, putative / 46 320 / 5,33	X	X		
98	0787	6019: amino acid ABC transporter, periplasmic amino acid-binding protein / 26 995 / 5.42	X	X		+
99	0791	6024 : peptidyl-prolyl cis-trans isomerase / 181853 / 5.05		X		**
100	0798	6031: cell division protein FtsH / 70 058 / 5,07 /20	X			+
101	0801	6034: delta-aminolevulinic acid dehydratase / 36878 / 5.23		X		+
102	0804	6038: NAD(P)H nitroreductase, putative / 24687 / 6.17		X		*
103	0814	6048: histidyl-tRNA synthetase / 41 746 / 5,45	X	X		**
104	0815	6050: adenylosuccinate synthetase / 46 250 / 5,77	X	X	X	*
105	0828	6063: ADP-L-glycero-D-mannoheptose-6-epimerase / 38 437 / 5,68	X	X		
106	0853	6089: conserved hypothetical protein / 23 136 / 5.67		X		+
107	0854	6090: histidyl-tRNA synthetase / 48 465 / 5.57	X	X		**
108	0875	6113: ribose-phosphate pyrophosphokinase / 35 598 /5.41	X	X		**
109	0876	6114: 50S ribosomal protein L25 / 20 956 / 6.60	X	X	X	*
110	0878	6116: threonine dehydratase / 55585 / 5.41		X		
111	0884	6122: superoxide dismutase / 21 893 / 5.78	X	X		*
112	0885	6124: replicative DNA helicase / 52 089 / 5,04	X	X		**
113	0889	6127: hypothetical protein / 21970 / 6.40		X		+
114	0894	6131: aminotransferase, class I / 44 013 / 5.79		X		**
115	0920	6158 : isocitrate dehydrogenase / 80163 / 5.57	X	X	X	*
116	0928	6166: hypothetical protein /43 815 / 9.01	X			+
117	0944	6182 . 5-methyltetrahydropteroyltriglutamate-homocysteine methyltransferase / 85 078 / 5.27	X	X		
118	0946	6184: peroxiredoxin 2 family protein/glutaredoxin / 26 912 / 4.80	X	X		*
119	0947	6186 : lipoamide dehydrogenase, putative / 44527 / 5.66	X	X		
120	0950	6189: succinate dehydrogenase, flavoprotein subunit / 66 787 / 5,84	X	X		+
121	0955	6194: 2-oxoglutarate dehydrogenase, E1 component / 105 082 / 6.24	X	X	X	
122	0956	6195: 2-oxoglutarate dehydrogenase, E2, dihydrolipoamide succinyltransferase / 41491 / 5.14		X		
123	0959	6199: succinyl-CoA synthetase, beta subunit / 41666 / 5.06		X		
124	0960	6200: succinyl-CoA synthetase, alpha subunit /30 548 / 6.00	X	X		
125	0983	6223 : phosphoribosylaminoimidazolecarboxamide formyltransferase .../ 56 803 / 5.90		X		

126	0997	6237: D-lactate dehydrogenase / 64001 / 6.32			X	
127	1031	6270 : 3-isopropylmalate dehydrogenase / 39172 / 4.91		X		**
128	1044	6284: ferredoxin--NADP reductase / 29 314 / 5.72	X	X		*
129	1046	6286: threonine synthase / 51870 / 5.31		X		*
130	1053	6294: class 5 outer membrane protein / 28 009 / 9.68 / 20	X	X	X	
131	1057	6297: gamma-glutamyltranspeptidase /65 071 / 5.99	X	X		+
132	1070	6309: 2-isopropylmalate synthase / 55 397 / 5.68		X		**
133	1073	6313: conserved hypothetical protein / 42 032 / 4.60		X		**
134	1127	6364: oxidoreductase, short chain dehydrogenase/reductase family / 25 917 / 5.99	X	X		**
135	1131	6368: chaperone protein HscA / 66166 / 5.18		X		**
136	1150	6387: dihydroxy-acid dehydratase / 64 503 / 5,89	X	X		*
137	1164/1126	6400-6362: hypothetical protein / 22 025 / 8.03 (duplicated gene)	X		X	+
138	1199	6435: GTP binding protein / 67 260 / 5.04	X	X		+
139	1201	6438: IMP dehydrogenase / 53 383 / 6.72	X			*
140	1206	6443: bacterioferritin B / 18075 / 4.60		X		**
141	1228	6467: homoserine dehydrogenase / 44 737 / 5.254 / 20	X	X		
142	1231	6470: ATP-dependent protease La / 90590 / 6.18		X	X	*
143	1238	6478: peptidyl-prolyl cis-trans isomerase-related protein / 53213 / 5.68	X	X		+
144	1240	6480: ABC transporter, ATP-binding protein / 60 779 / 5.09	X	X		**
145	1252	6492: phosphoribosylformylglycinamidine cyclo-ligase / 36 974 / 4.71	X			**
146	1285	6525: enolase / 46 134 / 4,78	X	X		+
147	1301	6541: 30S ribosomal protein / 61 177 / 4.9	X	X	X	*
148	1302	6542: integration host factor, beta subunit / 11796 / 9.98			X	**
149	1313	6554: trigger factor / 48 325 / 4.72	X	X		**
150	1320	6562: 50S ribosomal protein L9 / 15 747 / 6.62	X	X	X	
151	1323	6565: 30S ribosomal protein S6 / 13 949 / 6.37	X	X	X	**
152	1324	6566: thioredoxin reductase / 33961 / 5.16		X		
153	1328	6571: conserved hypothetical protein / 27021 / 6.41			X	*
154	1339	6583:prolyl-tRNA synthetase / 62 992 / 5.09	X	X	X	**
155	1341	6585:pyruvate dehydrogenase, E1 component / 99 562 / 5.5	X	X	X	**
156	1342	6586 : pyruvate dehydrogenase, E2, dihydrolipoamide acetyltransferase / 55 223 / 5,29	X	X		*
157	1343	6587: hypothetical protein / 16 339 / 4.99	X			**
158	1344	6588: pyruvate dehydrogenase, E3 component, lipoamide dehydrogenase / 62358 / 5.07		X		
159	1345	6590: hypothetical protein / 57 143 / 5.13		X		+
160	1347	6591: extragenic suppressor protein SuhB / 28 469 / 5,82	X	X		*
161	1356	6601: Glu-tRNA(Gln)amidotransferase, subunit A / 51 280 / 5,44	X			*
162	1358	6603: Glu-tRNA(Gln) amidotransferase, subunit B / 51 912 / 5,05	X	X		**
163	1372	6618:ATP-dependent Clp protease, ATP-binding subunit ClpX / 45 100 / 5.18		X		*
164	1379	7413462: nifS protein / 44832 / 5.62		X		**
165	1390	6628: glucokinase / 34 951 / 8.59	X		X	
166	1392	6630: glucose-6-phosphate 1-dehydrogenase / 54124 / 5.30	X	X	X	**
167	1425	6664: lysyl-tRNA synthetase, heat inducible / 57312 / 5.34	X	X		**
168	1429	6669: outer membrane protein PorA / 40 129 / 8.73	X	X	X	

169	1445	6686: recA protein / 37 612 / 5.18		X		*
170	1452	6693: conserved hypothetical protein / 40 598 / 8.33	X			*
171	1457	6698: transketolase / 71 659 / 5.45	X	X	X	*
172	1471	6711: tryptophanyl-tRNA synthetase / 37 616 / 5.65	X	X		*
173	1472	6713: clpB protein / 95 195 / 5.41		X		**
174	1483	6723: lipoprotein NlpD, putative / 42991 / 9.55			X	+
175	1506	6749: arginyl-tRNA synthetase / 62 803 / 5.24		X		
176	1518	6762: acetate kinase / 42 410 / 5.76	X	X		
177	1533	6778. H.8 outer membrane protein / 16 886 / 4.61 /17	X	X		
178	1536	6781: preprotein translocase SecA subunit / 103 295 / 5.05	X	X		*
179	1560	6807: glutaminyl-tRNA synthetase / 64 650 / 57.74	X	X		**
180	1567	6815: macrophage infectivity potentiator / 26 875 / 5.50	X	X		+
181	1572	6819: aconitate hydratase 2 / 92 716 7 5.42	X	X		
182	1574	6822: ketol-acid reductoisomerase / 36 439 / 5.65	X	X		**
183	1577	6825: acetolactate synthase III, large subunit / 62 813 / 5.88	X	X		
184	1581	6829: histidinol dehydrogenase / 46324 / 5.07	X	X		
185	1583	6831: imidazoleglycerol-phosphate dehydratase / 34002 / 8.61			X	**
186	1584	6833:3-hydroxyacid-dehydrogenase / 30 378 / 5.33		X		+
187	1594	6843: spermidine/putrescine ABC transporter, periplasmic .../ 40 234 / 5.52	X	X		+
188	1595	6845:alanyl-tRNA synthetase / 96 038/ 5.54	X		X	**
189	1604	6853: phosphoglycerate mutase / 25 959 / 5.59	X	X		**
190	1612	6862 : amino acid ABC transporter, periplasmic amino acid-binding protein / 27 68 / 4.87	X	X		+
191	1613	6863: fumarate hydratase, class I / 54 951 / 5,12	X	X		+
192	1621	6872: glutathione peroxidase / 20129 / 5.18		X		**
193	1636	gi 7443356 opacity protein, authentic frameshift / 27180 / 9.52			X	
194	1640	6890: phosphoserine aminotransferase / 41651 / 5.20		X		*
195	1642	6892: N utilization substance protein A / 55 752 / 4.54	X	X		**
196	1655	6907: adenine specific methylase, putative / 33 956 / 4,36	X			*
197	1684	6938: seryl-tRNA synthetase / 47 883 / 5.60	X			**
198	1691	6945: dihydropteroate synthase / 30 313 / 5.30		X		
199	1710	6965: glutamate dehydrogenase, NADP-specific / 48 490 / 5.98	X	X		**
200	1714	6969. multidrug efflux pump channel protein / 48 482 / 8.38 / lipo	X		X	+
201	1716	6971: membrane fusion protein / 40 209 / 8.60	X		X	
202	1796	7050: conserved hypothetical protein/ 20 931 / 5.73	X	X		
203	1809	—: putative; pilN protein,authentic frameshift / 22 258 / 9.00	X			
204	1810	7063: pilO protein / 19 870 / 4.74		X		
205	1811	7064: pilP protein / 20126 / 4.94		X		
206	1812	—.putative, pilQ protein, authentic frameshift / 83 151 / 10.75 / 25	X	X	X	
207	1835	7090: tyrosyl-tRNA synthetase / 47437 / 5.76		X		*
208	1838	7093: GTP-binding protein, putative / 39 376 / 4,80	X	X		**
209	1839	7094: formate--tetrahydrofolate ligase / 59063 / 5.85	X	X		+
210	1843	7099: transcriptional regulator, MarR family / 16 583 / 5.15		X		**
211	1849	7105: carbamoyl-phosphate synthase, small subunit / 40 587 / 5.54	X	X		

212	1854	7110: hypothetical protein / 25 131 / 8.95	X		X	**
213	1855	7111: carbamoyl-phosphate synthase, large subunit / 117 377 / 5.10	X	X		
214	1856	7112: transcriptional regulator, LysR family / 33367 / 5.55		X		+
215	1859	7116: S-adenosylmethionine:tRNA ribosyltransferase-isomerase / 38216 / 6.20		X		*
216	1861	7118: acetyl-CoA carboxylase, biotin carboxylase / 49 599 / 5,88	X	X	X	**
217	1862	7119: ribosomal protein L11 methyltransferase / 32144 / 4.36		X		
218	1864	7121:glutamate-1-semialdehyde 2,1-aminomutase / 45 315 / 5.33		X		*
219	1869	7127: fructose-bisphosphate aldolase / 38 337 / 5.48	X	X	X	+
220	1870	7128: hypothetical protein / 26 964 / 7.23	X		X	+
221	1903	7160: chromosomal replication initiator protein DnaA / 58 029 / 5.93		X		**
222	1920	7178: GMP synthase / 57686 / 5.53	X	X		
223	1921	7179: 3-oxoacyl-(acyl-carrier-protein) reductase / 26 068 / 5.95	X	X	X	*
224	1930	7187: glycyl-tRNA synthetase, beta chain / 74 574 / 5,86	X	X		
225	1934	7192: ATP synthase F1, beta subunit / 50 391 / 5.01	X	X	X	
226	1936	7194: ATP synthase F1, alpha subunit / 55 291 / 5.43	X	X	X	*
227	1937	7195: ATP synthase F1, delta subunit / 19 526 / 5.02		X		**
228	1938	7196: ATP synthase F0, B subunit / 17128 / 5.64		X		
229	1946	7205: outer membrane lipoprotein / 29 258 / 5.01	X	X	X	+
230	1953	7212: stringent starvation protein A / 23 165 / 6.23	X	X	X	**
231	1966	7226 :ABC transporter, ATP-binding protein / 29 286 / 5.58		X		*
232	1968	7228: aldehyde dehydrogenase A / 52257 / 5.20	X	X		
233	1972	7233: chaperonin, 60 kDa / 57 423 / 4.9	X	X	X	+
234	1982	7243: DNA polymerase I /103 184 / 5.21		X		*
235	1996	7259: phosphoribosylformylglycinamidine synthase / 143 854 / 5.31	X	X		*
236	2000	7264: conserved hypothetical protein / 33468 / 4.77		X		**
237	2039	7300 : major outer membrane protein PIB / 33 786 / 6.54	X	X	X	
238	2057	7319: 50S ribosomal protein L13 / 16212 / 9.72			X	**
239	2079	7341: aspartate-semialdehyde dehydrogenase / 39 858 / 5.40		X		*
240	2086	7348: GTP-binding protein / 41 930 / 5.52		X		*
241	2091	7353: hemolysin, putative / 21804 / 9.81			X	+
242	2096	7359: malate:quinone oxidoreductase / 53 9687 / 5.51	X	X		+
243	2101	7364: 30S ribosomal protein S2 / 26 899 / 9.04	X			**
244	2102	7365. elongation factor TS (EF-TS) / 30 330 / 5.30	X	X		**
245	2103	7366: uridylate kinase / 25896 / 6.17			X	*
246	2129	7385: argininosuccinate synthase / 49 664 / 5.18	X	X		*
247	2138	7395: peptide chain release factor 2 / 41 487 / 5.18	X			**
248	2154	7412: electron transfer flavoprotein, alpha subunit / 32 579 / 4.99		X		*
249	2155	7413. electron transfer flavoprotein, beta subunit / 26 948 / 6.08	X	X	X	**
250	2159	7417: glyceraldehyde 3-phosphate dehydrogenase / 35 845 / 5.40	X	X		*
			156	194	87	

REFERENCES (the contents of which are hereby incorporated in full)

[1] Tettelin *et al.* (2000) *Science* 287:1809-1815.

[2] Pizza *et al.* (2000) *Science* 287:1816-1820.

[3] Parkhill *et al.* (2000) *Nature* 404:502-506.

[4] Cole (2002) *Eur Respir J Suppl.* 36:78s-86s.

[5] McClelland *et al.* (2001) *Nature* 413:852-856.

[6] De Groot *et al.* (20001) *Vaccine* 19:4385-4395.

[7] Stephens (2000) *J Infect Dis* 181 Suppl 3:S521-523.

[8] Tettelin *et al.* (2001) *Science* 293:498-506.

[9] Weinstock *et al.* (2000) *Res Microbiol* 151:151-158.

[10] Wizemann *et al.* (2001) *Infect Immun* 69:1593-1598.

[11] Grifantini *et al.* (2002) *Nat Biotechnol.* 20:914-921.

[12] *http://www.ncbi.nlm.nih.gov/entrez*

[13] WO01/64922.

[14] WO01/64920.

[15] PCT/IB02/03904.

[16] Gennaro (2000) *Remington: The Science and Practice of Pharmacy.* 20th edition, ISBN: 0683306472.

[17] *Vaccine design: the subunit and adjuvant approach,* eds. Powell & Newman, Plenum Press 1995 (ISBN 0-306-44867-X).

[18] WO90/14837.

[19] WO02/26212.

[20] WO98/33487.

[21] WO00/07621.

[22] WO99/27960.

[23] WO98/57659.

[24] European patent applications 0835318, 0735898 and 0761231.

[25] Krieg (2000) *Vaccine* 19:618-622; Krieg (2001) *Curr opin Mol Ther* 2001 3:15-24; WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581 *etc.*

[26] WO99/52549.

[27] WO01/21207.

[28] WO01/21152.

[29] WO00/62800.

[30] WO00/23105.

[31] WO99/11241.

[32] Del Giudice *et al.* (1998) *Molecular Aspects of Medicine,* vol. 19, number 1.

[33] *Vaccine Design...* (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.

[34] Covacci & Rappuoli (2000) *J. Exp. Med.* 19:587-592.

[35] WO93/18150.

[36] Covacci *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 5791-5795.

[37] Tummuru *et al.* (1994) *Infect. Immun.* 61:1799-1809.

[38] Marchetti *et al.* (1998) *Vaccine* 16:33-37.

[39] Telford *et al.* (1994) *J. Exp. Med.* 179:1653-1658.

[40] Evans *et al.* (1995) *Gene* 153:123-127.

[41] WO96/01272 & WO96/01273, especially SEQ ID NO:6.

[42] WO97/25429.

[43] WO98/04702.

[44] Costantino *et al.* (1992) *Vaccine* 10:691-698.

[45] Costantino *et al.* (1999) *Vaccine* 17:1251-1263.

[46] International patent application PCT/IB02/03191.

[47] Watson (2000) *Pediatr Infect Dis J* 19:331-332.

[48] Rubin (2000) *Pediatr Clin North Am* 47:269-285, v.

[49] Jedrzejas (2001) *Microbiol Mol Biol Rev* 65:187-207.

[50] Bell (2000) *Pediatr Infect Dis J* 19:1187-1188.

[51] Iwarson (1995) *APMIS* 103:321-326.

[52] Gerlich *et al.* (1990) *Vaccine* 8 Suppl:S63-68 & 79-80.

[53] Gustafsson *et al.* (1996) *N. Engl. J. Med.* 334:349-355.

[54] Rappuoli *et al.* (1991) *TIBTECH* 9:232-238.

[55] *Vaccines* (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.

[56] Del Guidice *et al.* (1998) *Molecular Aspects of Medicine* 19:1-70.

[57] Hsu *et al.* (1999) *Clin Liver Dis* 3:901-915.

[58] International patent application WO99/24578.

[59] International patent application WO99/36544.

[60] International patent application WO99/57280.

[61] International patent application PCT/IB02/02069.

[62] International patent application WO02/02606.

[63] Kalman *et al.* (1999) *Nature Genetics* 21:385-389.

[64] Read *et al.* (2000) *Nucleic Acids Res* 28:1397-406.

[65] Shirai *et al.* (2000) *J. Infect. Dis.* 181(Suppl 3):S524-S527.

[66] International patent application WO99/27105.

[67] International patent application WO00/27994.

[68] International patent application WO00/37494.

[69] International patent application WO99/28475.

[70] Ross *et al.* (2001) *Vaccine* 19:4135-4142.

[71] Sutter *et al.* (2000) *Pediatr Clin North Am* 47:287-308.

[72] Zimmerman & Spann (1999) *Am Fam Physician* 59:113-118, 125-126.

[73] Dreesen (1997) *Vaccine* 15 Suppl:S2-6.

[74] *MMWR Morb Mortal Wkly Rep* 1998 Jan 16;47(1):12, 19.

[75] *Vaccines* (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.

[76] McMichael (2000) *Vaccine* 19 Suppl 1:S101-107.

[77] Schuchat (1999) *Lancet* 353(9146):51-6.

[78] International patent application WO02/34771.

[79] Dale (1999) *Infect Dis Clin North Am* 13:227-43, viii.

[80] Ferretti *et al.* (2001) *PNAS USA* 98: 4658-4663.

[81] Kuroda *et al.* (2001) *Lancet* 357(9264):1225-1240; see also pages 1218-1219.

[82] *J Toxicol Clin Toxicol* (2001) 39:85-100.

[83] Demicheli *et al.* (1998) *Vaccine* 16:880-884.

[84] Stepanov *et al.* (1996) *J Biotechnol* 44:155-160.

[85] Ingram (2001) *Trends Neurosci* 24:305-307.

[86] Rosenberg (2001) *Nature* 411:380-384.

[87] Moingeon (2001) *Vaccine* 19:1305-1326.

[88] EP-A-0372501

[89] EP-A-0378881

[90] EP-A-0427347

[91] WO93/17712

[92] WO94/03208

[93] WO98/58668

[94] EP-A-0471177

[95] WO00/56360

[96] WO91/01146

[97] WO00/61761

[98] WO01/72337

[99] *Research Disclosure*, 453077 (Jan 2002)

[100] Molloy *et al.* (2000) *Eur J Biochem* 267(10):2871-81

[101] Molloy *et al.* (2001) *Electrophoresis* 22(9):1686-96

[102] Phadke *et al.* (2001) *Proteomics* 1(5):705-20.

[103] Nouwens *et al.* (2000) *Electrophoresis* 21(17):3797-809.

[104] Chevallet *et al.* (1998) *Electrophoresis* 19(11):1901-9.

[105] Herbert *et al.* (1998) *Electrophoresis* 19(5):845-51.

[106] Doherty *et al.* (1998) *Electrophoresis* 19(2):355-63.

[107] Wilm *et al.* (1996) *Nature* 379(6564):466-9.

[108] WO99/24578.

[109] WO99/36544.

[110] WO99/57280.

[111] Nakai & Kanehisa *Proteins* 11(2):95-110

[112] Nakai (2000) *Adv Protein Chem* 54:277-344.

SEQUENCE LISTING

SEQ ID	NMB	Sequence
1	10	MAFLKLTEQNVQGKTVLIRADMNVPFKDGKISDDTRIRASLASIKYCVDNGASVIVMTHLGRPTEGEFHPEDDVAP VAAHLGSLLGKDVKVLNDWRENKPALNAGDVVMLQNVRINKGEKKNDLELGKAYASLCDVFVNDAFGTAHRAQAST EAVAQAAPVACAGVLMAGELDALGKALKQPARPMVAIVAGSKVSTKLTILESLADKVDQLIVGGGIANTFLLAEGK AIGKSLAEHDLVEESKKIMAKMAAKGGSVPLPTDVVVAKAFAADAEAVVKDIAADAEAVVKDIADVAEDEMILDIG PKSAAALADLLKAAGTVVWNGPVGVFEFDQFAGGTKALAEAIAQSKAFSIAGGGDTLAAIAKFGVTEQIGYISTGG GAFLEFLEGKELPAVAALEKRGA
2	18	MNTLQKGFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQKSAVTEYYLNHGEWPGNNTSAGVATS SEIKGKYVKSVEVKNGVVTAQMASSNVNNEIKGKKLSLWAKRQNGSVKWFCGQPVTRDKAKAANDDVTAAAAANGK KIDTKHLPSTCRDASDAS
3	30	MTRKILVTSALPYANGSIHLGHMVEHIQTDVWVRFQKLRGHACHYCCADDTHGTPVMLAAQKQGIAPEDMIAKVRE EHLADFTGFFIGYDNYYSTHSPENKQFSQDIYRALKANGKIESRVIEQLFDPEKQMFLPDRFVKGECPKCHAQDQY GDNCEVCGTTYSPTELINPYSAVSGTKPELRESEHFFFKLGECADFLKAWTSGNNPHDGKPHLQAEALNKMKEWLG EGEETTLSDWDISRDAPYFGFEIPDAPGKYFYVWLDAPVGYMASFKNLCDRIGVDFDEYFKADSQTEMYHFIGKDI LYFHALFWPAMLHFSGHRAPTGVYAHGFLTVDGQKMSKSRGTFITAKSYLEQGLNPEWMRYYIAAKLNSKIEDIDL NLQDFISRVNSDLVGKYVNIAARASGFIAKRFEGRLKDVADSELLAKLTAQSEAIAECYESREYAKALRDIMALAD IVNEYVDANKPWELAKQEGQDERLHEVCSELINAFTMLTAYLAPVLPQTAANAAKFLNLEAITWANTRDTLGKHAI NKYEHLMQRVEQKQVDDLIEANKQSIAAAAAPAAEEGKYEKVAEQASFDDFMKIDMRVAKVLNCEAVEGSTKLLKF DLDFGFEKRIIFSGIAASYPNPAELNGRMVIAVANFAPRKMAKFGVSEGMILSAATADGKLKLLDVDTGAQPGDKV G
4	38	MPQNTLNIVILAAGKGTRMYSKMPKVLHRIGGKPMVGRVIDTAAALNPQNICVVIGHGKEQVLDTVKRDVVWVEQT EQLGTGHAVKTALPHLSAEGRTLVLYGDVPLIDVETLETLLEAAGNEVGLLTDVPNDPTGLGRIIRDSNGSVTAIV EEKDADAVQKAVKEINTGILVLPNAKLENWLNSLSSNNAQGEYYLTDLIAKAVADGIKVHPVQVRASHLAAGVNNK LQLTELERIFQTEQAQELLKAGVTLRDPARFDLRGRLKHGQDVVIDVNCIFEGDIELGDNVEIGANCVIKNAKIGA NSKIAPFSHLESCEVGENNRIGPYARLRPQARLADDVHVGNFVEIKNAAIGKGTKANHLTYIGDAEVGCKTNFGAG TIIANYDGVHKHKTVIGDEVRIGSNCVLVAPVTLGNKVTTGAGSTITRNVEDNKLALARARQTVIEGWVRPEKDKQ
5	45	MFSFFRRKKKQETPALEEAQIQETAAKAESELAQIVENIKEDAESLAESVKGQVESAVETVSGAVEQVKETVAEML SEAEEAAEKAAEQVEAAKEAVAETVGEAVGQVQEAVATTEEHKLGWAARLKQGLTKSRDKMAKSLAGVFGGGQIDE DLYEELETVLITSDMGMEATEYLMKDVRDRVSLKGLKDGNELRGALKEALYDLIKPLEKPLVLPETKEPFVIMLAG INGAGKTTSIGKLAKYFQAQGKSVLLAAGDTFRAAAREQLQAWGERNNVTVISQTTGDSAAVCFDAVQAAKARGID IVLADTAGRLPTQLHLMEEIKKVKRVLQKAMPDAPHEIIVVLDANIGQNAVNQVKAFDDALGLTGLIVTKLDGTAK GGILAALASDRPVPVRYIGVGEGIDDLRPFDARAFVDALLD
6	51	MNTDNLHDILDEMVQVYSQKKQSRSETPAEIGAHFHPLLDRLCETAEAQNASDILISKGFPPSLKINSALTPQPQK ALTGEETAAIAASTMNAEQSEIFRRDGEINYSVQSRSGTRYRANAYHSQGSAGLVLRRINHVIPQMQELGLPEKLK DLAVAPRGLLIIVGPTGSGKSTTMATMLEHRNKTLPSHIVTIEDPIEFIYKPRRCIFTQREIGVDTINWQTAVQNA MRQSPDVVCIGEVRSRESMEYAMQLAQTGHLCIFTLHANTAPQSLERILNFYPKEQHNQILIDIALNLTGIICQRL ALKQDKTGRTAVVDLLINTPAIQDFILKGDLMNISKIMETAKTDGMQTMDQNLFELYRHGIISYEEALRQSVSANN LRLHIQLHKEGKTPELLYDRVNGLNLIS
7	52	MQITDLLAFGAKNKASDLHLSSGISPMIRVHGDMRRINLPEMSAEEVGNMVTSVMNDHQRKIYQQNLEVDFSFELP NVARFRVNAFNIGRGPAAVFRTIPSTVLSLEELKAPSIFQKIAESPRGMVLVTGPTGSGKSTTLAAMINYINETQP AHILTIEDPIEFVHQSKKSLINQRELHQHTLSFANALRSALREDPDVILVGEMRDPETIGLALTAAETGHLVFGTL HTTGAAKTVDRIVDVFPAGEKEMVRSMLSESLTAVISQNLLKTHDGNGRVASHEILIANPAVRNLIRENKITQINS VLQTGQASGMQTMDQSLQSLVRQGLIAPEVARRRAQNSESMSF
8	68	MQNNNEFKIGNRSVGYNHEPLIICEIGINHEGSLKTAFEMVDAAYNAGAEVVKHQTHIVEDEMSDEAKQVIPGNAD VSIYEIMERCALNEEDEIKLKEYVESKGMIFISTPFSRAAALRLQRMDIPAYKIGSGECNNYPLIKLVASFGKPII LSTGMNSIESIKKSVEIIREAGVPYALLHCTNIYPTPYEDVRLGGMNDLSEAFPDAIIGLSDHTLDNYACLGAVAL GGSILERHFTDRMDRPGPDIVCSMNPDTFKELKQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADKDIKKGEL LSGDNLWVKRPGNGDFSVNEYETLFGKVAACNIRKGAQIKKTDIE
9	89	MNQTSRDLTRISHNTKIVATLGPGSNNVELLEDMIRVGGLNVVRFNFSHGTPEFHQENALIVREAAKRAGQEIAII ADLQGPKIRVGKIAGGGIELNKGETLVLDAALEGEGTREAVGLDYRDLPDDVAAGDVLWLDDGLLTLTVESVEGSR IITRVENSHVLKSNKGINKRGGGLSAGALTEKDFRDLKTAIAIGCDYLAISFVKSAEDLHIARAKVEEEMKGSTAV RPGLVSKIERVEAIENLDEIILAGDGIMVARGDLAVEVGHAAVPALQKRMIRRARELRRFSITATQMMESMITNPV PTRAEVSDVANAVLDGTDAVMCSAETAVGAYPFETVSQMAIICAAAEKEQDSLNGVAEQVEYPEAVSTNLAVAGGA VSVARAVHAKAIVALTESGSTAFEISRHNITLPIFALTPSVSAQRRMAMYRGVRPLILATSTDHDTALNEVETMLV EHNILHSGDQYIITSGSQMRESGSTNTLEVLRVK
10	109	MLKCGTFFITRHIPRGCRRFFQPNQARQTEIYQIRGTVMQRRIITLLCAAGMAFSTQTLAANLEVRPNAPERYTVK QGDTLWGISGKYLYSPWQWGRLWDANRDQIHNPDLIYPDQVLVLRHVDGEPRLGLEQTDGIPVVKMSPDKEVSGYG IPAIDVNFYRIFMRHPQIVSRKETAAAPRLLSGPEGRLLYTKGTRVYTKGLKEPGRYLTYRINKNITDPDTGKFLG QEVAFSGIVRSLDYTDSVLEQRSKQAGERPKDNEYHTRTHPLITPLRTPSIQPLVVETAISEIQQGDYLMKMPEDT

		DRFNMMPHEPSRPVQAKIVSVFEGTRIAGQFQTITIDKGEADGLDKGTVLSLYKRKKTMQVDLSNNFKSRDTVELI STPAEEVGLAMVYRTSEHLSSAIILENISDISVGDTAANPGRDLDNIPDQGRSRVKFGFNRSE
11	115	MRSSDILIVDDEIGIRDLLSEILQDEGYSVALAENAEEARKLRHQARPAMVLLDIWMPDCDGITLLKEWAKNGQLN MPVVMMSGHASIDTAVEATKIGAIDFLEKPISLQKLLSAVENALKYGAAQTETGPVFDKLGNSAAIQEMNREVGAA VKCASPVLLTGEAGSPFETVARYFHKNGTPWVSPARVEYLIDMPMELLQKAEGGVLYVGDIAQYSRNIQAGIAFIV GKAEHRRVRVVASGSRAAGSDGIACEEKLAELLSESVVRIPPLRMQHEDIPFLIQGIACNVAESQKIAPASFSEEA LAALTRYDWPGNFDQLQSVVATLLLEADGQEIGAGAVSSLLGQNVPAEGAEDMVGGFNFNLPLRELREEVERRYFE YHIAQEGQNMSQVAQKVGLERTHLYRKLKQLGIGVSRRAGEKTEE
12	124	MAKEKFERSKPHVNVGTIGHVDHGKTTLTAALTTILAKKFGGAAKAYDQIDNAPEEKARGITINTSHVEYETETRH YAHVDCPGHADYVKNMITGAAQMDGAILVCSAADGPMPQTREHILLARQVGVPYIIVFMNKCDMVDDAELLELVEM EIRDLLSSYDFPGDDCPIVQGSALKALEGDAAYEEKIFELAAALDSYIPTPERAVDKPFLLPIEDVFSISGRGTVV TGRVERGIIHVGDEIEIVGLKETQKTTCTGVEMFRKLLDEGQAGDNVGVLLRGTKREDVERGQVLAKPGTITPHTK FKAEVYVLSKEEGGRHTPFFANYRPQFYFRTTDVTGAVTLEEGVEMVMPGENVTITVELIAPIAMEEGLRFAIREG GRTVGAGVVSSVIA
13	126	MSKKWYVVQAYSGFEKNVQRILEERIAREEMGDYFGQILVPVEKVVDIRNGRKTISERKSYPGYVLVEMEMTDDSW HLVKSTPRVSGFIGGRANRPTPISQREAEIILQQVQTGIEKPKPKVEFEVGQQVRVNEGPFADFNGVVEEVNYERN KLRVSVQIFGRETPVELEFSQVEKIN
14	128	MAKVSKRLKALRSSVEANKLYAIDEAIALVKKAATAKFDESVDVSFNLGVDPRKSDQVIRGSVVLPKGTGKITRVA VFTQGANAEAAKEAGADIVGFEDLAAEIKAGNLNFDVVIASPDAMRIVGQLGTILGPRGLMPNPKVGTVTPNVAEA VKNAKAGQVQYRTDKAGIVHATIGRASFAEADLKENFDALLDAIVKAKPAAAKGQYLKKVAVSSTMGLGIRVDTSS VNN
15	130	MSLNIETKKVAVEEISAAIANAQTLVVAEYRGISVSSMTELRANARKEGVYLRVLKNTLARRAVQGTSFAELADQM VGPLVYAASEDAVAAAKVLHQFAKKDDKIVVKAGSYNGEVMNAAQVAELASIPSREELLSKLLFVMQAPVSGFARG LAALAEKKAGEEAA
16	131	MAITKEDILEAVGSLTVMELNDLVKAFEEKFGVSAAAVAVAGPAGAGAADAEEKTEFDVVLASAGDQKVGVIKVVR AITGLGLKEAKDIVDGAPKTIKEGVSKAEAEDIQKQLEEAGAKVEIK
17	132	MCMNYSFTEKKRIRKSFAKRENVLEVPFLLATQIDSYAKFLQLENAFDKRTDDGLQAAFNSIFPTVSHNGYARLEF VHYTLGEPLFDIPECQLRGITYAAPLRARIRLVILDKEASKPTVKEVRENEVYMGEIPLMTPSGSFVINGTERVIV SQLHRSPGVFFEHDKGKTHSSGKLLFSARIIPYRGSWLDFEFDPKDLLYFRIDRRRKMPVTILLKALGYNNEQILD IFYDKETFYLSSNGVQTDLVADRLKGETAKVDILDKEGNVLVAKGKRITAKNIRDITNAGLTRLDVEPESLLGKAL AADLIDSETGEVLASANDEITEELLAKFDINGVKEITTLYINELDQGAYISNTLRTDETAGRQAARVAIYRMMRPG EPPTEEAVEQLFNRLFFSEDSYDLSRVGRMKFNTRTYEQKLSEAQQNSWYGRLLNETFAGAADKGGYVLSVEDIVA SIATLVELRNGHGEVDDIDHLGNRRVRSVGELTENQFRSGLARVERAVKERLNQAESENLMPHDLINAKPVSAAIK EFFGSSQLSQFMDQTNPLSEVTHKRRVSALGPGGLTRERAGFEVRDVHPTHYGRVCPIETPEGPNIGLINSLSVYA RTNDYGFLETPYRRVIDGKVTEEIDYLSAIEEGRYVIAQANADLDSDGNLIGDLVTCREKGETIMATPDRVQYMDV ATGQVVSVAASLIPFLEHDDANRALMGANMQRQAVPCLRPEKPMVGTGIERSVAVDSATAIVARRGGVVEYVDANR VVIRVHDDEATAGEVGVDIYNLVKFTRSNQSTNINQRPAVKAGDVLQRGDLVADGASTDFGELALGQNMTIAFMPW NGYNYEDSILISEKVAADDRYTSIHIEELNVVARDTKLGAEDITRDIPNLSERMQNRLDESGIVYIGAEVEAGDVL VGKVTPKGETQLTPEEKLLRAIFGEKASDVKDTSLRMPTGMSGTVIDVQVFTREGIQRDKRAQSIIDSELKRYRLD LNDQLRIFDNDAFDRIERMIVGQKANGGPMKLAKGSEITTEYLAGLPSRHDWFDIRLTDEDLAKQLELIKVSLQQK REEADELYEIKKKKLTQGDELQPGVQKMVKVFIAIKRRLQAGDKMAGRHGNKGVVSRILPVEDMPYMADGRPVDIV LNPLGVPSRMNIGQILEVHLGWAAKGIGERIDRMLKEQRKAGELREFLNRLYNGSGKKEDLDALTDEEIIELASNL RKGASFASPVFDGAKESEIREMLNLAYPSDDPEVEKLGFNDSKTQITLYDGRSGEAFDRKVTVGVMHYLKLHHLVD EKMHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEMLTVKSDDVNGRTKMYENIVKGEHKID AGMPESFNVLVKEIRSLGLDIDLERY
18	133	MNLLNLFNPLQTAGMEEEFDAIKIGIASPETIRSWSYGEVKKPETINYRTFKPERDGLFCAKIFGPVKDYECLCGK YKRLKFKGVTCEKCGVEVTLSKVRRERMGHIELAAPVAHIWFLKSLPSRLGMVLDMTLRDIERVLYFEAFVVTDPG MTPLQRRQLLTEDDYYNKLDEYGDDFDAKMGAEGIRELLRTLNVAGEIEILRQELESTGSDTKIKKIAKRLKVLEA FHRSGMKLEWMIMDVLPVLPPDLRPLVPLDGGRFATSDLNDLYRRVINRNNRLKRLLELHAPDIIVRNEKRMLQEA VDSLLDNGRRGKAMTGANKRPLKSLADMIKGKGGRFRQNLLGKRVDYSGRSVITVGPYLRLHQCGLPKKMALELFK PFIFHKLEKQGLASTVKAAKKLVEQEVPEVWDILEEVIREHPIMLNRAPTLHRLGIQAFEPILIEGKAIQLHPLVC AAFNADFDGDQMAVHVPLSLEAQMEARTLMLASNNVLSPANGEPIIVPSQDIVLGLYYMTRDRINAKGEGSLFADV KEVHRAYHTKQVELGTKITVRLREWVKNEAGEFEPVVNRYETTVGRALLSEILPKGLPFEYVNKALKKKEISKLIN ASFRLCGLRDTVIFADHLMYTGFGFAAKGGISIAVDDMEIPKEKAALLAEANAEVKEIEDQYRQGLVTNGERYNKV VDIWGRAGDKIAKAMMDNLSKQKVIDRAGNEVDQESFNSIYMMADSGARGSAAQIKQLSGMRGLMAKPDGSIIETP ITSNFREGLTVLQYFIATHGARKGLADTALKTANSGYLTRRLVDVTQDLVVVEDDCGTSDGFVMKAVVQGGDVIEA LRDRILGRVTASDVVDPSSGETLVEAGTLLTEKLVDMIDQSGVDEVKVRTPITCKTRHGLCAHCYGRDLARGKLVN AGEAVGVIAAQSIGEPGTQLTMRTFHIGGAASRAAAASQVEAKSNGTARFSSQMRYVANNKGELVVIGRSCEVVIH DDIGRERERHKVPYGAILLVQDGMAIKAGQTLATWDPHTRPMITEHAGMVKFENVEEGVTVAKQTDDVTGLSTLVV IDGKRRSSSASKLLRPTVKLLDENGVEICIPGTSTPVSMAFPVGAVITVREGQEIGKGDVLARIPQASSKTRDITG GLPRVAELFEARVPKDAGMLAEITGTVSFGKETKGKQRLIVTDVDGVAYETLISKEKQILVHDGQVVNRGETIVDG AVDPHDILRLQGIEALARYIVQEVQEVYRLQGVKISDKHIEVIIRQMLRRVNIADAGETGFITGEQVERGDVMAAN

		EKALEEGKEPARYENVLLGITKASLSTDSFISAASFQETTRVLTEAAIMGKQDELRGLKENVIVGRLIPAGTGLTY HRSRHQQWQEVEQETAETQVTDE
19	137	MPRRREVPKRDVLPDPKFGSVELTKFMNVLMIDGKKSVAERIVYGALEQIEKKTGKVAIEVFNEAIANAKPIVEVK SRRVGGANYQVPVEVRPSRRLALAMRWVRDAARKRGEKSMDLRLAGELIDASEGRGGALKKREEVHRMAEANKAFS HFRF
20	138	MARKTPISLYRNIGISAHIDAGKTTTTERILFYTGLTHKLGEVHDGAATTDYMEQEQERGITITSAAVTSYWSGMA KQFPEHRFNIIDTPGHVDFTVEVERSMRVLDGAVMVYCAVGGVQPQSETVWRQANKYQVPRLAFVNKMDRQGANFF RVVEQMKTRLRANPVPIVIPVGAEDNFSGVVDLLKMKSIIWNEVDKGTTFTYGDIPAELVETAEEWRQNMIEAAAE ASEELMDKYLGGDELTEEEIVGALRQRTLAGEIQPMLCGSAFKNKGVQRMLDAVVELLPAPTDIPPVQGVNPNTEE ADSRQASDEEKFSALAFKMLNDKYVGQLTFIRVYSGVVKSGDTVLNSVKGTRERIGRLVQMTAADRTEIEEVRAGD IAAAIGLKDVTTGETLCAESAPIILERMEFPEPVIHIAVEPKTKADQEKMGIALNRLAKEDPSFRVRTDEESGQTI ISGMGELHLEIIVDRMKREFGVEANIGAPQVAYRETIRKAVKAEYKHAKQSGGKGQYGHVVIEMEPMEPGGEGYEF IDEIKGGVIPREFIPSVDKGIRDTLPNGIVAGYPVVDVRIRLVFGSYHDVSSQLAFELAASQAFKEGMRQASPAL LEPIMAVEVETPEEYMGDVMGDLNRRRGVVLGMDDDGIGGKKVRAEVPLAEMFGYSTDLRSATQGRATYSMEFKKY SEAPAHIAAAVTEARKG
21	140	MANQKIRIRLKAYDYALIDRSAQEIVETAKRTGAVVKGPIPLPTKIERFNILRSPHVNKTSREQLEIRTHLRLMDI VDWTDKTTDALMKLDLPAGVDVEIKVQ
22	142	MTLGLVGRKVGMTRVFDEQGVSVPVTVLDMSANRVTQVKSKDTDGYTAVQVTFGQKKANRVNKAEAGHFAKAGVEA GRGLIEFALTEEKLAELKAGDEITVSMFEVGQLVDVTGTSKGKGFSGTIKRHNFGAQRTSHGNSRSHRVPGSIGMA QDPGRVFPGKRMAGQYGNTKATVQKLEVVRVDAERQLLLVKGAVPGAVNSDVVVRPSVKVGA
23	143	MELKVIDAKGQVSGSLSVSDALFAREYNEALVHQLVNAYLANARSGNRAQKTRAEVKHSTKKPWRQKGTGRARSGM TSSPLWRKGGRAFPNKPDENFTQKVNRKMYRAGMATILSQLTRDERLFAIEALTAETPKTKVFAEQVKNLGLEQVL FVTKQLDENVYLASRNLPNVLVLEAQQVDPYSLLRYKKVIITKDAVAQLEEQWV
24	144	MNQQRLTQVILAPIVSEKSNVLAEKRNQMTFKVLANATKPEIKAAVELLFGVQVADVTTVTIKGKVKRFGRTLGRR SDVKKAYVSLAAGQELDLEAAAAAADKE
25	154	MARLREFYKETVVPELVKQFGYKSVMEVPRIEKITLNMGVGEAVADKKVMEHAVSDLEKIAGQKPVVTVARKSIAG FKIRDNYPVGCKVTLRRDQMFEFLDRLITIALPRVRDFRGVSGKSFDGRGNYNMGVREQIIFPEIEYDKIDALRGL NITITTTAKTDEEAKALLSLFKPFKG
26	156	MSMHDPISDMLTRIRNAQRANKAAVAMPSSKLKCAIAKVLKEEGYIEDFAVSSDVKSILEIQLKYYAGRPVIEQIK RVSRPGLRIYKASSEIPSVMNGLGIAIVSTSKGVMTDRKARSQGVGGELLCIVA
27	157	MSRVAKNPVTVPAGVEVKFGAEALVIKGKNGELSFPLHSDVAIEFNDGKLTFVANNSSKQANAMSGTARALVSNMV KGVSEGFEKRLQLIGVGYRAQAQGKILNLSLGFSHPIVYEMPEGVSVQTPSQTEIVLTGSDKQVVGQVAAEIRAFR APEPYKGKGVRYVGEVVVMKEAKKK
28	159	MAKHEIEERGDGLIEKMVAVNRVTKVVKGGRIMAFSALTVVGDGDGRIGMGKGKSKEVPVAVQKAMDQARRSMIKV PLKNGTIHHEVIGRHGATKVFMQPAKEGSGVKAGGPMRLVFDAMGIHNISAKVHGSTNPYNIVRATLDGLSKLHTP ADIAAKRGLTVEDILGVNHG
29	168	MQNSTTEFLKPRQIDVNTFSATRAKVSMQPFERGFGHTLGNALRRILLSSMNGFAPTEVAIAGVLHEYSTVDGIQE DVVDILLNIKGIVFKLHGRSQVQLVLKKSGSGVVSAGDIELPHDVEILNPGHVICHLADNGQIEMEIKVEQGRGYQ SVSGRQVVRDENRQIGAIQLDASFSPISRVSFEVEPARVEQRTDLDKLVLDIETDGSIDPEEAVRSAARILIDQMS IFADLQGTPVEEVEEKAPPIDPVLLRPVDDLELTVRSANCLKAEDIYYIGDLIQRTETELLKTPNLGRKSLNEIKE VLASKGLTLGSKLEAWPPVGLEKP
30	171	MAKIIVVTSGKGGVGKTTTSASIATGLALRGYKTAVIDFDVGLRNLDLIMGCERRVVYDLINVIQGEATLNQALIK DKNCENLFILPASQTRDKDALTREGVEKVMQELSGKKMGFEYIICDSPAGIEQGALMALYFADEAIVTTNPEVSSV RDSDRILGILQSKSHKAEQGGSVKEHLLITRYSPERVAKGEMLSVQDICDILHIPLLGVIPESQNVLQASNSGEPV IHQDSVAASEAYKDVIARLLGENREMRFLEAEKKSFFKRLFGG
31	173	MTLTELRYIVAVAQERHFGRAARRCFVSQPTLSIAIKKLEEELAVSLFDRSSNDIITTEAGERIVAQARKVLEEAE LIRHLANEEQNELEGAFKLGLIFTVAPYLLPKLIVSLRRTAPKMPLMLEENYTHTLTESLKRGDVDAIIVAEPFQE PGIVTEPLYDEPFFVIVPKGHSFEELDAVSPRMLGEEQVLLLTEGNCMRDQVLSSCSELAAKQRIQGLTNTLQGSS INTIRHMVASGLAISVLPATALTENDHMLFSIIPFEGTPPSRRVVLAYRRNFVRPKALSAMKAAIMQSQLHGVSFI CD
32	193	MTHMIYPKTYDVIVVGGGHAGTEAALAAARMGAQTLLLSHNIETLGQMSCNPSIGGIGKGHLVRELDALGGAMALA TDKSGIQFRRLNASKGAAVRATRAQADRILYKAAIREMLENQENLDLFQQAVEDVTLDGERISGVITAMGVEFKAR AVVLTAGTFLSGKIHIGLENYEGGRAGDPAAKSLGGRLRELKLPQGRLKTGTPPRIDGRTIDFSQLTEQPGDTPVP VMSVRGNADMHPRQVSCWITHTNTQTHDIIRSGFDRSPMFTGKIEGVGPRYCPSIEDKINRFADKDSHQIFLEPEG LTTHEYYPNGISTSLPFDIQIALVRSMKGLENAHILRPGYAIEYDYFDPRNLKASLETKTIAGLFFAGQINGTTGY EEAAAQGLLAGANAVQYVRGQDPLLLRREQAYLGVLVDDLITKGVNEPYRMFTSRAEYRLQLREDNADMRLTEDGY KIGLVSEAQWRMFNEKREAVEREIQRLKTTWYTPQKLAEGEQIRVFGQKLSREANLHDLLRRPNLDYAALMTLEGA MPSENLSAEVIEQVEIQVKYQGYIDRQNEEIDSRRDIETLKLPDGIDYGKVKGLSAEVQQKLNQHKPETVGQASRI SGVTPAAVALLMVHLKRGFKDAK
33	196	MKRMLFNATQAEELRVAIVDGQNLLDLDIETLGKEQRKGNIYKGIITRIEPSLEACFVDYGTDRHGFLPFKEVSRS YFQDYEGGRARIQDVLKEGMEVIVQVEKDERGNKGAALTTFISLAGRYLVLMPNNPRGGGVSRRIEGEERQELKAA

		MAELDIPNGMSIIARTAGIGRSAEELEWDLNYLKQLWQAIEEAGKAHHDPYLLFMESSLLIRAIRDYFRPDIGEIL VDNQEVYDQVAEFMSYVMPGNIGRLKLYEDHTPLFSRFQIEHQIESAFSRSVSLPSGGAIVIDHTEALVSIDVNSA RATRGADIEDTAFKTNMEAAEEVARQMRLRDLGGLVVIDFIDMENPKHQRDVENVLRDALKKDRARVQMGKLSRFG LLELSRQRLKPALGESSHVACPRCAGTGVIRGIESTALHVLRIIQEEAMKDNTGEVRAQVPVDVATFLLNEKRAEL FAMEERLDVNVVLIPNIHLENPHYEINRIRTDDVEEDGEPSYKRVAEPEEDESAKPFGGEKAKAARPEPAVKGVRH TSPAPTAAPEKKTSWWDSFKAWLKRIFGGSETQAAPAAETSEKRSTANRSGSRANNRRQNPRRSKREGSKVEVREV AGKTAGQEARADKAETRNNGNRRRNERGDRAAERANEAEIQSRNVQPAATVADAAPSETEVQTGKRRRNGSRSERG QTAPETATVAETTVQTAENTPSEPHTAEDKGSKPKSERNRRERDSRDAKERRERNNQRDRRQNGKKRNIPSAAKIE QYLNIHDTADKVRSAAAHVFGETDANAPITVSIADPVAERDLPTASPAVSNGDAPVYDAAEKIRRATAAILPEGAT PKAEAQEMPSETATFTAAAEQARETAQTGGLVLIETDPAALKAWAAQPEVQAGRGLRRSEQPKPSEVATVPAEEMI QVETRQG
34	212	MTEQKHEEYGADSIQVLEGLEAVRKRPGMYIGDTQDGSGLHHMVFEVLDNAIDEALAGHCDKITVTIHADHSVSVA DNGRGMPTGIHPKEGRSAAEVIMTVLHAGGKFDNNSYKISGGLHGVGVSVVNALSDWVTLTIYRDGKEHFVRFVRG ETEEPLKIVGDSDKKGTTVRFLASTETFGNVEYSFDILAKRIRELSFLNNGVDIELTDERDGKHESFALSGGVAGF VQYMNRKKTPLHEKIFYAFGEKDGMSVECAMQWNDSYQESVQCFTNNIPQRDGGTHLTALRQVMTRTINNYIEANE VAKKAKVETAGDDMREGLTCVLSVKLPDPKFSSQTKDKLVSGEIGPVVNEVISQALTDFLEENPNEAKIITGKIVD AARAREAARKAREITRRKGVMDGLGLPGKLADCQEKDPALSELYLVEGDSAGGSAMQGRDRKFQAILPLKGKILNV EKARFEKMLASQEVATLITALGAGIGKEEFNAEKLRYHRIIIMTDADVDGAHIRTLLLTFFYRQMPELVERGYIYI AQPPLYKAKYGKQERYLKDELEKDQWLLGLALEKAKIISDGRTIEGAELADTAKQFLLAKTVIEQESRFVDELVLR AMLHASPIDLTSSENADKAVAELSGLLDEKEVALERIEGHEGHRFIKITRKLHGNVMVSYIEPKFLNSKAYQTLTQ TAAALKGMVGEGAKLYKGENGYDADSFETALDILMSVAQKGMSIQRYKGLGEMNPEQLWETTMDPAVRRLLKVRIE DAIAADEVFVTLMGDEVEPRRAFIENNALIAQNIDA
35	219	MSQRRVVITGLGQVSPVGNTVAEAWDTLLTGKSGIGAITRFDTSDINSRVAGEVRGFDIGQYISAKEARRMDVFIH YGIAAALQAIADSGLDDVENLDKDRIGVNIGSGIGGLPGIEVTGKAVIEGGARKINPFFIPGSLINLISGHVTILK GYRGPSYGMVSACTTGAHAIGDSLRMIKYGDADIMVAGGAEGAISTLGVGGFAAMKALSTRNDDPATASRPWDKGR DGFVIGEGAGILVLEELEHAKKRGAKIYAEIVGFGMSSDAYHITAPNEEGPALAVTRALKDAGINPEDVDYVNAHG ~~TSTPLGDANETKALKRAFGEHAYRTVVSSTKSMTGHLLGAAGGVEAVYSILAIHDGKIPPTINIFEQDVEAGCDLD~~ YCANEARDAEIDVAISNSFGFGGTNGTLVFKRFKG
36	246	MAIYQSGVIFDQVDTANPDCWTLDEYVKRGGYTALRKILSENISQTDVIDEVKTSGLRGRGGAGFPTGLKWSFMPR SFPGEKYVVCNTDEGEPGTFKDRDIIMFNPHALIEGMIIAGYAMGAKAGYNYIHGEIFEGYQRFEAALEQARAAGF LGKNILGSDFEFELFAHHGYGAYICGEETALLESLEGKKGQPRFKPPFPASFGLYGKPTTINNTETFSSVPFIIRD GGQAFADKGIPNAGGTKLFCISGHVERPGNYEVPLGTPFAEVLKMAGGMRGGKKLKAVIPGGSSAPVLPADIMMQT NMDYDSISKAGSMLGSGAIIVMDEDVCMVKALERLSYFYYDESCGQCTPCREGTGWLYRIVHRIVEGKGKMEDLDL LDSVGNQMAGRTICALADAAVFPVRSFTKHFRDEFVHYIEHGGPMKEHKWGGW
37	286	MNFTRLLNQVLSTVQKKGNTFSDSPLNSFGGGALVAGVASMLLNGKNRKTITKIGSTAALGYLAYRGYQMWQQNKG RATVTQSDFQPAGETEETYSRTVLRTMIAAAASDGMIDEAERRTIEQESGTDPETAAWLAAEYRLPASIEDIAAAV GNDEALAAEAYLAARLVCADLSRKETVFLARLSQALKLDDNLVESLERQLGF
38	294	MKLKTLALTSLTLLALAACSKQAETSVPADSAQSSSSAPAAPAELNEGVNYTVLSTPIPQQQAGKIEVLEFFGYFC PHCAHLEPVLSEHIKTFKDDTYMRREHVVWGDEMKPLARLAAAVEMAGESDKANSHIFDAMVNQKINLADTDTLKK WLSEQTAFDGKKVLAAFEAPESQARAAQMEELTNKFQISGTPTVIVGGKYQVEFKDWQSGMTTIDQLVDKVREEQK KPQ
39	329	MSVGLLRILVQNQVVTVEQAEHYYNESQAGKEVLPMLFSDGVISPKSLAALIARVFSYSILDLRHYPRHRVLMGVL TEEQMVEFHCVPVFRRGDKVFFAVSDPTQMPQIQKTVSAAGIEVELVIVEDDQLAGLLDWVGSRSTSLLQELGEGQ EEEESHTLYIDNEEAEDGPVPRFIHKTLSDALRSGASDIHFEFYEHNARIRFRVDGQLREVVQPPIAVRGQLASRI KVMSRLDISEKRIPQDGRMQLTFQKGGKPVDFRVSTLPTLFGEKVVMRILNSDAASLNIDQLGFEPFQKKLLLEAI HRPYGMVLVTGPTGSGKTVSLYTCLNILNTESVNIATAEDPAEINLPGINQVNVNDKQGLTFAAALKSFLRQDPDI IMVGEIRDLETADIAIKAAQTGHMVFSTLHTNNAPATLSRMLNMGVAPFNIASSVSLIMAQRLLRRLCSSCKQEVE RPSASALKEVGFTDEDLAKDWKLYRAVGCDRCRGQGYKGRAGVYEVMPISEEMQRVIMNNGTEVDILDVAYKEGMV DLRRAGILKVMQGITSLEEVTANTND
40	335	MSLQNIIETAFENRADITPTTVTPEVKEAVLETIRQLDSGKLRVAERLGVGEWKVNEWAKKAVLLSFRIQDNEVLN DGVNKYFDKVPTKFADWSEDEFKNAGFRAVPGAVARRGSFVAKNVVLMPSYVNIGAYVDEGAMVDTWATVGSCAQI GKNVHLSGGVGIGGVLEPLQAAPTIIEDNCFIGARSEIVEGVIVEEGSVISMGVFIGQSTKIFDRTTGEIYQGRVP AGSVVVSGSMPSKDGSHSLYCAVIVKRVDAQTRAKTSVNELLRGI
41	336	MGFLQGKKILITGMISERSIAYGIAKACREQGAELAFTYVVDKLEERVRKMAAELDSELVFRCDVASDDEINQVFA DLGKHWDGLDGLVHSIGFAPKEALSGDFLDSISREAFNTAHEISAYSLPALAKAARPMMRGRNSAIVALSYLGAVR AIPNYNVMGMAKASLEAGIRFTAACLGKEGIRCNGISAGPIKTLAASGIADFGKLLGHVAAHNPLRRNVTIEEVGN TAAFLLSDLSSGITGEITYVDGGYSINALSTEG
42	337	MSRPVPAVFGSVFHSQMPVLAYREGKWQPTEWQSSQDLSLAPGAHALHYGSECFEGLKAFRQADGKIVLFRPTANI ARMRQSADILHLPRPETEAYLDALIKLVKRAADEIPDAPAALYLRPTLIGTDPVIGKAGSPSETALLYILASPVGD YFKVGSPVKILVETEHIRCAPHMGRVKCGGNYASAMHWVLKAKAEYGANQVLFCPNGDVQETGASNFILINGDEII TKPLTDEFLHGVTRDSVLTVAKDLGYTVSERNFTVDELKAAVENGAEAILTGTAAVISPVTSFVIGGKEIEVKSQE RGYAIRKAITDIQYGLAEDKYGWLVEVC

43	351	MTILSDVKALGQQIWLDNLSRSLVQSGELAQMLKQGVCGVTSNPAIFQKAFAGDALYADEIAALKQQNLSPKQRYE TMAVADVRAACDVCLAEHESTGGKTGFVSLEVSPELSKDAQGTVEEARRLYAAIGCKNAMIKVPATDAGIDALETL VSDGISVNLTLLFSRAQTLKAYAAYARGIAKRLAAGQSVAHIQVVASFFISRVDGALDTTLPDHLKGKIAIALAKA AYQDWAQYFGSPEFAALETKGANRVQLLWASTGVKNPAYPDTLYVDSLIGAHTVNTVPDATLKAFIDHGTAKATLT EGVEEAQAQLAETAALGIDVETLATRLQEDGLKQFEEAFEKLLAPLA
44	359	MSIKNAVKLIEESEARFVDLRFTDTKGKQHHFTVPARIVLEDPEEWFENGQAFDGSSIGGWKGIQASDMQLRPDAS TAFVDPFYDDATVVLTCDVIDPADGQGYDRDPRSIARRAEAYLKSSGIGETAYFGPEPEFFVFDGIEFETDMHKTR YEITSESGAWASGLHMDGQNTGHRPTVKGGYAPVAPIDCGQDLRSAMVNILEELGIEVEVHHSEVGTGSQMEIGTR FATLVKRADQTQDMKYVIQNVAHNFGKTATFMPKPIMGDNGSGMHVHQSIWKDGQNLFAGDGYAGLSDTALYYIGG IIKHAKALNAITNPSTNSYKRLVPHFEAPTKLAYSAKNRSASIRIPSVNSSKARRIEARFPDPTANPYLAFAALLM AGLDGIQNKIHPGDPADKNLYDLPPEEDALVPTVCASLEEALAALKADHEFLLRGGVFSKDWIDSYIAFKEEDVRR IRMAPHPLEFEMYYSL
45	382	MTKQLKLSALFVALLASGTAVAGEASVQGYTVSGQSNEIVRNNYGECWKNAYFDKASQGRVECGDAVAAPEPEPEP EPAPAPVVVVEQAPQYVDETISLSAKTLFGFDKDSLRAEAQDNLKVLAQRLSRTNVQSVRVEGHTDFMGSDKYNQA LSERRAYVVANNLVSNGVPVSRISAVGLGESQAQMTQVCEAEVAKLGAKVSKAKKREALIACIEPDRRVDVKIRSI VTRQVVPAHNHHQH
46	390	MYTRIMEISPWTLRSAKLEKEHKRLQESLTSLGNGYMGMRGSFEETYSADSHLGTYIAGVWFPDKTRVGWWKNGYP KYFGKAINAFNFSKVKIFVDGQEVDLAKNDVAGFSVELDMQHGVLRRSFTVFGVRFNVCKFLSVAQKELAVIRWEA VSVDGKTHQVRIDSIIDADVKNEDSNYEEKFWQVLDKGVSDSLSYIAAQTVANPFGVEQFIVNAEQTFAGSFKALG GSQTDWQVSNSFESEVGSTPETFEKRVIVTTSRDYQSLEAVKAAGRALSEKIAGVAFETLLDAHKAGWLHRWEIAD VVIEGSDEAQQGIRFNLFQLFSTYYGEDARLNIGPKGFTGEKYGGATYWDTEAYAVPLYLALAEPEVTRNLLQYRR NQLPQAQHNAREQGLAGALYPMVTFTGIECHNEWEITFEEIHRNGAIPYAIYNYTNYTGDEGYLAKEGLEVLVEVS RFWADRVHFSKRNGKYMIHGVTGPNEYENNINNNWYTNTLAAWVLDYTREALAKYPRPDLNVRADELEKWADISAN MYRPHDEELGVFVQHDGFLDKDIRPVSALSPDDLPLNQKWSWDKILRSPFIKQADVLQGIYFFSDRFNIDEKRRNF DFYEPMTVHESSLSPCIHSILAAELGKEEKAVEMYQRTARLDLDNYNNDTEDGLHITSMTGSWLAIVQGFAQMKTW GGKLSFAPFLPSAWTGYAFHINYRGRLIKVAVGKENVVFTLLKGESLDLQVYGKDITLDGSHTVALEK
47	391	MTFTAVLFDLDGVITDTAEYHYRAWKKLAEELGISIDRKFNEQLKGVSRDDSLKRILAHGGKTVSEAEFAELTRRK NDNYVEMIQAVKPEDVYPGILPLLEALRANGKKIALASASKNGPFLLERMGLTHFFDAIADPAAVAHSKPAPDIFL AAAEGVDADIRQCIGIEDAAAGVAAIKAAGALPIGVGKAEDLGSDIALVSGTAELTYAYLQSVWEQSGR
48	426	MEQQQRYISVLDIGTSKVLALIGEVQDDDKINIVGLGQAPSRGLRAGMVTNIDATVQAIRQAVNDAELMADTKITH VTTGIAGNHIRSLNSQGVVKIKDGEVTQADIDRAIETAKAINIPPDQKILDAVVQDYIIDTQLGVREPIGMSGVRL DTRVHIITGASTAVQNVQKCIERCGLKSDQIMLQPLASGQAVLTEDEKDLGVCVIDIGGGTTDIAVYMNGAIRHTS VIPAGGNLITKDLSKSLRTPLDAAEYIKIHYGVASCDTEGLGEMIEVPGVGDRTSRQVSSKVLAAIISARIQEIFG VVLGELQKSGFPKEVLNAGIVLTGGVSMMTGIVEFAEKIFDLPVRTGAPQEMGGLSDRVRTPRFSTAIGLLHAACK LEGNLPQPENGAVQEREGGGGLLARLKRWIENSF
49	427	MEFVYDVAESAVSPAVIKVIGLGGGGCNAINNMVANNVRGVEFISANTDAQSLAKNHAAKRIQLGTNLTRGLGAGA NPDIGRAAAQEDREAIEEAIRGANMLFITTGMGGGTGTGSAPVVAEIAKSLGILTVAVVTRPFAYEGKRVHVAQAG LEQLKEHVDSLIIIPNDKLMTALGEDVTMREAFRAADNVLRDAVAGISEVVTCPSEIINLDFADVKTVMSNRGIAM MGSGYAQGIDRARMATDQAISSPLLDDVTLDGARGVLVNITTAPGCLKMSELSEVMKIVNQSAHPDLECKFGAAED ETMSEDAIRITIIATGLKEKGAVDFVPAREVEAVAPSKQEQSHNVEGMIRTNRGIRTMNLTAADFDNQSVLDDFEI PAILRRQHNSDK
50	446	MSQTIDELLLPHRNAIDTIDAEILRLLNERAQHAHAIGELKGTGAVYRPEREVAVLRRIQDLNKGPLPDESVARLF REVMSECLAVERPLTIAYLGPQGTFTQQAAIKHFGHAAHTMACPTIDDCFKQVETRQADYLVAPVENSTEGSVGRT LDLLAVTALQACGEIVLRIHHNLLRKNNGSTEGIAKVFSHAQALAQCNDWLGRHLPNAERIAVSSNAEAARLVAES DDGTVAAIAGRTAAEIYGLDMVAECIEDEPNNTTRFLVMGHHETGASGSDKTSLAVSAPNRAGAVASLLQPLTESG ISMTKFESRPSKSVLWEYLFFIDIEGHRRDAQIQTALERLGERASFVKVIGSYPTAVL
51	462	MQAFSLYPPVGHPDSAKKRQNRADVFLPFWKQDNFLGKSVQYRFEFAQIYFTMPKPCAGVTMGRGDFFFSNLFHQE SARMKKSVLAVLAALSLAACGGSEKNAVQPQADAASAANAEAAATDTLNIYNWSNYVDESTVEDFKKANNLKLTYD LYENNETLEAKMLTGKSGYDLVVPGIAFLPRQIEAGAYQKVNKDLIPNYKNIDPELLKMLETADPGNQYAVPYFSG VNTIAITAKGKELLGGKLPENGWDLLFKPEYTHKLKSCGIALWDTPSEMFPILLNYLGKDPKGSNPEDLKAAAEVL KSIRPDVKRFSPSIIDELARGDICLAAGNGGDLNLAKARSEEVKNNVGIEVLTPKGMGFWIESWLIPADAKNVANA HKYINYTLDPEIAAKNGIAVTFAPASKPAREKMPAELVNTRSIFPNEQDMKDGFVMPQMSTDAKKLSVSLWQKIKV GTN
52	466	MRTNYCGLISEQYLDQTVTVKGWVHRRRDHGGVIFIDLRDREGIVQVVIDPDTPEAFAAADSSRNEYVLSITGRVR NRPEGTTNDKMISGKIEILAKEIEVLNAAATPPFQIDDENISENVRLTNRVIDLRRPVMQRNLRLRYQVAMGVRRY LDAQGFIDIETPMLTRSTPEGARDYLVPSRVHPGEFFALPQSPQLFKQLLMVAGFDRYYQITKCFRDEDLRADRQP EFTQIDLETSFLNEDEIMDITEGMAKQVFKDALNVDLGDFPRMPYSEAMFYYGSDKPDMRINLKFTELTDLMKTEE FKVFRGAADMKGGRVVALRVPNGAEFSRKEIDEYTKFVGIYGAKGLAYIKVNDVSNLSNGEDSGLQSPIVKYLSEN ALKEIIARTGAQNGDIIFFGADKAKVVNEAIGALRIKVGLEHGKDNGYFTDEWKPLWVVDFPMFEYDEEADRYVAV HHPFTAPKEGHEDLMVSDPANCLARAYDMVLNGWEIGGGSIRIHRADVQEKVFAALKISPEEQQEKFGFLLDNLKF GAPPHGGLAFGLDRLVTLMTGAESIRDVIAFPKTQRAQCLLTNAPNSVDDKQLRELSLRLRQKATETKEV
53	477	MRENKIIFTGPVGVGKTTAIAAISDEALVQTDASASDMTLDRKRNTTVAMDYGAISLDEDTKVHLYGTPGQERFNF

		MWEILSQGSMGLVLLLDNARTNPLKDLEFFLHSFRGLLEKAPVVVGITKMDIRSQPGIDVYHKYLAKHNLNVPVFE IDARKEDDVKQLVSAMLFSIDPGLEV
54	530	MTVPHIPRGPVMADIAAFRLTEEEKQRLLDPAVGGIILFRRNFQNIEQLKTLTAEIKALRTPELIIAVDHEGGRVQ RFIEGFTRLPAMSTLGEIWDKDGASAAETAAGQVGRVLATELSACGIDLSFTPVLDLDWGNCPVIGNRSFHRNPEA VARLALALQKGLTKGGMKSCGKHFPGHGFVEGDSHLVLPEDWRSLSELETADLAPFRIMSREGMAAVMPAHVVYPQ VDTKPAGFSEIWLKQILRRDIGFKGVIFSDDLTMEGACGAGGIKERARISFEAGCDIVLVCNRPDLVDELREDFRI PDNPTLAQRWQYMANTLGSAAAQAVMQTADFQAAQAFVAGLASPQDTAGGVKVGEAF
55	540	MFFKHIEAAPADPILGLGEAFKAETRPEKVNLGIGVYKDASGATPLVKAVKEAEKRLLESETTKNYLTIDGVADYN AQTQILLFGKDHEIIASRRAKTAQSLGGTGALRIAAEFAKRQLNAQTIWISNPTWPNHNAIAKAVGIQDKPYRYYD AAKHGLDWDGMIEDLSQAQKGDIVLLHGCCHNPTGIDPTPEQWETLAKLSAEKGWLPLFDFAYQGFGNGLEEDAYG LRVFLKHNTELLIASSYSKNFGMYNERVGAFTLVAEDEETAARAHSQVKTIIRTLYSNPASHGANTIALVLKNDDL KAQWIAELDEMRGRIKAMRQKFVGLLKAKGASQNFDFIIKQNGMFSFSGLTPEQVDRLKNEFAIYAVRSGRINVAG ITDNNIDYLCESIVKVL
56	546	MKMQAVVVNKNVAGDVEVIEREVRPLEYGEALVEVEYCGVCHTDLHVAAGDYGEKPGRVLGHEGIGLVKEVADGVK NLKVGDRVSIAWLFQSCGSCEYCNTGRETLCRSVLNAGYTADGGMATHCIVSADYAVKVPEGLDPAQASSITCAGV TTYKAIKVSGVRPGQWIAIYGAGGLGNLGVQYAKKVFGAHVVAIDINDDKLAFAKETGADLVVNAAKEDAAKVIQE KTGGAHAAVVTAVSAAAFNSAVNCVRAGGRVVAIGLPPESMDLSIPRLVLDGIEVVGSLVGTRKDLEEAFQFGAEG LVVPKVQLRALDEAPAIFQEMREGKITGRMVIDMKKECGCGHHH
57	564	MEIILGIVMFTVIVLVLALMILFAKSKLVSEGDITIKVNGEKELTMPAGGKLLGALANEGIFIPSACGGGGSCGQC RVVVKSGGGDILPTELSHISKREAREGCRLSCQVNVKTDMDIEVPEEVFGVKKWECTVISNDNKATFIKELKLAIP EGEEVPFRAGGYIQIEAPPHTVAYKDFDIPKEYHEDWDKYNLWQYVSKVDEPILRAYSMASYPEEKGIIMLNVRIA TPPPRVPDAPPGQMSSYIWSLKPGDKVTISGPFGEFFAKDTDAEMVFIGGGAGMAPMRSHIFDQLKRLNSKRKITF WYGARSKREMFYVEDFDQLAAEFPNFTWHVALSDPLPEDNWDGYTGFIHNVVYENHLKNHEAPEDCEFYMCGPPIM NQSVIKMLKDLGVEDENILLDDFGG
58	589	MNLIQQLEQEEIARLNKEIPEFAPGDTVVVSVRVVEGTRSRLQAYEGVVIARRNRGLNSNFIVRKISSGEGVERTF QLYSPTVEKIEVKRRGDVRRAKLYYLRGLTGKAARIKEKLPARKG
59	595	MSRVLLVDDDALLTELLTEYLSAEGLNVRSVPDGEAGVQEILSGQYDVVVLDSMMPKMNGLDVLKNVRARSTVPII MLTAKGDDIDRIIGLEMGADDYVPKPCTPRELLARINAILRRAQHSGEQNNAPNSISVSDVVLYPAKRQASVKDMP LELTSTEFNLLEVLMRHAGQVVSKETLSVEALDRKLAKFDRSIDVHISSIRHKLGDASLIQTVRGLGYLFVKN
60	604	MKAARFYDKGDIRIEDIPEPTVAPGTVGINVAWCGICGTDLHEFMEGPIFIPPCGHPHPISGESAPVTMGHEFSGV VYAVGEGVDDIKVGQHVVVEPYIIRDDVPTGEGSNYHLSKDMNFIGLGGCGGGLSEKIAVKRRWVHPISDKIPLDQ AALIEPLSVGHHAYVRSGAKEGDVALVGGAGPIGLLLAAVLKAKGIKVIITELSKARKDKARESGVADYILDPSEV DVVAEVKKLTNGEGVDVAFECTSVNKVLDTLVEACKPAANLVIVSIWSHPATINVHSVVMKELDVRGTIAYCNDHA ETIKLVEEGKINLEPFITQRIKLDELVSKGFERLIHNNESAVKIIVSPNL
61	610	MLPVRFTRVSDGIKRLTPASNQTAFYHPFENPFCRYSSFYWSIAIMTATTASSAKPYLKIQGLVKKFGDNYAVDNI DLDIYQHEIFALLGSSGSGKSTLLRMLAGMESPNQGKIIILDGQDITKLAPYDRPINMMFQSYALFPHMTVEQNIAF GLKQDKMPKGEIAARVEEMLRLVQMTKFAKRKPHQLSGGQQQRIALARSLAKRPKILLLDEPLGALDKKLRQQTQL ELVNTLEQVGVTCIMVTHDQEEAMTMATRIAIMSDGQLQQVGTPSDVYDYPNSRFTAEFIGETNIFDGVVIEDHAD YAVIECEGLENHVRIDHGLGGPSEQDLWVSIRPEDIDLYKEKPEYLGDYNWAKGTVKEIAYLGSFAIYHIKLGNGR VVKSQVPAPYWYVRNITPPTWDETVYISWPENQPTPLFR
62	617	MHVSELQTLHISKLLELAEEHGIENANRFRKQDLVFAIVRQMMKKGEGFTCSGTLEILPDGFGFLRSADTSYLAGP DDIYVSPTQIRRFNLHTGDTIEGSVRVPKDNERYFALVRLDTINGDHPEVCRHKILFENLTPLFPTEQLKLERDLK SEENLTGRAIDLISPIGKGQRALLVAPPKSGKTVMLQNIAHAVTANYPEVELIVLLIDERPEEVTEMSRSVRGEVV SSTFDEPAQRHVQVAEMVLEKAKRMVEHKKDVVILLDSITRLARAYNTVVPTSGKILTGGVDANALHRPKRFFGAA RNVEEGGSLTIIATALVETGSRMDDVIYEEFKGTGNMELHLDRRMAEKRLFPAININKSGTRREELLVPNDQLQRM WLLRKFLHPMDEIEAAEFLIGKIKASKNNDDFFELMRGK
63	618	MADNYVIWFENLRMTDVERVGGKNASLGEMISQLTEKGVRVPGGFATTAEAYRAFLAHNGLSERISAALAKLDVED VAELARVGKEIRQWILDTPFPEQLDAEIEAAWNKMVADAGGADISVAVRSSATAEDLPDASFAGQQETFLNINGLD NVKEAMHHVFASLYNDRAISYRVHKGFEHDIVALSAGVQRMVRSDSGASGVMFTLDTESGYDQVVFVTSSYGLGEN VVQGAVNPDEFYVFKPTLKAGKPAILRKTMGSKHIKMIFTDKAEAGKSVTNVDVPEEDRNRFSITDEEITELAHYA LTIEKHYGRPMDIEWGRDGLDGKLYILQARPETVKSQEEGNRNLRRFAINGDKTVLCEGRAIGQKVGQGKVRLIKD ASEMDSVEAGDVLVTDMTDPDWEPVMKRASAIVTNRGGRTCHAAIIARELGIPAVVGCGNATELLKNGQEVTVSCA EGDTGFIYAGLLDVQITDVALDNMPKAPVKVMMNVGNPELAFSFANLPSEGIGLARMEFIINRQIGIHPKALLEFD KQDDELKAEITRRIAGYASPVDFYVDKIAEGVATLAASVYPRKTIVRMSDFKSNEYANLVGGNVYEPHEENPMLGF RGAARYVADNFKDCFALECKALKRVRDEMGLTNVEIMIPFVRTLGEAEAVVKALKENGLERGKNGLRLIMMCELPS NAVLAEQFLQYFDGFSIGSNDMTQLTLGLDRDSGLVSESFDERNPAVKVMLHLAISACRKQNKYVGICGQGPSDHP DFAKWLVEEGIESVSLNPDTVIETWLYLANELNK
64	623	MKKTLVAAAILSLALTACGGGSDTAAQTPSAKPEAEQSGKLNIYNWSDYVDPETVAAFEKETGIKTRSDYYDSNET LEAKVLTGKSGYDLTAPSIANVGRQIKAGAYQKIDKAQIPHYGNIDKDLLKMMEAVDPGNEYAVPYFWGINTLAIN TQQVKKALGTDKLPENEWDLVFKPEYTAKLKSCGISYFDSAIEQIPLALHYLGKDPNSENPEDIKAAVDMMKAVRG DVKRFSSSGYIDDMAAGNLCAAIGYGGDLNIAKTRAEEAANGVEIKVLTPKTGVGVWVDSFMIPRDAQNVANAHRY IDYTLRPEVAAKNGSFVTYAPASRPARELMDEKYTSDASIFPNKELMEKSFIVSPKSAESVKLGVKLWQGLKAGK

65	631	MAKVLIVPVSAGLDASAAAQAFAKALDAQIFQAVDATAETLLAQGKSDDWFDALVGKVAALDAANLVIEGIAPDAD KIYLAGKNVELALSLDAAAVFAVRSDNADADELANRVNLAKQFFAAAPGVLEGFVVDGAAASVAEAAAEKTGLTFF GSSDALKDVSVLAGREAKRLSPAQFRYNLIDFARQADKRIVLPEGAEPRTVQAAAICHEKGIARCVLLAKREEVEA VAKERGISLPDSLEIIDPASLVEQYVEPMCELRKSKGLTPEDARKQLQDTVVLGTMMMAQNDVDGLVSGAVHTTAN TIRPALQLIKTAPGASLVSSVFFMLLPNQVLVFGDCAVNPNPTAQQLADIAIQSADSAKAFGIDPKVAMISYSTVN SGSGPDVDTVIEATKLAREKRPDLAIDGPLQYDAATVPGVGKSKAPGSPVAGQATVLVFPDLNTGNCTYKAVQRNA NVLSVGPLLQGLRKPVNDLSRGALVEDIVFTIALTAVQAKQMEG
66	634	MKTSIRYALLAAALTAATPALADITVYNGQHKEAAQAVADAFTRATGIKVKLNSAKGDQLAGQIKEEGSRSPADVF YSEQIPALATLSAANLLEPLPASTINETRGKGVPVAAKKDWVALSGRSRVVVYDTRKLSEKDLEKSVLNYATPKWK NRIGYAPTSGAFLEQVVAIVKLKGEAAALKWLKGLKEYGKPYAKNSVALQAVENGEIDAALINNYYWHAFAREKGV QNVHTRLNFVRHRDPGALVTYSGAAVLKSSQNKDEAKKFVAFLASKEGQRALTAVRAEYPLNPHVVSTFNLEPIAK LEAPQVSATTVSEKEHATRLLEQAGMK
67	637	MHDKTWSGRFNEPVSELVKQYTASIGFDRRLAEWDIQGSLAHAQMLKETGVLDEGDLADIRRGMAEILEEIRSGKI EWSSDLEDVHMNIERRLTDKIGDAGKRLHTGRSRNDQVATDIRLWLRDQITVIQSLIQSLQTALLDLAEQNAETVM PGFTHLQVAQPVSFGHHMLAYVEMLGRDNERMADCRCRVNRMPLGAAALAGTTYPIQREITAELLGFEQICQNSLD AVSDRDFAIEFTAAASLVMVHLSRLSEELILWMSPRFGFIDIADRFCTGSSIMPQKKNPDVPELVRGKSGRVIGHL IGLITLMKSQPLAYNKDNQEDKEPLFDTADTLIDTLRIYADMMRGVTVKPDNMRAAVMQGFATATDLADYLVKKGM PFRDAHEVVAQAVRHADQAGVDLSELPLEVLQGFSDLIADDVYGVLTPEGSLNARNHLGGTAPEQVRFQVKRWREM LA
68	641	MADFNQILTPGDVDGGIINVVNEIPAGSNHKIEWNRKLAAFQLDRVEPAIFAKPTNYGFIPQTLDEDGDELDVLLV TEQPLATGVFLEARVIGVMKFVDDGEVDDKIVCVPADDRNNGNAYKTLSDLPQQLIKQIEFHFNHYKDLKKAGTTK VESWGDAEEAKKVIKESIERWNKQA
69	663	MKKALATLIALALPAAALAEGASGFYVQADAAHAKASSSLGSAKGFSPRISAGYRINDLRFAVDYTRYKNYKAPST DFKLYSIGASAIYDFDTQSPVKPYLGARLSLNRASVDLGGSDSFSQTSIGLGVLTGVSYAVTPNVDLDAGYRYNYI GKVNTVKNVRSGELSAGVRVKF
70	697	MKEHKARKRFGQNFLQDTRIISDIVNAVRPQADDVVIEIGPGLAAITEPLAKKLNRLHVVEIDRDIVCRLKTLPFA DKLVIHEGDVLQFDFNGIAGKKKIVGNLPYNISTPLLFKLAEVADDVVDMHFMLQKEVVERMVAAPKSNDYGRLGV MLQYFFDMEMLIDVPPESFDPAPKVDSAVVRMIPVKHRIGKADDFEHFAKLVKLAFHQRRKTIRNNLKELAGDDDL QAVGINPQDRAEHIAPEKYVALSNYLAGKVV
71	703	MKKILLTVSLGLALSACATQGTVDKDAQITQDWSVEKLYAEAQDELNSSNYTRAVKLYEILESRFPTSRHAQQSQL DTAYAYYKDDEKDKALAAIDRFRRLHPQHPNMDYALYLRGLVLFNEDQSFLNKLASQDWSDRDPKANREAYQAFAE LVQRFPNSKYAADATARMVKLVDALGGNEMSVARYYMKRGAYIAAANRAQKIIGSYQNTRYVEESLAILELAYKKL DKPRLAADTRRVLETNFPKSPFLKQPWRSDDMPWWRYWH
72	711	MSSGNIHIHSMTGFANAAAECGSKRINLDLRAVNHRFLDIQIRMPDDLRYLESGIREKISSHIARGKVECKIQIQD AENGSQSLELNRDLVGQLAEINKDLRKHHDLAKLGVADILRFPGVLASQRENTEELAKSITELTEKALKDFTAARK REGKKLGEHLLQRLEAMEEIIDALSELFPTLLETHKEKIRARLVEAVGSIDNDRLQQEFALFIQKSDIDEEFSRLR THIAEVRRIVTEHKGSSGKRLDFLMQELNREANTLGSKSIAAECTQASVELKVLIEQMREQVQNIE
73	720	MLNITLPDGSVRQYESPVTVAQIAASIGAGLAKATVAGRVNGKLVDACDPIVEDSAVQIITPKDQEGIEIIRHSCA HLVGHAVKQLYPNAKMVIGPVIEEGFYYDIATEKPFTPEDVAAIEARMKELIAQDYDVVKIMTPRAEAIKIFQERG EEYKLRLIDDMPEVEAMGMYHHQEYVDMCRGPHVPNTRFLKNFKLTKLAGAYWRGDSNNEMLQRIYGTAWATKDEL KAYIQRIEEAEKRDHRKLGKQLDLFHLQDEAPGMVFWHPKGWALWQVIEQHMRKELNAAGYKEVKTPQIMDKTFWE KSGHWDNYKDNMFVTSSEKREYAVKPMNCPGHVQIFNNGLRSYRDLPMRLAEFGSCHRNEPSGALHGLMRVRGFVQ DDAHIFCTEDQIVSEARAFNELLIRIYKQFGFHDVSVKLSLRPEKRAGSDDVWDKAEQGLREALTACGVEWGELPG EGAFYGPKIEYHVRDALGRSWQCGTLQLDFVLPERLNAEYVTENNDRARPVMLHRAILGSLERFIGILIENHAGSF PLWLAPVQLVIMNITENQADYCREVAAKLQAAGFRAELDLRNEKIGYKIRDNSQYRFPYQIVVGDKEKQENKVAVR RKAEDLGSLDLDDFIAQLQQEITDALVNH
74	724	MENVNRIVAEGIAAVEAAQDFNALEQIKARYLGKTGELTGLLKTLGQMSPEERKTIGAHINECKNRFQTAFNAKRE ALNEVKLQARLAAEALDITLPGRAQEGGSLHPVTLTLQRVVELFHGMGFEVADGPEIEDDFHNFQALNIPANHPAR AMQDTFYVENGDVLRTHTSPIQIRYMLDKKEPPIRIIAPGRVYRVDSDATHSPMFHQAEGLWVEEGVTFADLKAVF TDFIRRFFERDDLQVRFRPSFFPFTEPSAEIDIMGENGKWLEVGGCGMVHPNVLKNVNIDPEKYTGFAFGIGLDRF AMLRYNVNDLRLFFDNDLNFLKQFAK
75	728	MQFSYSWLKTQADTELSSDKLEHLLTMSGLEVEEAETAAPAFAGVVIAEVKSVEKHPDADRLNVTRVDAGTGGLVQ IVCGAPNVKAGIKVPCSLPGAVLPGNFKIKPTKMRGEVSDGMLCSTDELGLPDDGVNGLHILPEDAPVGTNIREYL DLDDTLFTLKITPNRADCLSIKGIAREVSALTGCAFRQPEIHTAPITGSRKQPVQINAPADCGRFISRVIENVNAR ATTPDWMKQRLERSGIRSISALVDIGNYVMLEIGQPMHVFDADKLSGSLHIRRAREGETLECLNEKTVSLSENTLV VADEKGVLSLAGLMGGAASAVSDGTQNIVLEAAWFAPEIIAGKSRQYGFGSDSSFRFERGVDYRLQADAIERATEL VLQICGGAAGEMVEAQGELPEAKQVGLRLDRLKTVLGVDIPAEQVETILQHLGLQPEKTAEGFRVTAPSFRFDIEI EADLIEEIGRVYGYENIPDDYTSGRLKMLELPETRRPRFAVYNEMAARGYREVVSYAFVDEQWEQDFAANADPIRL QNPLAAQYAVMRSTLIGGLVEILQNNLNRKQNRVCVFEIARVFSKGSDGQFVQNERIGGLWYGAVMPEQWGGKTRN ADFYDIKADVENLLKNKAVEFVKTGHPALHPGRAANIVSDGKVIGFVGELHPKWLQKYDLPQAPLVFEIDMAAVLE CGKTRYRVVSKFQPVRRDLAFVMPEAMSHDDLLLVLKGAANKLVQEISVFDVYRGTGLPEGMKSVAVKVILQDMEN TLTDEAVEPLIGKLIGAATAAGARLRS

76	743	MGGQKTHFGFSTVNEDEKAGKVAEVFHSVAKNYDIMNDVMSAGLHRVWKHFTINTAHLKKGDKVLDIAGGTGDLSR GWAKRVGKEGEVWLTDINSSMLTVGRDRLLNEGMILPVSLADAEKLPFPDNYFNLVSVAFGLRNMTHKDAALKEMY RVLKPGGTLLVLEFSKIYKPLEGAYDFYSFKLLPVMGRLIAKDAESYQYLAESIRMHPDQETLKQMMLDAGFDSVD YHNMSAGIVALHKGVKF
77	757	MSEIGLVKIYFGKVRDLYEIDDKRMLMVASDRLSAFDVILDDPIPSKGEILTQISNFWFKKLAHIMPNHFTGQTVY DVLPENEAKALEKRAVVAKKLTPVKVEAIVRGYLAGSGWKDYQKTGSVCGIQLPEGMQEAQQLPEVIFTPSTKAAV GDHDENISFEECGRIIGKELAEEVRAKAVRLYTEAAEYAKSRGIIICDTKFEFGLDENGTLTLMDEVLTPDSSRFW PADQYKVGTNPPSFDKQFVRDWLEQSGWNKKAPAPKVPADVIQKTVEKYREALTLLTQD
78	758	MMFDKHVKTFQYGNQTVTLETGEIARQAAAAVKVSMGDTVVLAVTTNKEVKEGQDFFPLTVDYLERTYAAGKIPG GFFKREGKQSEKEILTSRLIDRPIRPLFPEGFYHDIQIVAMVVSVDPEIDSDIPAMLGASAALVLSGVPFAGPIGA ARVGYVNGVYVLNPTKAELAKSQLDLVVAGTSKAVLMVESEAKILPEDVMLGAVVYGHDQMQVAINAINEFADEVN PELWDWKAPETNEELVAKVRGIAGETIKEAFKIRQKQARSAKLDEAWSAVKEALITEETDTLAANEIKGIFKHLEA DVVRSQILDGQPRIDGRDTRTVRPLNIQTSVLPRTHGSALFTRGETQALAVATLGTSRDEQIIDALSGEYTDRFML HYNFPPYSTGEVGRMGAPKRREIGHGRLAKRALLAVLPKPEDFSYTMRVVSEITESNGSSSMASVCGGCLSLLSAG VPLKAHVAGIAMGLILEGNKFAVLTDILGDEDHLGDMDFKVAGTTEGVTALQMDIKIQGITKEIMQIALAQAKEAR LHILDQMKAAVAGPQELSAHAPRLFTMKINQDKIREVIGKGGETIRSITAETGTEINIAEDGTITIAATTQEAGDA AKKRIEQITAEVEVGKVYEGTVVKILDNNVGAIVSVMPGKDGLVHISQIAHERVRNVGDYLQVGQVVNVKALEVDD RGRVRLSIKALLDAPAREENAAE
79	763	MKIANSITELIGNTPLVKLNRLTEGLKAEVAVKLEFFNPGSSVKDRIAEAMIEGAEKAGKINKNTVIVEATSGNTG VGLAMVCAARGYKLAITMPESMSKERKMLLRAFGAELILTPAAEGMAGAIAKAKSLVDAHPDTYFMPRQFDNEANP EVHRKTTAEEIWRDTDGKVDVFVAGVGTGGTITGVGEVLKKYKPEVKVVAVEPEASPVLSGGEKGPHPIQGIGAGF IPTVLNTKIYDSITKVSNEAAFETARAIAEKEGILVGISSGAAVWSALQLAKQPENEGKLIVVLLPSYGERYLSTP LFADLA
80	778	MPSETSSPRKENETEVHIPAAPFIVKQSGSNALAVCALVLAALGLGTSGFLFVQGQNVLKNQELAFNQKIDKAALG ESENAALLKDNLNRQAAIQSELDRLDGNVKANGEQILEMQKSYRELTKGRADWLVDETETILNLAAQQLVLTGNIQ TAVGVLEHIDSRLSRFNQAELLPIKQAVSSDLAELKNRPYVDISGTALRLDRLETAVSGLPLMLDGVLKPGVQVKN EAASASWWQNVWEKSLGTLKGLVEIRRLENNDAMLISPEQAYFVRENLRLRLRLLDARTALMQRNSEVYQGDLNNAEA AVRQYFDAKSPATQSWLKELAELKALDVRMTADDGLKNSLNAVRAYRDGTRMTAAENQEAEQAASEPANEKTASEP AAASDVKTIEAPSLPSERKPEQPAKKQTVPEKAGRSPSAKGERA
81	791	MIILHTNKGDIKIELDFDKAPVTAKNFEQYVKDGFYDGVIFHRVIKGFMIQGGGMDENMNEKETRDPIQNEASNGL PNDKYTIAMARTSDPHSASAQFFINTADNAFLNFRSKELYGKTVVQDWGYAVFGKVVDGFDVVDAIEGVSTKRHGY HDDVPSEPVVIIKAEAV
82	804	MTVLSKEQVLSAFKNRKSCRHYDAARKISAEDFQFILELGRLSPSSVGSEPWQFIVVQNPEIRQAIKPFSWGMADA LDTASHLVVFLAKKNARSDSPFMLESLKRRGVTEPDAVAKSLARYQAFQADDIKILDDSRALFDWCCRQTYIALAN MMTGAAMAGIDSCPVEGFNYAEMERILSGQFGLFDAAEWGVSVAATFGYRVQEIATKARRPLEETVIWA
83	814	MQTWQLPEHIADVLPTNARQLESAREQLLALFRVHGYELVQPPLMEYAHSLLTHIDAGLSLKTILVTDRLSGRQLG IRADITPQVARIDAHLLSANQGINRLCYAGPVLHAQPDGLLNMREPLQAGAEMYGFADIRGDIELIDLMLKSMKIA DMGKVLLSLGHIGIFRALSDAAHLDAGQSATLLALMQDKDTGAVEAQVKAWKLDGMWAKAFSLLPRLYGGREVLSD ARGRLPDLSAVGGALGELQAVCDAFPDCEIHIDLSELRVDNYHTGLLYAAYAADFHDAVARGGRYDGLGGYFGRAR PATGFSFDLRSFIGRLPAIERQPAVLVDAEDAEAAHEAVEALREQGQCVVIDYGIGHNVSEELAGRLKKTDGVWQV VKR
84	815	MAMAKNVVVIGAQWGDEGKGKIVDWLAEEAGGVVRFQGGHNAGHTLVVGGKKTILRLIPSGILHESLDCFIGSGVV VSPEALLGEIDELNAAGVKNVEGRLKIAPTCPLILPYHIALDQAREASRGKGKIGTTGRGIGPAYEDKVARRAIRA ADLLHPEKLREKLDAVLAYYNVQLQHLHNAEPVKAEDVMAVIEKVAPRIAPMITDVSRVLNEKNKNGEKLLFEGAQ GALLDIDYGTYPFVTSSNCLAGAASAGAGVGPQMLDYVLGIVKAYTTRVGSGPFPTELFDEVGVGLAERGHEFGSV TGRARRCGWFDAAALKRSIQINGISGMCITKLDVMDGVETINICVGYELPDGGKTDILPCGSDAVETCKPIYETMP GWRESTFGVKDYGALPENAKAYLKRIEEVCGAPVAIVSTGPDREETIVLHHPFA
85	828	MTIIVTGAAGFIGSNIVKALNQRGITDIVAVDNLSKGEKFKNLAECEIAHYLDKHEFIRQVREHILPYQNIEAVFH QGACSDTMNHDGLYMMDNNYQYTLDLLDWCQDERIPFLYASSAAVYGKGEIFREERELEKPLNVYGYSKFLFDQVL RRRMKEGLTAQVVGFRYFNVYGQHEQHKGRMASVAFHHFHQYREHGYVNLFGSNDGYGNGEQTRDFVSVEDVAKVN LYFFDHPELSGIYNLGTGRSQQFNELAAATVNACRAAEGKPEMSLKELVEEELIRYIPFPDALKGKYQSFTQADIT KLREAGYKEEFFDVKSGVDRYVKWMLENLA
86	854	MAQKIQSVKGMNDLLPVKQKDFKLTAAFWQAFEDTVGRWTRAYGYQQIRTPIVEQTGLFVRSIGEETDVVGKEMYT FSDSNDSLSLSLRPEGTASCLRAVVEHNLLYNSPQKLWYMGPMFRRRERPQKGRYRQFHQVGIEALGFEGPDIDAEI IAMSADLWEKLGIREYLTLEINSLGNREERAAHRAALVEYLTRYEDKLDEDSKRRLKTNPLRVLDTKNPDLQEICN AAPRLVDYLGEDSQNHYVRFKAMLDGLGIQYIENPRLVRGLDYYNQTVFEWTTDKLGAQATVCGGGRYDGLIEELG GKPAPSIGFAMGIERLLLLVSEYGSLEVNAAPDVYAMHQGEGADLQVMKYAQALRAQGFNVMQHSGYQSLKAQMKK ADNSGARFALIVAQDELANGTVTLKDMNGAHGQQTVAAEDLTPTLQQWKNA
87	875	MAAYDSLMVFTGNANPELAQRVVRHLDISLGNASVSKFSDGEVAVELLENVRGRDVFILQPTCAPTNDNLMEILTM ADALKRASAGRITTAIPYFGYARQDRRPRSVRVPISAKLVANMLYSAGIDRVLTVDLHADQIQGFFDIPVDNIYAT PILLNDIKQQRIENLTVVSPDIGGVVRARAVAKSLNADLAIIDKRRPKANVAEVMNIIGDIQGRTCLIVDDMIDTA NTLCKAAVALKERGAERVLAYASHAVFSGEAVSRIASSEIDQVVVTDTIPLSEAAKNCDRIRQVTIAGLLAETVRR

		ISNEESVSYLFNEEVMTGSMLLP
88	876	MTYEIQASVREAQGTGASRRLRREGQIPGILYGEGQEPVAIAVDHKTVFYALEKESFHTALIKLSLNGETKDVIVR DFQMHPFRREVQHIDFQAVKADQLVRIRVPLHIVNAENSQAVKLQGGRVSLLNTSVEVVALPANIPAFLDLDCAEV VAGDILHLSDIKLPEGVESVSLKRNENLAVATVTGKKR
89	878	MNTPLPYSDYLIRILTASVYDVAVETPLEPARSLSVRLKNNILLKREDLQPVFSFKIRGAYNKMSKLPKDALACGV IAASAGNHAQGVALSAQRLGCRAVIVMPETTPKIKVDAVKSHGGEVVLRGVSYNDAYDYAMELAEKEGLTYIAPFD DPDVIAGQGTVGMEIVSQHPDPIRAVFVPIGGGGLAAGVAAFIKQVRPEIKVIGVQTNDSCCMKQSVEAGEIVHLK DVGLFSDGTAVKVVGNETFRLCKELLDEIITVDTDAVCGAVKDIFDDTRSITEPAGALALAGLKAYIAREGAENQT LIAVTSGANMNFHRLRHVSERSELGEGNEGIFAVTIPEERGSFLKFVNILGNRNITEFNYRYGDDEKAHIFVGLQA AGPQDLAVIGSRLDEAGLPNVDLTNNEIAKIHIRYMVGGRTDKVENERLVSFEFPERPGALARFLNHMQGGWNITL FHYRNHGADYGRILVGIDVPPHDAAAFDGFLESLGYSYHEETQNAAYKLFLA
90	884	MEHKLPQLPYELDALSPHLSKETLEFHYGKHHQTYITNLNNQIKGTEFENLPLEEIVKKSSGGVFNNAAQTWNHTF YWLGFTSKGQGKPAGELAAAIDAKWGSFEKFQEAFNACAAGTFGSGWAWLVKTPAGGLDLVSTSNAATPLTTENTP LLTCDVWEHAYYIDYRNSRPNYLKGFWEIVNWDEVAKRFAALS
91	885	MNDYAAMPSEDREVGALSLPPHSMEAEQSVLGGLMLENPAWDRIADVVSGEDFYRHEHRLIFRSIAKLINESRPAD VITVQEDLQRNEELEAAGGFEYLITLAQNTPSAANIRRYAEIVRERSIMRQLAEVGTEIARSAYNPQGRDAGQLLD EAENKVFQIAESTAKSKQGFLEMPDLLKEVVQRIDMLYSRDNPDEVTGVPTGFIDLDKKTSGLQPGDLIIVAGRPS MGKTAFSINIAEHVAVEGRLPVAVFSMEMGGAQLVMRMLGSVGRLDQSVLKTGRLEDEHWGRLNEAVVKLSDAPVY IDETPGLTALELRARARRLARQFNNKLGLIVIDYLQLMAGSGRSDNRASELGEISRSLKALAKELQVPIIALSQLS RTVESRTDKRPMMSDLRESGAIEQDADLIMFYRDEYYNQDSPMKGLAECIIGKHRNGPVGKIFLTWTGQFTKFDN AAYIPEEAKIED
92	894	MNTLLNQLKPYPFARLREAMQGISAPEGLEAVPLHIGEPKHPTPKVITDALTASLHELEKYPLTAGLPELRQACAN WLKRRYDGLTVDADNEILPVLGSREALFSFVQTVLNPVSDGIKPAIVSPNPFYQIYEGATLLGGGEIHFANCPAPS FNPDWRSISEEVWKRTKLVFVCSPNNPSGSVLDLDGWKEVFDLQDKYGFIIASDECYSEIYFDGNKPLGCLQAAAQ LGRSRQKLLMFTSLSKRSNVPGLRSGFVAGDAELLKNFLLYRTYHGSAMSIPVQRASIAAWDDEQHVIDNRRMYQE KFERVIPILQQVFDVKLPDASFYIWLKVPDGDDLALARNLWQKAAIQVLPGRFLARDTEQGNPGEGYVRIALVADV ATCVKAAETIVSLYR
93	920	MTQKSTIVYTHTDEAPALATQSLLPIVQAFARHADIDVKTSDISLSGRILAAFPEYLTEAQRVPDALAELGELVKQ PDANVIKLPNISASVPQLTAAIKELQSKGFAVPDYPADPQTDEEKAVRERYDRIKGSAVNPVLREGNSDRRAPKAV KNFAKKNPHSMGAWTKDSKTHVATMQSGDFFHNEQSVIVPEATSVSIVFTDKQGNKKELREPVALKAGEIIDATVM SKKALLAFLAEQVKDAKAKGVLFSLHMKATMMKVSDPIIFGHAVKVFFAPVFEKFGDKLAAAGVNVNNGFGNLLAN LDKLDADTRTAVEAEIAAVYAANPDLAMVDSDKGITNLHVPSDVIVDASMPAMIRNSGRMWDKNGKAQDTKAVIPD SSYAGVYQATIDFCREHGAFDPTTMGTVPNVGLMAQAAEEYGSHNKTFEIEADGQVQVIDAAGKVLMQHDVEAGDI WRMCQTKDAPVKDWVQLAVNRARLSNTPAVFWLDENRPHDKSLLAKVKAYLAELDTNGLDIRVLAPEEAAKFSLGR LKNGEDTISVTGNVLRDYLTDLFPILELGTSAKMLSIVPLMNGGGMFETGAGGSAPKHVQQFLEENHLRWDSLGEF LALAVSFEHLAQKTGNAKAQVLADTLDAATEKLLLNDKSPKRKAGELDNRGSHFYLTLYWAQELAAQDKDAELKAA FTPLAAALTADEAKIVAELSAVQGKAADIGGYYAANPEKAAQVMRPSVTFNQALNAL
94	944	MTTLHFSGFPRVGAFRELKFAQEKYWRKEISEQELLAVAKDLREKNWKHQVAANADFVAVGDFTFYDHILDLQVAT GAIPARFGFDSQNLSLEQFFQLARGNKDQFAIEMTKWFDTNYHYLVPEFHADTEFKANAKHYVQQLQEAQALGLKA KPTVVGPLTFLWVGKEKGAVEFDRLSLLPKLLPVYVEILTALVEAGAEWIQIDEPALAVDLPKEWVEAYKDVYATL SKVSAKILLSTYFGSVAEHAALLKALPVDGLHIDLVRAPEQLDAFADYDKVLSAGVIDGRNIWRANLNKVLETVEP LQAKLGDRLWISSSCSLLHTPFDLSVEEKLKANKPDLYSWLAFTLQKTQELRVLKAALNEGRDSVAEELAASQAAA ADYEAAMKKEIALVVEEQEKLDLDVLVHGEAERNDMVEYFGELLSGFAFTQYGWVQSYGSRCVKPPIIFGDVSRPE AMTVAWSTYAQSLTKRPMKGMLTGPVTILQWSFVRNDIPRSTVCKQIALALNDEVLDLEKAGIKVIQIDEPAIREG LPLKRADWDAYLNWAGESFRLSSAGCEDSTQIHTHMCYSEFNDILPAIAAMDADVITIETSRSDMELLTAFGEFQY PNDIGPGVYDIHSPRVPTEAEVEHLLRKAIEVVPVERLWVNPDCGLKTRGWKETLEQLQVMMNVTRKLRAELAK
95	946	MALQDRTGQKVPSVVFRTRVGDTWKDVSTDDLFKGKKVVVVFSLPGAFTPTCSSSHLPRYNELFGAFKENGVDAIYC VSVNDTFVMNAWAAEEESDNIYMIPDGNGEFTEGMGMLVGKEDLGFGKRSWRYSMLVNDGVVEKMFIEPEEPGDPF KVSDADTMLQFVAPDWKAQESVAIFTKPGCQFCAKAKQALQDKGLSYEEIVLGKDATVTSVRAITGKMTAPQVFIG GKYIGGSEDLEAYLAKN
96	947	MKKIQADVVVIGGGTAGMGAFRNARLHSDNVYLIENNVFGTTCARVGCMPSKLLIAAAEARHHALHTDPFGVHLDK DSIVVNGEEVMQRVKSERDRFVGFVVADVEEWPADKRIMGSAKFIDEHTVQIDEHTQITAKSFVIATGSRPVILPQ WQSLGNRLIINDDVFSWDTLPKRVAVFGPGVIGLELGQALHRLGVKVEIFGLGGIIGGISDPVVSDEANAVFGEEL KLHLDAKTEVKLDADGNVEVHWEQDGEKGVFVAEYMLAAVGRRPNVDNIGLENINIEKDARGVPVADPLTMQTSIP HIFIAGDASNQLPLLHEAADQGKIAGDNAGRYPNIGGGLRRSTIGVVFTSPQIGFVGLKYAQVAAQYQADEFVIGE VSFKNQGRSRVMLVNKGHMRLYAEKATGRFIGAEIVGPAAEHLAHLLAWAHQMKMTVPQMLDMPFYHPVIEEGLRT ALRDADAKLKA
97	955	MMDEKLNFSYLFGSNAPYIEELYEAFLENPDAVDEKWKQYFTDLSKQPGTVAVDVAHTPIRESFVTLAKKKIASAV AGGADEAMLKKQVSVLRLISAYRIQGVGAAQLDPLKRIPPRDIEALDPKFHGLSDADMALQFNMGEGDFANRGKLP LSQIISNLKQTYCGHIALEYIYIPNTEERRWVRNYFESVLSTPHYNADQKRRILKEMTAAETLERYLHTKYVGQKR FGVEGGESAIAGLNYLIQNAGKDGVEEVIIGMAHRGRLNVLVNILGKKPGDLFAEFEGRAEIKLPSGDVKYHMGFS

		SDIATPHGPMHVSLAFNPSHLEIVNPVVEGSARAKQKRLGENGRDKVLPVLIHGDSAFIGLGVNQATFNLSKTRGY TTGGTVHIVINNQIGFTTSDIRDTRSTVHCTDIAKMVSAPVIHVNGDDPERVCFAIQAALDYRKKFHKDIVIDVVC YRKWGHNEGDDPTLTQPMMYKKVSQHPGARALYTEQLIAEGVVTQAEADGYIQAYRDALDKGEHVEQTTLSNFQRT QIDWSKYQGKDWREHIETGLPAADIERLTEKFTAVPEGFALHPTAKRVIEARKAMASGKQAIDWGMAETLAYASLV TKGHGVRISGEDSGRGTFSHRHAVLHDQKREKWDDGTYVPLRHMGEGMGEFLVIDSILNEEAVMAFEYGFACSAPD KLTIWEAQFGDFANGAQVTIDQFLSSGETKWGRLCGLTTILPHGYDGQGPEHSSARVERWLQLCSENNMQVIMPSE ASQMFHLLQRQVLGSYRKPLVIFMSKRLLRFKGAMSPLENFTEGSTFRPVIGDTAERASNDSVKRVVLCAGQVYYD LEAGRAERKLEDDVAIRVEQLYPFPYDEVKAELAKYPNAKSVVWAQEEPKNQGAFYQIRHRIEDVISEEQKLSYA GRPSSASPAVGYSSKHIAQLKQLVEDALAL
98	956	MIIDVKVPMLSESVSEGTLLEWKKKVGEAVARDEILIDIETDKVVLEVPSPQAGVLVEIVAQDGETVVADQVLARV DTAATAAAEAPAAAPAEAAPAAAPAATQNNAAMPAAAKLAAETGVDVNALQGSGRDGRVLKEDVQNAAAKPAGAAA PAVALPAGARPEERVPMSRLRARVAERLLASQQENAILTTFNEVNMKPIMDLRAKYKEKFEKEHGVKLGFMSFFVK AAVAALKKYPVVNASVDGKDIVYHGYFDIGIAIGSPRGLVVPILRDADQMSIADIEQAIVDYAKKAKDGKIAIEDL TGGTFSITNGGTFGSMMSTPIINPPQSAILGMHATKERAVVENGQVVVRPMMYLALSYDHRIIDGREAVLTLVAIK DALEDPARLLLDL
99	959	MNLHEYQAKELLASYGLPVQGGILAHNGEEAAAAYDKLGGKFAVVKAQVHAGGRGKAGGVKVVKSREEAKEVAESL IGTNLVTYQTDANGQPVNSVLVCEDMYPVQTELYLGAVVDRSTRRITFMASTEGGVEIEKVAAETPEKIFKVTVDP LVGLQPCQAREVAFQLGLKDKQINEFVKLMTGAYKAFVENDFALFEVNPLAVRENGALACVDGKIGIDSNALYRLP KIAELRDKSQENERELKASEFDLNYVALEGNIGCMVNGAGLAMATMDIIKLKGGQPANFLDVGGGATKDRVVEAFK LILEDKSVQGVLINIFGGIVRCDMIAEAIVAAVKEINVNVPVVVRLEGNNAELGAKILNESGLKLTSADGLNDAAE KIVAAVNA
100	960	MSVLINKDTKVLVQGFTGKNGTFHSEQALAYGTKVVGGVTPGKGGQTHLNLPVFNTMKEAVKETGADASVIYVPAP FVLDSIVEAVDSGVGLVVVITEGVPTLDMLKAKRYLETNGNGTRLVGPNCPGVITPGECKIGIMPGHIHTPGRIGI ISRSGTLTYEAVAQTTKLGLGQSTCIGIGGDPIPGMNQIDALKLFQEDPDTDAIIMIGEIGGTAEEEAAEYIQSNV SKPVVGYIAGVTAPKGKRMGHAGAIISGGKGTAEEKFAAFEKAGIAYTRSPAELGTTMLEVLKAKGLA
101	983	MSSIKRALISLSDKTGAVEFAQTLHKLGVEILSTGGTAKLLADAGVPVIEVADYTGFPEMLDGRVKTLHPKIHGGI LGRRDLDEHVAKMEEHGIGNIDLVCVNLYLFAATIAKPNCTLEDAIENIDIGGPTMVRSAAKNWKHVAIVTDTADF PAIAAELEANNGALSDKTRFNLSRKAFSHTAQYDGMISNYLTSLSDDVLSGTPEIAGFPGRFNQSWIKVQDMRYGE NPHQRAAFYRDIDPAAGSLAAYKQLQGKELSYNNIADADAAWEAVKSFDVPACVIVKHANPCGVAIASNTLDAYKL AYATDTTSAFGGIIAFNREVDGATVKQITDNQFMEVLMAPKFTAEALEIAAAKKNVRVLEVPLEAGANRFELKRVG GGLLVQTPDIHRISRADLKVVSKRQPTEQEWNDLLFVWNVAKYVKSNAIVFGKGGQTYGIGAGQMSRVDSTRIAAR KAQDAGLDLNGACAASDAFFPFRDGVDVIAEQGIKAIIHPAGSMRDQEVFDAADEHGIAMVVTGIRHFRH
102	997	MSASQLLSRLTQTVGEKYIITDPAKTEQYRQGYRFGEGKALAVVRPGSILEMWKILQACVEADVIVITQAANTGLT GGSTPDGNDYDRDIVIVNTMRMNIIQTINNNEQVVCLPGSTLNQLELLLKPLGREPHSVIGSSCIGASVLGGVCNN SGGALVQRGPAYTEMALFAQINEEGRLELVNHLGIDLGNTPEEILTNLQGHHYQNKDITQDAGKGHDHAYCEHVRQ VDEPTAARFNADPARHYEASGCAGKLMVFAVRLDTFPQEKQTAVFYIGTNDINELTDIRRAALGEFESLPVSGEYI HRHAFDIADVYGKDTFYVIKKFGTHQLPKLFDLKARVDRFGKKVSFLPKHFSDKAMQFVSKFLPDHLPKSMRDYRD KYEHHLILKMGGKGVDEARAFLKEYFAHHGGAFFECNAEETQAAMLHRFAVASAAIRYRAVHDDEVEDLVALDIAL RRDDRDWFEKLPPEIDNKIIHKLYYGHFMCHVFHQDYIIKKGNDCMALEHEMLHLLDQRGAQYPAEHNVGHLYEAK PALKQFYRKLDPTNSFNPGVGKTSKKKNWAE
103	1031	MTKHIAILRGDGIGPEIVAETVRVLDKLIAQGLDAGYEYAPLGGEAYDEYGHPYPEFTQNLCRKADAVLLGAVGSP QYDNLDRPLRPERGLLAIRKDLNLFANLRPAVLYPELANASTLKPEIVAGLDILIVRELTGDIYFGEPRGIRVLEN GEREGYNTMKYSESEIRRIAHVAFQSAQKRSKKVCSVGKANVLETTELWREIFEEIGKEYPDVELSHMYVDNAAMQ LVRAPKQFDVIATGNIFGDILSDEASMLTGSIGMLPSASLDENGKGLYEPSHGSAPDIAGQNKANPLATILSLAML LRYSLNDEARAQQVENAVQKVLQQGLRTSDIYEEGTKLVSCSEMGDAVLAAL
104	1044	MAAFNTQKVLSVHHWTDAYFTFTCTRDESLRFENGQFVMVGLMVDGKPLMRAYSVASANWEEHLEFFSIKVQDGPL TSRLQHLKVGDDVLISKKPTGTLVAGDLNPGKHLYLLSTGTGIAPFLSITKDPEIYEQFEKIILVHGVRYKKDLAY YDRFTKELPEHEYLGDLVKEKLIYYPIVSREEFEHHGRLTDLMVSGKLFEDIGLPKINPQDDRAMLCGSPAMLKDT CKVLDDFGLTVSPKTGVRGDYLIERAFVDQ
105	1046	MKYISTRGETAHKPFSEVLLMGLAPDGGLMLPEHYPQIGRETLDKWRGLAYPELAFEIMRLFVTDIPEDDLRDILN RTYTEAAFGTKEITPVRTLSDGIKIQALSNGPTLAFKDMAMQFLGNAFEYVLNKEGKKLNILGATSGDTGSAAEYA LRGKKGVNVFMLSPDGKMSAFQRAQMYSLQDENIHNIAVKGMFDDCQDIVKAVQNDAAFKEKYHIGTVNSINWGRI VAQVVYYFAGYFNATSSNDETVSFCVPSGNFGNVCAGHIAKQMGLPIRRLIVATNENDVLDEFFKTGAYRPRNSAH TYVTSSPSMDISKASNFERFVFDLMDRDPAEINTLWAEVAAGKGFDLRFALDKVGGKYGFTSGKSTHADRLATIKQ VYEQDQELIDPHTADGVKVAREVREEGEMVVCLETALAAKFDATIREAVGDAAIPRPAALEGLENLPQRVQTVPNS ADAVKGIIEQTLA
106	1053	MKKTVFTCAMIALTGTAAAAQELQTANEFTVHTDLSSISSTRAFLKEKHKAAKHISVRADIPFDANQGIRLEAGFG RSKKNIINLETDENKLGKTKNVKLPTGVPENRIDLYTGYTYTQTLSDSLNFRVGAGLGFESSKDSIKTTKHTLHSS RQSWLAKVHADLLSQLGNGWYINPWSEVKFDLNSRYKLNTGVTNLKKDINQKTNGWGFGLGANIGKKLGESASIEA GPFYKQRTYKESGEFSVTTKSGDVSLTIPKTSIREYGLRVGIKF
107	1070	MTQTNRVIIFDTTLRDGEQSPGAAMTKEEKIRVARQLEKLGVDIIEAGFAAASPGDFEAVNAIAKTITKSTVCSLS RAIERDIRQAGEAVAPAPKKRIHTFIATSPIHMEYKLKMKPKQVIEAAVKAVKIAREYTDDVEFSCEDALRSEIDF

		LAEICGAVIEAGATTINIPDTVGYSIPYKTEEFFRELIAKTPNGGKVVWSAHCHNDLGLAVANSLAALKGGARQVE CTVNGLGERAGNASVEEIVMALKVRHDLFGLETGIDTTQIVPSSKLVSTITGYPVQPNKAIVGANAFSHESGIHQD GVLKHRETYEIMSAESVGWATNRLSLGKLSGRNAFKTKLADLGIELESEEALNAAFARFKELADKKREIFDEDLHA LVSDEMGSMNAESYKFISQKISTETGEEPRADIVFSIKGEEKRASATGSGPVDAIFKAIESVAQSGAALQIYSVNA VTQGTESQGETSVRLARGNRVVNGQGADTDVLVATAKAYLSALSKLEFSAAKPKAQGSGTI
108	1073	MIKISTRFDAGSVVVKDLTDPSNIRLALRPDNASDFAQWFYFRLQGAAYQNCIMHFENAAEAAYPKGWEGYQACAS YDRRNWFRVPTSYENGVLTVNHTPLSNSVYYAYFEPYSEEQHLNLLGDAQGSGLCRIDDLGSTVQGRDINLLTIGN QVESDLKIWITARQHPGETMAEWFIEGLLGRLLDPQDPTARALLDRATFYIVPNMNPDGSALGNLRTNAAGANLNR EWENPTVEKSPEVFFVREKMLETGVDLFLDIHGDEGLPFVFVAGTEGVPNYNPRIAALEAQFKNALLNASPDFQDE YGYEKDAPGEANMTLATNWVGNRFNCLAYTLEMPFKDNANLPDDDFGWNGQRSLRLGEAALSAILNVIGDLR
109	1127	MATLSDKTILVTGASQGLGEQVAKAYAAAGATVILVARHQKKLEKVYDAIVEAGYPEPFAICFDLISAEEKEFEHF AATIAEATQGKLDGIVHCAGYFYALSPLDFQTVAEWVNQYRINTVAPMGLTRALFPLLKQSPDASVIFVGESHGET PKAYWGGFGASKAALNYLCKVAADEWERFGNLRANVLVPGPINSPQRIKSHPGEAKSERKSYGDVLPAFVWWASAE SKGRSGEIVYL
110	1131	MALLQISEPGMSAAPHRHRLAAGIDLGTTNSLVATVRSGSAACLPDAEGRVTLPSVVRYLENGGIEVGKTALSAQK TDPLNTVSSAKRLIGRTLADLHQNTHYLPYRFGDNQRVIELHTRQGVKTPVEVSAEILKTLKSRAEETLGGDLVGV VITVPAYFDDAQRQATKDAARLAGLNVLRLLNEPTAAAIAYGLDNASEGTFVVYDLGGGTFDVSVLQLTKGLFEVK ATGGNSALGGDDFDHRLFCRLLEQNGLSQLNEQDSQLLLSLVRAAKEQLTTQTEARIQATLSDGMAIDTSISRAEF HNLTQHLVMKTLEPVTQALKDAGVGKNEVKGVIMVGGSTRMLHVQQAVATFFGQTPLNNLNPDEVVALGAAIQANV LAGNKTDGEWLLLDVTPLSLGLETYGGLAEKIIPRNSTIPTARAQDFTTFKDGQTAMTIHVVQGERELVADCRSLA KFTLRGIPPMAAGAARIRVTFQIDADGLLSVSAQEQSTGVQAQIEVKPSYGLDDDTITQMLKDSMSNAAEDMAARA RAEAVVEAESLTDAVNAALELDSDLLDAEELQQIRQGIADLQGRLKDGKAEDIRAAAAKLGSITDNFAAKRMNRNI QRALTGQSVDNI
111	1150	MPEYRSKTSTHGRNMAGARALWRATGVMETDFGKPIIAVANSFTQFVPGHVHLHNMGQLVAREIEKAGAIAKEFNT IAIDDGIAMGHSGMLYSLPSRDLIADSIEYMVNAHCADALVCISNCDKITPGMLIAAMRLNIPTIFVSGGPMEAGK VIGVANIQPERRLDLIDAMIESADDNVSNRQVEEVEQNACPTCGSCSGMFTANSMNCLTEALGLSLPGNGSYLATH AGRKELFLEAGRMIVEITKRYYEQNDETVLPRSIATKKAFENAMTMDIAMGGSTNTILHLLAVANEAGVDFKMADI DRLSRVVPCICKTAPNNHDYYMEDVHRAGGIFAILKELDKAGKLHTDVHTIHAPTLKDAIEQWDVTNPENTRAIER FKAAPGGVRTTQAFSQNRMWKTLDLDREKGCIRDVAHAYSQDGGLAVLFGNIAERGCVVKTAGVDESILKFTGRAR VFESQEDAVEGILGNQIVAGDIVIIRYEGPKGGPGMQEMLYPTSYLKSKGLGKACALLTDGRFSGGTSGLSIGHAS PEAAEGGAIGLVHEGDTVEIDIPNRSIHLAISDEELAARRAEMEARGSKAWKPKNRDRYVSAALRAYGAMATSADK GAVRDVAQIER
112	1201	MRIVEKAYTFDDVLLVPAHSTVLPRDVKLQTKLTREITLNLPLLSAAMDTVTEARLAISMAQEGGIGIIHKNMPPE MQARAVSKVKRHESGVVKDPVTVAPTTLIREVLEMRAQRKRKMSGLPVVENGKVVGIVTNRDLRFENRVDLPVSAI MTPRERLVTVPEGTSIDEARELMHTHKVERVLVLNEKDELKGLITVKDILKTTEFPNANKDSEGRLRVGAAVGTGG DTEERVKALVEAGVDVIVVDTAHGHSQGVIDRVRWVKETYPHIQVIGGNIATAKAALDLVAAGADAVKVGIGPGSI CTTRIVAGVGVPQLTAIHNVAEALKGTGVPLIADGGIRFSGDIAKALAAGAYSVMLGGMFAGTEEAPGEIELYQGR SYKSYRGMGSLGAMSQGSADRYFQDKTDSTDKYVPEGIEGRVPYKGPIVNIIHQLTGGLRSSMGYLGCANIAEMHE KAEFVEITSAGMSESHVHDVQITKEAPNYHR
113	1206	MKGDRLVIRELNKNLGLLLVTINQYFLHARILKNWGFEELGEHFFKQSIVEMKAADDLIERILFLEGLPNLQELGK LLIGESTEEIIACDLTKEQEKHEALLAAIATAEAQQDYVSRDLLEKQKDTNEEHIDWLETQQELIGKIGLPNYLQT AAQED
114	1228	MKPVNIGLLGLGTVGGGTAAVLRDNAEEISRRLGREIRISAVCDLSEEKARQTCPSAAFVKDPFELVAREDVDVVV ELFGGTGIAKDAVLKAIENGKHIVTANKKLLAEYGNEIFPLAEKQNVIVQFEAAVAGGIPIIKALREGLAANRIKS IAGIINGTSNFILSEMREKGSAFADVLKEAQALGYAEADPTFDIEGNDAGHKITIMSALAFGTPMNFSACYLEGIS KLDSRDIKYAEELGYRIKLLGITRKTGKGIELRVHPTLIPESRLLANVNGVMNAVRVNADMVGETLYYGAGAGALP TASAVVADIIDIARLVEADTAHRVPHLAFQPAQVQAQTILPMDEITSSYYLRVQAKDEPGTLGQIAALLAQENVSI EALIQKGVIDQTTAEIVILTHSTVEKHIKSAIAAIEALDCVEKPITMIRMESLHD
115	1231	MTQKEKHFEEYAALATLPLRDVVVYPHMVLPLFVGRPKSIAALENAITREEPVFLLAQTDAAVEEPIAADLYQTGT VAQVLQVLKLPDGTVKVLVEGLYRGRVLTIEDTGGLFVSHIETVVEEDTGGNTDLEAVRRTLLAQFEQYAKLNKKI PAEIIGSINGIAENSRLTDTVAAHLQLKLAQRQQILEIPEIGKRMEFLLAQLESELDIMQAEKRIRGRVKRQMEKS QREYYLNEQIKAIHKELGEEDENGELDALEADIKKAGMTKEAEEKCLSELKKLKMMPPMSAESTVVRNYIDTLLEL PWKKKSRVSKDIAKAGLVLDADHYGLEKVKERILEYLAVQKRMDKLKGPILCLVGPPGVGKTSLGESIAKATGRKY VRMALGGVRDESEIRGHRRTYIGSMPGKILQNMAKAGVKNPLFLLDEIDKLGNDFRGDPASALLEVLDPEQNNKFA DHYAEVDYDLSDVMFIATSNSLNIPTPLLDRMEIIRLSGYTEDEKINIAMQYLVPKQMKRNGVKEGELAIEESAVR DIIRYYTREAGVRSLDREIAKICRKVVMQITLDEDKKRLSETKKTSKAKPKAVKVNEKNLHDYLGVRRFDYGVAES ENRIGQVTGLAWTEVGGELLTVEAAALPGKGVIQCTGQLGDVMKESVSAAWSVVRSRAESVGLAPDFYEKKDIHIH VPEGATPKDGPSAGIAMTLAAVSFTKIPVRADVAMTGEITLRGEVLPIGGLKEKLLAALRGGIKHVLIPKDNVKD LEEIPENVKTGLTIHPVKWIDEVLALGLESQPEPWAEPSGAEAAAESASKPKPRSRATKH
116	1240	MISTNGITMQFGAKPLFENVSVKFGEGNRYGLIGANGSGKSTFMKILGGDLEQTAGEVAIENGVRLGKLRQDQFAY EDMRVLDVVMMGHTEMWAAMTERDAIYANPEATEDDYMKAAELEAKFAEYDGYTAEARAAELLSGVGISEDLHNAK MAEVAPGFKLRVLLAQALFSKPDVLLLLDEPTNNLDINTIRWLEGVLNQYDSTMIIISHDRHFLNEVCTHMADLDYN

		TITIYPGNYDDYMLASAQSRERALKDNAKAKEKLQELQEFVARFSANKSKARQATSRLKQADKIKSEMVEVKPSTR QNPYIRFEADEKAKLHRQAVEVEKLAKRFETQLFKNLNFILEAGQRLAIIGPNGAGKSTLLKLLAGAYNPEYSDGL LPDEGTIKWAEKASVGYYPQDHENDFDVDMDLSEWMRQWGQEGDDEQVIRGTLGRLLFGSNDVVKKVKVLSGGEKG RMLYGKLLLLKPNVLVMDEPTNHMDMESIESLNMALEKYNGTLIFVSHDRQFVSSLATQIIELDGKGGYEHYLGDY ESYLEKKGVA
117	1252	MSTSLSYRDAGVDIDAGDQLVENIKPFAKRTMRPEVLGDLGGFGALVEIGKKYQNPVLVSGTDGVGTKLKLAFDWD KHDTVGIDLVAMSVNDILVQGAEPLFFLDYFACGKLDVPRATDVIKGIAQGCEESGCALIGGETAEMPGMYPVGEY DLAGFAVGVVEKENVITGRSIGVGDVVLGLASNGAHSNGYSLIRKIIERDNPDLDAEFDNGKTLREAVIAPTRLYV KPILAALEKFTIKGMAHITGGGITENVPRVLPENTVAQIDAKSWELPKLFQWLQKAGNVETQEMYRTFNCGIGMVV IVAAEDADAVQGLLGEQGETVYRLGLIREROGDEHOTQVA
118	1301	MSMENFAQLLEESFTLQEMNPGEVITAEVVAIDQNFVTVNAGLKSESLIDVAEFKNAQGEIEVKVGDFVTVTIESV ENGFGETKLSREKAKRAADWIALEEAMENGDILSGIINGKVKGGLTVMISSIRAFLPGSLVDVRPVKDTSHFEGKE IEFKVIKLDKKRNNVVVSRRAVLEATLGEERKALLENLQEGSVIKGIVKNITDYGAFVDLGGIDGLLHITDLAWRR VKHPSEVLEVGQEVEAKVLKFDQEKQRVSLGMKQLGEDPWSGLTRRYPQGTRLFGKVSNLTDYGAFVEIEQGIEGL VHVSEMDWTNKNVHPSKVVQLGDEVEVMILEIDEGRRRISLGMKQCQANPWEEFAANHNKGDKISGAVKSITDFGV FVGLPGGIDGLVHLSDLSWTESGEEAVRKYKKGEEVEAVVLAIDVEKERISLGIKQLEGDPFGNFISVNDKGSLVK GSVKSVDAKGAVIALSDEVEGYLPASEFAADRVEDLTTKLKEGDEVEAVIVTVDRKNRSIKLSVKAKDAKESREAL NSVNAAANANAGTTSLGDLLKAKLSGEQE
119	1302	MTKSELMVRLAEVFAAKNGTHLLAKDVEYSVKVLVDTMTRSLARGQRIEIRGFGSFDLNHRPARIGRNPKTGERVE VPEKHVPHFKPGKELRERVDLALKENAN
120	1313	MMSVTVETLENLERKVVLSLPWSEINAETDKKLKQTQRRAKIDGFRPGKAPLKMIAQMYGASAQNDVINELVQRRF YDVAVAQELKVAGFPRFEGVEEQDDKESFKVAAIFEVFPEVVIGDLSAQEVEKVTASVGDAEVDQTVEILRKQRTR FNHVEREARNGDRVIIDFEGKIDGEPFAGGASKNYAFVLGASQMLPEFEAGVVGMKAGESKDVTVNFPEDYHGKDV AGKTAVFTITLNNVSEATLPEVDADFAKALGIADGDVAKMREEVQKNVSREVERRVNEQTKESVMNALLKAVELKA PVALVNEEAARLANEMKQNFVNQGMADAANLDLPLDMFKEQAERRVSLGLILAKLVDENKLEPTEEQIKAVVANFA ESYEDPQEVIDWYYADPSRLQAPTSLAVESNVVDFVLGKAKVNEKALSFDEVMGAQA
121	1320	MQIILLEKIGGLGNLGDIVTVKNGYARNFLIPAGKAKRATEANMKEFEARRAELEAKQAEILADARVRQEKLDGQT VTVAQKAGVDGRLFGSVTNADIAAAIVAAGIEAVKANVRLPNGPLKAVGEYEVEVALHTDAVAKITVAVVAATE
122	1323	MRHYEIVFIVHPDQSEQVPAMVERYKTMIAEANGKIHRLEDWGRRQLAYPINKIHKAHYVLMNIETTPEVVEELET AFRFNDAILRHLTIKTKHAVTEASPMLGGEKAKNLLSGASEEAVAQ
123	1324	MSQHRKLIILGSGPAGYTAAVYAARANLNPVIITGIAQGGQLMTTTEVDNWPADADGVQGPELMARFLAHAERFGT EIIFDQINAVDLQKRPFTLKGDMGEYTCDALIVATGASAKYLGLPSEEAFAGKGVSACATCDGFFYKNQDVAVVGG GNTAVEEALYLANIAKTVTLIHRRSEFRAEKIMIDKLMKRVEEGKIILKLESNLQEVLGDDRGVNGALLKNNDGSE QQIAVSGIFIAIGHKPNTDIFKGQLEMDEAGYLKTKGGTADNVGATNIEGVWAAGDVKDHTYRQAITSAASGCQAA LDAERWLGSQNI
124	1328	MTDTAENQTQNNWQAGHPRSIRSFVLRQSHMTAAQQRAIDTLWDSFGIDYQATPADLDARFGSSRPKILEIGFGMG TATAEIARRLPETDFLAIDVHGPGVGNLLKLIDENHLENIRVMRHDAVEVVENMLQDGSLDGIHIFFPDPWHKKRH HKRRLIQAPFIAKLLPKLKTGGYIHLATDWEEYAQQMLEVLSSFDSLQNTAADYAPTPDYRPETKFEARGKRLGHG VWDLVFKRIG
125	1339	MKASQFFISTLKEAPAEAALASHKLMIRAGLIKANASGLYTWMPMGLRVLRKVENVVREEMARAGSVELLMPVVQP AELWQESGRWEFYGKELLRLKDRHDRDFCMGPTCEEVIADIVRKEINSYKQLPKNFYHIQTKFRDEVRPRFGVMRA REFVMKDAYSFHADYASLQTTYQDMYDAYCRIFTRLGLAFRPVAADTGSIGGTGSHEFQVLAESGEDVIAYSDTSD YAANIELAPTLPLKGERAAAQAELVKVHTPNVKTIDSLVDFLSIPIEKTLKSIVVEGENEGELILLLLRGDHEFND IKAEKLAGVKSPLTMASPAAIVEQFGANGGSLGPVGFAGKVYADFATEKGADWVIGANEDDYHYTGFNFGRDAAEP EFVDLRNVVEGDESPDGQGRLKLARGIEVGHVFQLRDKYTQAMNVSFLDNNGKSQIMEMGCYGIGITRVVAAAIEQ NNDEKGIIWTKAMAPFEVVIVPMNYKKSDTVREAADKIYAELLAAGADVLLDDRDERAGVLLNDSELLGIPHRIVI GDRALKEGNVEYAERRDNEAQAVAIGEIVARVTASLNA
126	1341	MSTQLHDVDPIETQEWLDALSSVLEYEGGERAQYLLENLVKYCRDKGVRMPHGTTTPYLNTVSVENEKGIPGDQNI EHRIRAFVRWNAAAIVLRAGKKDLELGGHIASFQSAATMYEVGFNHFWKAKGEGEEGDLVFFQGHVAPGIYARAFV EGRLTEDQLNNFRQEVDGHGLPSYPHPHLLPDFWQFPTVSMGLGPIMAIYQARFLKYLESRGLAKTKGRKVWCFCG DGEMDEPESQGAIALAAREGLDNLIFVINCNLQRLDGPVRGNGKIIQELEGNFAGAGWNVVKVIWGRRWDRLLAKD KDGILRQRMEECLDGDYQTYKSKDGAYVREHFFNTPELKALVADMTDEQLWALNRGGHDPQKVYNAYDRAANHADG KPTVILAKTIKGYGMGASGEGQNVAHQAKKMDKASLKQFRDRFDIPVTDEQIESGDLPYLTFAPDTEEYKYLHARR DALGGYLPQRKPTQEVLEVPELSAFDAQLKSSGEREFSTTMAFVRILSTLLKDKKIGKRVVPIVPDESRTFGMEGM FRQYGIWNPKGQQYTPQDKDQLMFYKESVDGQILQEGINEPGAMADWIAAATSYANSNFAMIPFYIYYSMFGFQRI GDLAWAAGDMHARGFLLGGTAGRTTLNGEGLQHEDGHSHIQADLIPNCVSYDPTFQYEVAVIVQDGLRRMYANNED VFYYITLMNENYTHPDMPEGAEQDILKGMYLLKAGGKGDKKVQLMGSGTILQEVIAGAELLKADFGVEADIWSCPS FNLLHRDAVEVERFNRLHPLEAEKVPFVTSQLQGHDGPVIAATDYIRSYADRIRAYIPNDYHVLGTDGFGRSDSRA NLRRFFEVDRYNVAVAALAALAEQGKVSKETVQQAIEKYGIKADSAPSWKR
127	1342	MSIVEIKVPDIGGHENVDIIAVEVKAGDTIAVDDTLITLETDKATMDVPADAAGVVKEVKVKVGDKISEGGVILTV ETGAAAAEAAPAAAEAQPAPAAAPAAAGGATVQVAVPDIGGHTDVDVIAVEIKVGDTVAEDDTLITLETDKATMDV PCTAAGVVKAVFLKVGDKVSEGSAIIEVETVGSAAAAPAQAAQAAAPAAAPPPTAAAAPAAAPAPSAPAAAKIDEA

		AFAKAHAGPSARKLARELGVDLGQVKGTGLKGRIMGDDIKAFVKSVMQGGAAKPAAASASLGGGLDLLPWPKVDFS KFGNVEVKELSRIKKISGQNLSRNWVVIPHVTVHEEADMTELEEFRKQLNKEWEREGVKLSPLAFIIKASVSALKA FPEFNASLDGDNLVLKNYFNIGFAADTPNGLVVPVIKDVDQKGLKQISQELTELSKKAREGKLKPQEMQGACFTIS SLGGIGGTGFTPIVNAPEVAILGVCKSQIKPVWNGKEFAPRLMCPLSLSFDHRVIDGAAGMRFTVFLAKLLKDFRR ITL
128	1343	MGNFLYRGISCQQDEQNNGQLKPKGNKAEVAIRYDGKFKYDGKATHGPSVKNAVYAHQIETGLYDGCYISTTTDKE IAKKFATSSGIENGYIYVLNRDLFGQYSIFEYEVEHPENPNEKEVTIRAEDCGCIPEEVIIAKELIEIN
129	1344	MALVELKVPDIGGHENVDIIAVEVNVGDTIAVDDTLITLETDKATMDVPAEVAGVVKEVKVKVGDKISEGGLIVVV EAEGTAAAPKAEAAAAPAQEAPKAAAPAPQAAQFGGSADAEYDVVVLGGGPGGYSAAFAAADEGLKVAIVERYKTL GGVCLNVGCIPSKALLHNAAVIDEVRHLAANGIKYPEPELDIDMLRAYKDGVVSRLTGGLAGMAKSRKVDVIQGDG QFLDPHHLEVSLTAGDAYEQAAPTGEKKIVAFKNCIIAAGSRVTKLPFIPEDPRIIDSSGALALKEVPGKLLIIGG GIIGLEMGTVYSTLGSRLDVVEMMDGLMQGADRDLVKVWQKQNEYRFDNIMVNTKTVAVEPKEDGVYVTFEGANAP KEPQRYDAVLVAAGRAPNGKLISAEKAGVAVTDRGFIEVDKQMRTNVPHIYAIGDIVGQPMLAHKAVHEGHVAAEN CAGHKAYFDARVIPGVAYTSPEVAWVGETELSAKASGRKITKANFPWAASGRAIANGCDNGFTKLIFDAETGRIIG GGIVGPNGGDMIGEVCLAIEMGCDAADIGKTIHPHPTLGESIGMAAEVALGTCTDLPPQKKK
130	1347	MNPFLNTAFKAARRAGQMMIRAAGNLDAVKTDSKAFNDFVSDVDRNSEIILVEALKEAYPHHKITCEESGSHGKAA AEYEWIIDPLDGTTNFLHGHPQYAISMALLHKGVLQEALVYAPERNDVYMASRGKGALLNDRRIRVSNRIELNRCL IGTGFPVVDQSMMDKYLAILKDFLAKTAGGRREGAASLDLCAVATGRFDGFFEFNLKPWDIAAGALIVQEAGGIVT DMSGEDGWLESGDIVAANPKVLAQMLKIISAHV
131	1356	MTQYTLKQASVLLQSKQISAVELASAYLAAIAEKNPALNGYITIDQDKTLAEARAADERIAQGNASALTGVPVAYK DIFCQTGWRSACASKMLDNFISPYTATVVQNLLDEGMVTLGRTNMDEFAMGSTNENSFYGAAKNPWNLEHVPGGSS GGSAAVVAARLAPAALGSDTGGSIRQPASHCGITGIKPTYGTVSRFGMVAYASSFDQTGPMAQTAEDCAILLNAMA GFDPKDSTSLEREKEDYTRDLNQPLKGLKIGLPKEYFGEGNSADVLTALQNTIDLLKAQGAELIEVSLPQTKLSIP AYYVLASAEASTNLSRYDGVRYGHRAAQFADLEEMYGKTRAEGFGSEVKRRIMIGTYVLSHGYYDAYYLKAQKLRR LVADDFQTAFARCDLILAPTAPTAAPKIGADASPVETYLSDIYTIAVNLAGLPALTLPAGFSGGGLPVGVQLVGNY FAEAKILGAAHQIQLNSDWHGKRPE
132	1358	MTWETVIGLEIHVQLNTKSKIFSGASTAFGAEPNAHASVVECALPGVLPVMNREVVEKAIKLGLALDAKINQKNVF DRKNYFYPDLPKGYQISQLDLPIVEHGKLEIVVGDDVKTINVTRAHMEEDAGKSVHEGLNGATGIDLNRAGTPLLE VVSEPEMRSAAEAVAYAKALHSLVTWLDICDGNMAEGSFRVDANVSVRPKGQEEFGTRREIKNLNSFRFLEQAINY EAEAQIEILEDGGKVQQATMLFDPEKGETRVMRLKEDAHDYRYFPDPDLLPVIISDAQMQKAKAEMPELPKEMAAR FVADYGVSEYDARLLTASRAQAAYFEEAAKESGQGKLTANWMNGELAAALNKEGMELADSPITAPRLAALVGKIAD GTLSSKLAKKAFEAMWAEPEATIAEIIEKHGLQQMTDTGEIEAMVDEVLANNAKAVEQFKSGNEKALNAIVGQVMK ASKGKANPAQVQELIKAKLA
133	1372	MSNENRTCSFCGKSKSHVKHLIEGENAFICDECVSNCIEILHEDGNDGTPSESAGGEPEESGKLPTPAEIVANLND HVIGQEQAKKALAVSVYNHYKRLRHPKAGANVELSKSNILLIGPTGSGKTLLAQSLARKLDVPFVMADATTLTEAG YVGEDVEQIITKLLGKCDFDVEKAQRGIVYIDEIDKISRKSDNPSITRDVSGEGVQQALLKLIEGTVASVPPQGGR KHPNQEFINVDTTNILFICGGAFAGLEKVIRQRTEKGGIGFGASVHSKDENADITKLFGIVEPEDLIKFGLIPELI GRLPVIATLEELDEDALINILTEPKNALVKQYQALFGMENVELEFEEGALRSIARQAMERKTGARGLRSIVERCLL DTMYRLPDLKGLKKVVVGKAVIEEGREPELVFES
134	1379	MTVKTPVYLDYAATPPVDKRVAEKMIPYLTETFGNPASNSHSFGWEAEEAVEKARADIAALINADSKEIVFTSGAT ESNNLAIKGAAHFYKSKGNHLITVKTEHKAVLDTMRELERQGYEVTYLDVQENGLVDLDVLKAAIREDTILVSVMW VNNEIGVVQDIPAIGEICRERKIIFHVDAAQACGKVPVDVEAAKVDLLSMSGHKVYGPKGIGALYVRRKPRVRLEA QMHGGGHERGFRSGTLPTHQIVGMGEAFRIAKEELAQDTAHYLKLRDIFLKGIEGIEEVYINGDLEHRVPNNLNVS FNFVEGESLIMAVKELAVSSGSACTSASLEPSYVLRALGRNDELAHSSLRITFGRMTTEEEVQFAAELIKSKIGKL RELSPLWEMFKDGIDLNSIEWAAH
135	1390	MSSTPNKQAGYPRLVADIGGTNARFALETAPRVIEKAAVLPCKDYDTVTDAVRAYLNQSGATAVRHAAFAIANPIL GDWVQMTNHHWAFSIETTRQTLGLDTLILLNDFTAQALAVTQTSSKDLMQVGGQKPVEFAPKAVIGPGTGLGVSGL VHSHAGWVALAGEGGHTSFPPFDDMEVLIWQYAKNKYGHVSAERFLSGAGLSLVYEALAAKQKAKPAKLMPSEITE KALSGASPLCRQTLDIFCAMLGTVASNLALTLGARGGVYLCGGIIPRVLEYFKTSPFRSRFENKGRFEAYLAAIPV YVVLSEFPGISGAAAALDNHLRNV
136	1392	MSTQTNFDLVLFGATGDLAMRKLLPCLYQAHVAGLLHPEGRILGVSRSELDTEGFLAKVETSSKIHVKENFSDEAW ASFVERFAYLKVDVTQPDDFAALGDLVKARKETDNVVIYLSTAPKFFAQACENLAAIGLNADNVRVVLEKPLGTDL ASSQQINTDVARYFKEGQIYRIDHYLGKESLQNLLALRFANVMFEPLWNNKYIESVQLTIAEQLGVEERGEFYDIT GALRDMVQNHLMQMLCMTAMEAPASLDADAVRDEKVKVIKSLKPLTVESVNENVVRGQYTAARGMNGYLEEINVPQ DSFTETYVAIKAEIENERWKGVPFYLRTGKRMAGKVAEIVLNFKDLNSHIFEGSRTAPNRLVIELQPYESVRLYTQ MKTPGAGNKVETVPLATDLGKALEGRRAEAYERLLLDVINGKLALFNRRDELEAAWEYVMPILENWTNNTTPPHGY GAHSWGPEAARELLARDGHKWHEEQ
137	1425	MSEQNHPQTEPQLDENQIIALRREKLHNIRQQRNAYPNDFKRDSFAADLHAQYGEIGKEELDPQGIPVKVAGRMML KRQMGKASFATIQDVSGQIQLYLNNKGVSQEVLDDFNHWDLGDIVGAEGTLFKTNHGELTVRVSGIRLLSKSLRPL PDKHKGLSDQETKYRQRYVDLIANEESRNTFIKRSQIIQSVRNFMVGEHYLEVETPMMHPIPGGATAKPFVTHHNA LDIPLYLRIAPELYLKRLVVGGLERVFEINRSFRNEGMSVRHNPEFTMIEFYEAFSDYERMMQMAEDIIRNASRTV NGTANITYNGKEVDLESPFERLTILEAIKKYNPHYTDEQLNDAEWLKKEIVKHGESLPPSPGIGSLQLALFEGCAE

		GKLWNPTFIVDYPVEVSPLARASDTKQGLTERFELFVVGRELANGYSELNDPEDQAERFKAQVVQKDAGDDEAMHY DADYIRAMEFGLPPTGGCGIGIDRLVMLLTDSQTIRDVILFPQMRPE
138	1429	MRKKLTALVLSALPLAAVADVSLYGEIKAGVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKISDFGSF IGFKGSEDLGDGLKAVWQLEQDVSVAGGGATQWGNRESFIGLAGEFGTLRAGRVANQFDDASQAIDPWDSNNDVAS QLGIFKRHDDMPVSVRYDSPEFSGFSGSVQFVPIQNSKSAYTPAYYTKNTNNNLTLVPAVVGKPGSDVYYAGLNYK NGGFAGNYAFKYARHANVGRNAFELFLIGSGSDQAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGDKTK NSTTEIAATASYRFGNAVPRISYAHGFDFIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAWLKRNTGIGNYTQ INAASVGLRHKF
139	1445	MSDDKSKALAAALAQIEKSFGKGAIMKMDGSQQEENLEVISTGSLGLDLALGVGGLPRGRIVEIFGPESSGKTTLC LEAVAQCQKNGGVCAFVDAEHAFDPVYARKLGVKVEELYLSQPDTGEQALEICDTLVRSGGIDMVVVDSVAALVPK AEIEGDMGDSHVGLQARLMSQALRKLTGHIKKTNTLVVFINQIRMKIGVMFGSPETTTGGNALKFYSSVRLDIRRT GSIKKGEEVLGNETRVKVIKNKVAPPFRQAEFDILYGEGISWEGELIDIGVKNDIINKSGAWYSYNGAKIGQGKDN VRVWLKENPEVANEIDAKIRALNGVEMHITEGTQDETDGERPEE
140	1452	MQNIFDPLVIRGKSLTPIVQGGMGVGVSASGLSSAVARENGIGTIASVDLRHLHEDLLAESQINPSEEKYTSLNCT ALDREIQKAKSASEGKGLIAVNVMKAVKDHAAYVRQACESGADAVVMGAGLPLDLPEMTEGYHKDVALLPILSESR GININVLKRWMKKGILPDAIVVEHPAHAAGHLGASTVEGVNDAKFDFKRVIEETFEVFKSLGLESEKIPLILAGGMA NFEKVKTALKNWGASAVQIGTAFAVTEEGDAHLNFKKTLAGAETEKVVEFMSVAGLPARGVRTKFLDSYIKRESKL QTNAKADPRRCTQGLNCLTSCGLRDGLSKAGQFCIDIQLAAAFRGEVDKGLFFRGKDRCPSAMPSAPSARRYNIC
141	1457	MSQLANAIRFLSADAVQKANSGHPGAPMGMAEMAETLWTKFLNHNPANPKFYNRDRFVLSNGHASMLLYSLLHLTG YNLSIEDLKNFRQLHSKTPGHPEYGYTDGVETTTGPLGQGIANAVGMALAEKILAAEFNKDGLNIVDHYTYVFMGD GCLMEGVSHEACSLAGTLGLGKLIVLYDDNNISIDGKVDGWFTENIPQRFESYGWHVVPNVNGHDTAAIQAAIEAA RAETGKPSIICCKTLIGKGSANKEGSHKTHGAPLGADEIEATRKHLGWTYPAFEIPQEIYDAWNAKEQGAKLEADW NELFAQYQAKYPAEAAEFVRRMDKKLPDNFDEYVQAALKEVCAKAETIATRKASQNSIEILAKELPELVGGSADLT PSNLTDWSNSVSVTRDKGGNYIHYGVREFGMGAIMNGLVLHGGVKPFGATFLMFSEYERNALRMAALMKINPVFVF THDSIGLGEDGPTHQPIEQTATLRLIPNMDVWRPCDTAESLVAWAEAVKAADHPSCLIFSRQNLKFQARSEQQLND IKRGGYVISEAQGNAQAVIIATGSEVELALEAQKALAAQNIAVRVVSMPSTNVFDRQDAAYQAAVLPEGLPRIAVE AGHADGWYKYVGLNGAVVGINRFGESAPADLLFKAFGFTVDNVVDTVKSVL
142	1471	MSKKRVLTGVTTTGIPHLGNYVGAIRPAVRAAQNLDTESFLFLADYHGIIKCHEPEMIHQSTQAVAATWLACGLDP ERTTFYRQSDTPEVMELNWILTCITAKGLMNRAHAYKAAVQANAENGQEDPDFGVEMGLFSYPILMTADILMFNAN EVPVGRDQIQHVEMARDIAGRFNHRFRELFTLPEVKIDENVELLVGLDGRKMSKSYGNTIPLWENDKKTQKSVNKI ITNMKEPGEPKQPDESPLFEIYKAFSTPSETVEFTKMLADGLAWGEAKKLLAAKINAELAEPRERYNELTADPSQI EEILQAGAAKARKEARELLDKVRDAVGIRPLK
143	1472	MRYDKLTAKFQQALAEAQSLALAADGSYLEAGFVLKALLDDQNSGAAALLAHAGVNVPQVKQRLQQHLNSLPKVSG QGGDILPSRELQAVLNLMDKAATKRSDAYIASELFLLALVQQNDATGKILKEAGATEQNINAAIDAVRGGQNVNDA NAEDQRDALKKYTLDLTQRARDGKLDPVIGRDDEIRRAIQVLQRRTKNNPVLIGEPGVGKTAIVEGLAQRIVNGEV PESLRNKRLLVLDLAALIAGAKYRGEFEERLKGVLNDLAKDDGNTLIFIDEIHTLVGAGKTDGAMDAGNMLKPALA RGELHCIGATTLDEYRQYIEKDAALERRFQKVLVGEPSVEDTIAILRGLQERYEIHHGIDITDPAIVAAAELSDRY ITDRFLPDKAIDLIDEAASRVKMEKETKPEAMDKIDRRLIQLRMEKAHVEKEKDDASKKRLELIDEEINGLQKEYA DLDEIWKAEKAISDGAANIKKQIDEVKIKIEQAKRQGDLALASKLMYEDLEHLEKQRAAAERADTDSTKPANKLLR NNVGAEEIAEVVSRMTGIPVSKMMEGERDKLLKMEEVLHRRVVGQDEAVRAVSDAIRRSRSGLADPNKPYGSFLFL GPTGVGKTELCKALAGFLFDSEDHLIRIDMSEYMEKHAVARLIGAPPGYVGYEEGGYLTEQVRRKPYSVILLDEVE KAHPDVFNILLQVLDDGRLTDGQGRTVDFKNTVIVMTSNIGSQHIQQMGIQDYEAVKEVVMEDVKEHFRPEMINRI DEVVVFHGLDQDNIRNIAKIQLKGLEKRLEKQNLRLAVSDAALDIIAKAGFDPIYGARPLKRAIQSEIENPLAKAL LAGNYAPESEIRVEADGDRLKFA
144	1506	MNLHQTVEHEAAAAFAAAGIADSPIVLQPTKNAEHGDFQINGVMGAAKKAKQNPRELAQKVAEALADNAVIESAEV AGPGFINLRLRPEFLAQNIQTALNDARFGVAKTDKPQTVVIDYSSPNLAKEMHVGHLRSSIIGDSISRVLAFMGNT VIRQNHVGDWGTQFGMLVAYLVEQQKDNAAFELADLEQFYRAAKVRFDEDPAFADTAREYVVKLQGGDETVLALWK QFVDISLSHAQAVYDTLGLKLRPEDVAGESKYNDDLQPVVDDLVQKGLAVEDDGAKVVFLDEFKNKEGEPAAFIVQ KQGGGFLYASTDLACLRYRIGRLKADRLLYVVDHRQALHFEQLFTTSRKAGYLPENVGAAFIGFGTMMGKDGKPFK TRSGDTVKLVDLLTEAVERATALVKEKNPELGADEAAKIGKTVGIGAVKYADLSKNRTSDYVFDWDAMLSFEGNTA PYLQYAYTRVQSVFRKAGEWDANAPTVLTEPLEKQLAAELLKFEDVLQSVADTAYPHYLAAYLYQIATLFSREYEA CPILKAEGASRNSRLQLAKLTGDTLKQGLDLLGIDVLDVM
145	1518	MSQKLILVLNCGSSSLKGAVLDNGSGEVLLSCLAEKLNLPDAYITFKVNGEKHKVDLSAHPDHTGAVEALMEELKA HGLDSRIGAIGHRVVSGGELYSESILVDDEVIAGIEKCIPLAPLHNPAHLLGLRAAQSIFKGLPNVVVFDTSFHQT MPEVAYKYAVPQELYEKYGLRRYGAHGTSYRFVADETARFLGKDKKDLRMVIAHLGNGASITAVANGESRDTSMGL TPLEGLVMGTRSGDIDPSVFGFLAENANMTIAQITEMLNKKSGLLGISGLSNDCRTIEEEAAKGHKGAKLALDMFI YRLAKYIGSMAVAAGGLDALVFTGGIGENSDIIRERVIGYLGFLGLNIDQEANLKARFGNAGVITTADSKAVAVVI PTNEELMIAHDTARLSGL
146	1533	MKAYLALISAAVIGLAACSQEPAAPAAEATPAAEAPASEAPAAEAAPADAAEAPAAGNCAATVESNDNMQFNTKDI QVSKACKEFTITLKHTGTQPKASMGHNLVIAKAEDMDGVFKDGVGAADTDYVKPDDARVVAHTKLIGGGEEASLTL DPAKLADGEYKFACTFPGHGALMNGKVTLVD
147	1536	MLTNIAKKIFGSRNDRLLKQYRKSVARINALEEQMQALSDADLQAKTAEFKQRLADGQTLDGILPEAFAVCREASR

		RTLGMRHFDVQLIGGMVLHDGKIAEMRTGEGKTLVATLAVYLNALAGKGVHVVTVNDYLASRDAGIMEPLYNFLGL TVGVIISDMQPFDRQNAYAADITYGTNNEFGFDYLRDNMVTDQYDKVQRELNFAVVDEVDSILIDEARTPLIISGQ ADDNIQLYQIMNTVPPHLVRQETEEGEGDYWVDEKAHQVILSEAGHEHAEQILTQMGLLAENDSLYSAANIALMHH LMAALRAHSLFHKDQHYVIQDGEIVIVDEFTGRLMSGRRWSEGLHQAVEAKEGVEIKRENQTLASITFQNYFRLYT KLSGMTGTADTEAFEFQSIYNLETVIIPTNRPVQRKDFNDQIFRSAEEKFEAVVKDIEECHKRGQPVLVGTTSIEN SELVSKLLTQAGLPHNVLNAKEHEREALIVAQAGKVGAITVATNMAGRGTDIVLGGNLKHQTDAIRADETLSDEEK QAQIAALEDGWQAEHDKVMEAGGLHIIGTERHESRRIDNQLRGRSGRQGDPGSSRFYLSFEDPLLRLFALDRAAAI LNRLAPERGVAIEHNLLTRQIEGAQRKVEGRNFDMRKQVLEYDDVANEQRKVIYSQRNEILTSKDISDLMQEIRSD VVSDLVDTYMPPDSMEEQWDIPTLENRLAAEFRLHEDIQSWLKADNAIDGQDIKERLIERIENEYAAKTELVGKQA MADFERNVMLQVIDNQWREHLAAMDYLRQGIHLRSYAQKNPKQEYKREAFTMFQDLWNGIKFHIASLLTSVQIEQN PVAVVEEQPIGNIQSIHSESPDMEELLGQSQTDLVTEAFNPDGTDFSPEALEARGQIVHRNDPCPCGSGLKYKQCH GKLA
148	1560	MLNKDQFADNHFIRTIIEEDLESGKHTAVQTRFPPEPNGYLHIGHAKSICLNFGLAYIYDGLCNLRFDDTNPEKEN DEYVNAIKEDVEWLGFHWAGEPRFASNYFDQLYDYAVGLIKDGKAYVDDLTPEEMREYRGTLTEAGKNSPYRDRSV EENLDLFTRMKNGEFPDGSKTLRLKIDMASGNINMRDPVIYRIRRAHHHNTGDKWCIYPMYDYTHCISDAIEGITH SLCTLEFEAHRPLYDCVLDNIPAPHATRPRQYEFSRLELLYTITSKRKLNQLVVEKHVSGWDDPRMPTISGMRRRG YTPEGLRLFAKRAGISKSENIVDMSVLEGAIREELENSAPRLMAVLNPLKVTLTNFETGRTQSRRAAFHPNHEEMG EREVPISQTIYIEADDFAENPPKGFKRLIPGGEVRLRHGYVIKCDEVVKDEAGNVVELKCSIDHDTLGKNPEGRKV KGVIHWVSAEHAAEIKVRLYDRLFTVERPDAVRGEDGEYLPFTDFLNPESVKEITAYAEPAAKDLPAESRWQFERI GYFVTDRKDHGKDTPVFNRTVTLKDSWQPK
149	1572	MLEAYRKAAAERAALGIPALPLNAQQTADLVELLKSPPAGEGEFLVELLAHRVPPGVDDAAKVKASFLAAVAEGSA SSPLISPEYATELLGTMLGGYNIHALIELLDDDKLASIAAKGLKHTLLMFDSFHDVQEKAEKGNKYAQEVLQSWAD AEWFASRAKVPEKITVTVFKVDGETNTDDLSPAPDAWSRPDIPLHALAMLKNPRDGITPDKPGEVGPIKLLEELKA KGHPVAYVGDVVGTGSSRKSATNSVIWHTGEDIPFVPNKRFGGVCLGGKIAPIFFNTQEDSGALPIEVDVSALKMG DVVDILPYEGKIVKNGETVAEFELKSQVLLDEVQAGGRINLIIGRGLTAKAREALKLPASTAFRLPQAPAESKAGF TLAQKMVGRACGLPEGQGVRPGTYCEPRMTTVGSQDTTGPMTRDELKDLACLGFSADMVMQSFCHTAAYPKPVDVK THKELPAFISTRGGVSLRPGDGVIHSWLNRLLLPDTVGTGGDSHTRFPIGISFPAGSGLVAFAAATGVMPLDMPES VLVRFSGKLQPGVTLRDLVNAIPLYAIKQGLLTVAKAGKKNIFSGRILEIEGLPDLKVEQAFELTDASAERSAAGC TVKLNKEPIIEYMKSNVVLMKNMIANGYQDPRTLERRIKAMEKWLANPELLEADKDAEYAAVIEINMDDIKEPIIA CPNDPDDVCFMSERSGTKIDEVFIGSCMTNIGHFRAASKLLEGKADTPVRLWIAPPTKMDAKQLSDEGHYGVLGRA GARMEMPGCSLCMGNQAQVREGATVMSTSTRNFPNRLGKNTFVYLGSAELAAICSKLGKIPTVEEYQANIGIINEQ GDKIYRYMNFNEIDSYNEVAETVNV
150	1574	MQVYYDKDADLSLIKGKTVAIIGYGSQGHAHAANLKDSGVNVVIGLRQGSSWKKAEAAGHVVKTVAEATKEADVVM LLLPDETMPAVYHAEVTANLKEGATLAFAHGFNVHYNQIVPRADLDVIMVAPKGPGHTVRSEYKRGGGVPSLIAVY QDNSGKAKDIALSYAAANGGTKGGVIETTFREETETDLFGEQAVLCGGVVELIKAGFETLTEAGYAPEMAYFECLH EMKLIVDLIFEGGIANMNYSISNNAEYGEYVTGPEVVNASSKEAMRNALKRIQTGEYAKMFIQEGNVNYASMTARR RLNADHQVEKVGAQLRAMMPWITANKLVDQDKN
151	1577	MQLSGAQIIVQSLKAEGVEYVFGYPGGAVIEIYDALFQLNKFKHILTRHEQAAVHAADAYARVSGKVGVALVTSGP GVTNALTGIATAYTDSIPMVVISGQVGNSLIGTDAFQEVDTVGITRPCVKHNFLVTDINELAETIKKAFQIAASGR PGPVVVDVPKDVTQAMAKFSYPQEDIFIRSYQPVVQGHIGQIKKAVQMLASAKRPVVYFGGGVVLGNASEELTRFV RMTGAPCTGTLMGLGAYPSGDRQFLGMLGMHGTYEANLAMQNADVVLAVGARFDDRVVSVPSKFFEKAKKVIHIDV DPSSIAKRVKVDIPIVGDVKNVLSEMVALWQKQESVPSEDALGKWWKTIEEWRSRDCLWFDNGSEIIKPQYVIQKL AEITGNSAIITSDVGQHQMFAAQYYPFERPRQWLNSGGLGTMGVGLPYAIGAKLAAPDQDVFCITGDGSIQMNIQE LSTCFQYRIPVNVITLNNGYLGMVRQWQEIYYGGRESETYFDSLPDFVKLAEAYGHIGIRVDKKSDVEGALLEALN QKDRLVFIDFLTDQKQNVMPMVGNGKGLDEMVLPPHMRADGKA
152	1581	MKKLNTQSPDFQAGLKALLAFETAQNPETERIVADICADVQKRGDAALIEYTNKFDQTNAKSIDDLILTQADLNAA FERIPNDVQTALQTAARRVESYHQRQKMESWSYTDEDGTLLGQQITPLDRVGIYVPGGKAAYPSSVIMNAMPAHVA GVKEIIMVVPTPKGERNDIVLAAAYVAGVTKVFTVGGAQAVAALAYGTETIPQVDKITGPGNAFVAAAKRRVFGVV GIDMVAGPSEILVIADGTTPADWVAMDLFSQAEHDEIAQAILIGTSQAYLDEVEAAMDRLIETMPRRDIIEASLGN RGAMILAKDLDEACEIANYISPEHLELSVENPQEWAKKIRHAGAIFMGRYTGESLGDYCAGPNHVLPTSRTARFSS PLGTYDFQKRSSLIQVSEQGAQKLGETASVLAHGESLTAHARAAEFRMK
153	1583	MNLTKTQRQLHNFLTLAQEAGSLSKLAKLCGYRTPVALYKLKQRLEKQAEDPDARGIRPSLMAKLEKHTGKPKGWL DRKHRERTVPETAAESTGTAETQIAETASAAGCRSVTVNRNTCETQITVSINLDGSGKSRLDTGVPFLEHMIDQIA RHGMIDIDISCKGDLHIDDHHTAEDIGITLGQAIRQALGDKKGIRRYGHSYVPLDEALSRVVIDLSGRPGLVYNIE FTRALIGRFDVDLFEEFFHGIVNHSMMTLHIDNLSGKNAHHQAETVFKAFGRALRMAVEHDPRMAGQTPSTKGTLT A
154	1595	MKTSELRQKFLKFFETKGHTVVRSSSLVPHDDPTLLFTNAGMNQFKDVFLGFDKRPYSRATTAQKCVRAGGKHNDL ENVGYTARHHTFFEMMGNFSFGDYFKRDAIHFAWEFLTSPEWLNIPKDKLLATVYAEDDEAYNIWLNEIGMPSERI VRIGDNKGAKYASDNFWQMGDTGPCGPCSEIFYDHGEEIWGGIPGSPEEDGDRWIEIWNCVFMQFNRDEQGNMNPL PKPSVDTGMGLERIAAVMQHVHSNYEIDLFQDLLKAVARETGAPFRMEEPSLKVIADHIRSCSFLIADGVLPSNEG RGYVLRRIIRRAVRHGYKLGQSKPFFHKLVADLVKEMGGAYPELKEKQAQIEEALKNEESRFAQTLETGMALLENA LVKGGKTLGGEIIFKLYDTYGFPYDLTADICRERNIEPDEAGFEREMEAQRARARAAQSFKANAQLPYDGQDTEFK

		GYSERQTESKVLALYKDGEQVNELNEGDSGAVVIDFTPFYAESGGQVGDVGYIFSGENRFEVRDTQKIKAAVFGQF GVQTSGRLKVGDSVTAKVDDEIRNANMRNHSATHLMHKALRDVLGRHVEQKGSLVTAESTRFDISHPQAVTAEEIA EVERRVNEAILANVAVNAAIMSMEDAQKTGAMMLFGEKYGEEVRVLQMGGFSTELCGGTHVSRTGDIGLFKIISEG GIAAGVRRIEAITGLNALKWAQEQERLVKDIIAETKAQTEKDVLAKIQAGAAHAKALEKELARAKAELAVHAGAKL LDDAKDLGAAKLVAAQIEADAAALREIVTDLTGKSDNAVILLAAVNDGKVSLCAGVSKPLTGKVKAGDLVKFAAEQ VGGKGGGRPDLAQAGGTDADKLPAVLDSVKDWVGAKLV
155	1604	MELVFIRHGQSEWNAKNLFTGWRDVKLSEQGLAEAAAAGKKLKENGYEFDIAFTSVLTRAIKTCNIVLEESDQLFV PQIKTWRLNERHYGQLQGLDKKQTAEQYGDEQVRIWRRSYDTLPPLLDKDDEFSAHKDRRYAHLPADVVPDGENLK VTLERVLPFWEDQIAPAILSGKRVLVAAHGNSLRALAKHIEGISDEDIMGLEIPTGQPLVYKLDDNLKVIEKFYL
156	1621	MGIYDFQMKDAEGNAVDLSGYRGKVLLIVNTATRCGLTPQYEALQKLYAQYTAEGLEILDFPCNQFREQAPESSGE IAQVCMMKFGTKFKIFDKIEVNGANTAPLYAYLKSVKPQDKGNHLFKDFVLKLAALGEKRDEGDIKWNFTKFLVNR DGEVVERFAPSVTPEEIEADIRALL
157	1636	LLFSSLLFSSLLFSSLLFSSAAQAASEDSSRSPYYVQADLAYAAERITHDYPKPTGTDKDKISTVSDYFRNIRAHS YHPRVSVGYDFGGWRIAADYASYRKWNNNKYSVNIKKGRETQDNREELKTENQENGSFHAASSLGLSAIYDFKLND KFDKFKPYIGARVAYGHVKHQVHSVETKTTIVTSKPAATSPQGGPIIET
158	1640	MSLYPIYNFSAGPAVLPEAVLETARQEMLDYNGTGFPVMAMSHRSEMFLSILHHAEQDLRQLLKVPDNYKILFLQG GATTQFNMAAMNLAHGFRTADAVVTGNWSRIAYEQMSRLTDTEIRLAAHGGEQFDYLDLPPVETWDVAPDSAFVHF AVNETVNGLQYREVPCLSEGMPPLVCDMSSEILSREFDVADYGLIYAGAQKNIGPAGVTVVIVREDLLERCPNDIP DVFNYRSHINRDGMYNTPSTYAIYMSGLVFRWLQAQGGVKKIEAVNRLKAQTLYETIDGSDGFYINRIRPNARSKM NVVFQTGDEELDRRFVLEAELQGLCLLKGYKTVGGMRASIYNAMPLEGVRALADFMRDFQRRYG
159	1642	MSREMLQLAEALASEKNVDAEVVFQALEFALSTAAKKKADREHMDVRVQINRDTGEYQTFRRWLIVADEDYTYPDV EKTIEEIQEEIPGTTIQIGEYYEEQLPNEGFGRQAAQTAKQIILQRIRDAEREQNLNEFLAVKEDIVSGTVKRVER HGIIVEVVAGKLDALIPRDQMIPRENFRSGDRIRALFLRVEEIGNTGRKQVILSRTSGDFLVKLYANEVPEIADGM LEIRAVARDPGQRAKVAVKANDQRIDPQGTCIGVRGSRVNAVSNELSGERIDVVLWSPEPAQFVMSALSPAEVSRI VIDEDKHAVDVIVAEDQLALAIGRGGQNVRLASDLTGWQLNIMTSAEADERNAAEDAAIRRLFMDHLNVDEETADV LVQEGFATLEEVAYVPAAELLAIEGFDEEIVDMLRNRARDAILTMAIAAEEKLGEVSDDMRNLEGIDADMLRSLAE AGITTRDDLAELAVDELIETTGVNEETAKAVILTAREHWFTEDK
160	1655	MVHIMFNQAAQELTTIRDILRFAVSRFNEAGLFFGHGTDNAHDEAAYLILHTLNLPLDMLAPYLDAKLLEAEKEEV LAVIERRAVEHIPAAYLTHQAWQGEFDFYVDERVIIPRSFIYELLGDGLRPWIEYDELVHNALDLCTGSGCLAIQM AHHYPDAQIDAVDVSLDALEVAGINVEDYGLEERIRLIHTDLFEGLEGTYDLIVSNPPYVDAESVELLPEEYLHEP ELALGSGADGLDATRQILLNAAKFLNPKGVLLVEIGHNRDVLEAAYPELPFTWLETSGGDGFVFLLTREQLLGEE
161	1684	MLDIQLLRSNTAAVAERLARRGYDFDTARFDTLEERRKSVQVKTEELQASRNSISKQIGALKGQGKHEEAQAAMNQ VAQIKTDLEQAAADLDAVQKELDAWLLSIPNLPHESVPAGKDETENVEVRKVGTPREFDFEIKDHVDLGEPLGLDF EGGAKLSGARFTVMRGQIARLHRALAQFMLDTHTLQHGYTEHYTPYIVDDTTLQGTGQLPKFAEDLFHVTRGGDET KTTQYLIPTAEVTLTNTVADSIIPSEQLPLKLTAHSPCFRSEAGSYGKDTRGLIRQHQFDKVEMVQIVHPEKSYET LEEMVGHAENILKALELPYRVITLCTGDMGFGAAKTYDLEVVWVPAQNTYREISSCSNCEDFQARRLKARFKDENGK NRLVHTLNGSGLAVGRTLVAVLENHQNADGSINIPAALQPYMGGVAKLEVK
162	1691	MARHVWQAGRFEIGLDKPKIMGIVNLTPDSFSDGGVYSQNAQTALAHAEQLLKEGADILDIGGESTRSGADYVSPE EEWARVEPVLAEVAGWGVPISLDTRRTVIMEKALALGGIDIINDVAALNDEGAVELLARQADTGICLMHMQGLPKT MQINPKYQDVVGEVARYLKARSAECIAAGIAPQRIILDPGFGSGFGKPLQHNIALMRHLPELMAETGFPLLIGVSR KSTIGELTGEANAAERVHGSVAAALASVARGAQIVRVHDVKATADALKVWEALGINL
163	1710	MTDLNTLFANLKQRNPNQEPFHQAVEEVFMSLDPFLAKNPKYTQQSLLERIVEPERVVMFRVTWQDDKGQVQVNRG YRVQMSSAIGPYKGGLRFHPTVDLGVLKFLAFEQVFKNALTTLPMGGGKGGSDFDPKGKSDAEVMRFCQAFMTELY RHIGADTDVPAGDIGVGGREIGYLFGQYKKIRNEFSSVLTGKGLEWGGSLIRPEATGYGCVYFAQAMLQTRNDSFE GKRVLISGSGNVAQYAAEKAIQLGAKVLTVSDSNGFVLFPDSGMTEAQLAALIELKEVRRERVATYAKEQGLQYFE KQKPWGVAAEIALPCATQNELDEEAAKTLLANGCYVVAEGANMPSTLGAVEQFIKAGILYAPGKASNAGGVATSGL EMSQNAIRLSWTREEVDQRLFGIMQSIHESCLKYGKVGDTVNYVNGANIAGFVKVADAMLAQGF
164	1716	MAFYAFKAMRAAALAAAVALVLSSCGKGGDAAQGGQPAGREAPAPVVGVVTVHPQTVALTVELPGRLESLRTADVR AQVGGIIQKRLFQEGSYVRAGQPLYQIDSSTYEAGLESARAQLATAQATLAKADADLARYKPLVAAEAVSRQEYDA AVTAKRSAEAGVKAAQAAIKSAGISLNRSRITAPISGFIGQSKVSEGTLLNAGDATVLATIRQTNPMYVNVTQSAS EVMKLRRQIAEGKLLAADGVIAVGIKFDDGTVYPEKGRLLFADPAVNESTGQITLRAAVPNDQNILMPGLYVRVLM DQVAVDNAFVVPQQAVTRGAKDTVMIVNAQGGMEPREVTVAQQQGTNWIVTSGLKDGDKVVVEGISIAGITGAKKV TPKEWASSENQAAAPQSGVQTASEAKPASEAK
165	1796	MIMAKKISILVGSLRRASFARKVALNAAEMFPEGWQAEIVEIGHLPLYNFDYDDPAVEDVPLPESYTAFRETIKAS DGILFVTSENNRTIPACLKNAVDIGSKPNADVAWKNKPAGIISHSVGKMGGYSSQKNLRLALSYFDMPVTGQPEVF LGNSPTLFDENGKLIDSARDFVQSYINQFVGLIERNAK
166	1809	MNNLIKINLLPYREEMNKRKQQQFKTLMYGAVLTGVAAVAATYLFIDNMINNQSERNTLLETSIAHLDTELSEIQK LKQEKDAFLIKKNKIEELQLKRLQAAKILDSLNEAVPGSTYLTSLDAVTADSYRLSGRTSSDNRVAAMMRAMPNTG IFKQPELLSIKKNNSHQEFTLQATLQPIVKAAESKENPASGNAQEAN
167	1810	MASKSSKTNLDLNNLHLLNLPARLFIALLAVAAVLGLGYAGLFKSQMESLEEYEAKETELKNTYKQKSIDAASLNN LRDELASIRSAFDIMLKQLPTDAEIPNLVQELHQAGSSNGLRLDSVMPQPPVDDGPIKRLPYSISITGNYEQISQF TRDVGSLSRIITLESLKIAQSPENGGNPDGKSSILNLSAIATTYQAKSVEELAAEAAQNAEQK

168	1811	MKHYALLISFLALSACSQGSEDLNEWMAQTRREAKAEIIPFQAPTLPVAPVYSPPQLTGPNAFDFRRMETDKKGEN APDTKRIKETLEKFSLENMRYVGILKSGQKVSGFIEAEGYVYTVGVGNYLGQNYGRIESITDDSIVLNELIEDSTG NWVSRKAELLLNSSDKNTEQAAAPAAEQN
169	1812	MNTKLTKIISGLFVATAAFQTASAGNITDIKVSSLPNKQKIVKVSFDKEIVNPTGFVTSSPARIALDFEQTGISMD QQVLEYADPLLSKISAAQNSSRARLVLNLNKPGQYNTEVRGNKVWIFINESDDTVSAPARPAVKAAPAAPAKQQAA APSTKSAVSVSEPFTPAKQQAAAPFTESVVSVSAPFSPAKQQAAASAKQQAAAPAKQQAAAPAKQQAAAPAKQTNI DFRKDGKNAGIIELAALGFAGQPDISQQHDHIIVTLKNHTLPTTLQRSLDVADFKTPVQKVTLKRLNNDTQLIITT AGNWELVNKSAAPGYFTFQVLPKKQNLESGGVNNAPKTFTGRKISLDFQDVEIRTILQILAKESGMNIVASDSVNG KMTLSLKDVPWDQALDLVMQARNLDMRQQGNIVNIAPRDELLAKDKALLQAEKDIADLGALYSQNFQLKYKNVEEF RSILRLDNADTTGNRNTLISGRGSVLIDPATNTLIVTDTRSVIEKFRKLIDELDVPAQQVMIEARIVEAADGFSRD LGVKFGATGKKKLKNDTSAFGWGVNSGFGGDDKWGAETKINLPITAAANSISLVRAISSGALNLELSASESLSKTK TLANPRVLTQNRKEAKIESGYEIPFTVTSIANGGSSTNTELKKAVLGLTVTPNITPDGQIIMTVKINKDSPAQCAS GNQTILCISTKNLNTQAMVENGGTLIVGGIYEEDNGNTLTKVPLLGDIPVIGNLFKTRGKKTDRRELLIFITPRIM GTAGNSLRY
170	1835	MSVIQDLQSRGLIAQTTDIEALDALLNEQKIALYCGFDPTADSLHIGHLLPVLALRRFQQAGHTPIALVGGATGMI GDPSFKAAAERSLNSAETVAGWVESIRNQLTPFLSFEGGNAAIMANNADWFGSMNCLDFLRDIGKHFSVNAMLNKES VKQRIDRDGAGISFTEFAYSLLQGYDFAELNKRHGAVLEIGGSDQWGNITAGIDLTRRLHQKQVFGLTLPLVTKSD GTKFGKTEGGAVWLNAKKTSPYQFYQFWLKVADADVYKFLKYFTFLSIEEIDAIEAKDKASGSKPEAQRILAEEMT RLIHGEEALAAAQRISESLFAEDQSSLTESDFEQLALDGLPAFEVSDGINVVEALVKTGLASSNKEARGFVNSKAV LLNGKPAEANNPNHAAERPDDACLLNGEHKRFGKYTILRRGKRNHALLVWK
171	1838	MSLKCGIVGLPNVGKSTLFNALTQSGIEAANYPFCTIEPNVGIVEVPDPRMAELAKIVNPQKMQPAIVEFVDIAGL VAGASKGEGLGNQFLANIRETDAIVNVVRCFDDDNIVHVAGRVDPIADIETIGTELALADLASVEKAIVREEKRAR SGDKDAQKLVDLCKKLLPHLDEGKPVRSFGLDAEERAMLKPLFLLTAKPAMYVGNVAEDGFENNPHLDRLKELAAK ENAPVVAVCAAMESEIAELEDDEKAEFLAEMGLEEPGLNRLIRAGYDLLGLQTYFTAGVKEVRAWTIHKGDTAPQA AGVIHTDFERGFIRAQVISYDDFVSLGGEAKAKEAGKMRVEGKEYVVVQDGDVMHFLFNV
172	1843	MPTQSKHASINIGLIQAREALMTQFRPILNQANITDQQWRIIRLLAENGTLDFQDLANQACILRPSLTGILTRLEK AGLVVRLKPSNDQRRVFLKLTAEGEKLYEEIGEEVDERYDAIEEVLGREKMLLLKDLLAELAKIEDALNS
173	1849	MSTPALLVLADGSVFHGTSIGYEGSTSGEVVFNTSMTGYQEILTDPSYCKQIVTLTYPHIGNTGTNAEDEESRSVY AAGLIIRDLPLLHSNFRASESLHDYLVRNKTVAIADIDTRRLTTLLREKGAQGGAILTGADATIEKAQELIAAFGS MVGKDLAKEVSCTETYEWTEGEWALGKGFVTPDEQPYHVVAYDFGVKTNILRMLASRGCRLTVVPAQTSAEDVLAL NPDGVFLSNGPGDPEPCTYAIKAVQKLIESGKPIFGICLGHQLISLAIGAKTLKMRFSHHGANHPVQDLDSGKVVI TSQNHGFAVDADTLPANARITHKSLFDNTLQGIELTDKPVFCFQGHPEASPGPQDVGYLFDKFIGNMKAAKRA
174	1854	MSIPINFNNLKYLLNDMRNKNRIIEAFPFNYNQRQYAVILTRYKPDEPRPDDYAQAKLEFFNLNSENSIFAYADFY EVHFKSATDFINFFKINVQAGAAKIREIFQSFSNLFADFIPTQTKKDLDIIYKKIVATRLEPNSPNTIYCYDVRRN GKDKAGKPNRRSVENSEKAKILRPELYEKFKADSNYSFFFSDNPSDEKTDAEIIREVTNRQ
175	1855	MPKRTDLKSILIIGAGPIVIGQACEFDYSGAQACKALREEGYKVILVNSNPATIMTDPEMADVTYIEPIMWQTVEK IIAKERPDAILPTMGGQTALNCALDLARNGVLAKYNVELIGATEDAIDKAEDRGRFKEAMEKIGLSCPKSFVCHTM NEALAAQEQVGFPTLIRPSFTMGGSGGGIAYNKDEFLAICERGFDASPTHELLIEQSVLGWKEYEMEVVRDKNDNC IIICSIENFDPMGVHTGDSITVAPAQTLTDKEYQIMRNASLAVLREIGVDTGGSNVQFAVNPANGEMIVIEMNPRV SRSSALASKATGFPIAKVAAKLAVGFTLDELRNDITGGKTPASFEPSIDYVVTKIPRFAFEKFPAADDRLTTQMKS VGEVMAMGRTIQESFQKALRGLETGLCGFNPRSEDKAEIRRELANPGPERMLFVADAFRAGFTLEEIHEICAIDPW TETAYLYSTYEEECESRPSDRKKVMILGGGPNRIGQGIEFDYCCVHAALALRESGFETIMVNCNPETVSTDFDTSD PNRIAHNEEEALVKAEEIGYPLVVRPSYVLGGRAMQVVHSAEELQKYMREAVQVSEDSPVLLDFFLNNAIEVDVDC VSDGKDVVIGGIMQHVEQAGIHSGDSGCSLPPYSLSEEIQDEIRRQTKAMAYALGVVGLMNVQFAVQDGVVFVLEV NPRASRTVPFVSKATGVPLAKVGARCMAGISLKEQGVEKEVVPDFYAVKEAVFPFIKFPGVDTILGPEMRSTGEVM GVGASFGEAYYKAQLGAGERLNPTGKIFLSVREEDKERVIKTAKNFQVLGYGICATRGTAQYLTEHGLIVQTINKV PEGRPHIGDALKNGEIALVVNTVSSDPQSVSDSHIIRQSALQQRVPQYTTTAGGEAMSEGAKSRDHLGVYSVQELH GRLKNRN
176	1859	MDISDFDFTLPEKLIAQHPPEVRGSSRLLVALPDMPLQDRVFGDLPDYVEAGDVLVFNNTKVMKARLFGQKDSGGR IEALIERVLDNHTALAHIRSSKSPKPGMGLVFEGGIRAVTVGREGELFCLRFEGGETVYELLEQNGHLPLPPYIER AADADDDSRYQTVYAKYQGAVAAPTAGLHFTEELLHRLKDKGAVTAEVTLHVGAGTFQPVRVDKIEEHKMHSEWFE VPSETAAAVEAAKARGNKVWAVGTTSMRALESAARATGRLKAGQGDTDIFITPGYRFNVVDRLVTNFHLPKSTLLM LVSAFSGMGHIRAAYRHAVEREYRFFSYGDAMVLGRNEGVVR
177	1861	MLKKVLIANRGEIALRVLRACREMGIATVAVHSEADKDSLHVKLADESVCIGPAASAQSYLNVPAIIAAAEVSCAD AVHPGYGFLAENADFAEQVEQSGFTFIGPKPDTIRLMGDKVSAKHAMIAAGVPCVPGSDGALPDDGEEILKIADKV GYPVIIKASGGGGGRGMRVVEKKEDLLQSVEMTKAEAGAAFGNPMVYMERYLQRPRHVEIQVIADEHGNAIYLAER DCSLQRRHQKVIEEAPAPFITEKERAKIGNACADACKRIGYRGAGTFEFLYEDGEFFFIEMNTRVQVEHPVTELIT GVDIVQEQLRIAAGLPLQYKQKDIQVEGHAFECRINAEDPYNFIPSPGLIESCHLPGGFGIRVDSHIYQGYRIPPY YDSLIGKICVHGKTREQAMAKMRVALAELAVTGIKTNTPLHRDLFADAGFQKGGVSIHYLEHWLEDRKAKQDK
178	1862	MPYQQITVNVNDAVAERLADALMEHGALSAAIEDAYAGTQNEQAIFGEPGMPAEQIWQQSKVIALFGEHDEAAAII

		QTATQECGLKDLAYTGETIEDQDWVRLTQSQFDPIRISDRLWITPSWHEVPEGSAVNLRLDPGLAFGTGSHPTTRL CLKWLDTQLKNGESVLDYGCGSGILTIAALKLGAGFAVGVDIDEQAVRAGKDNAAQNNVDAQFFLPDGLPQGQFDV VVANILANPLRMLGEMLAARTKQGGRIVLSGLLDEQAEELGGIYSQWFDLDPAETEEGWARLSGVKR
179	1864	MNRNEILFDRAKAIIPGGVNSPVRAFGSVGGVPRFIKKAEGAYVWDENGTRYTDYVGSWGPAIVGHAHPEVVETVC EAALGGLSFGAPTEGEIVIAEEIAKIMPSVERLRLVSSGTEATMTAIRLARGFTGRDKIIKFEGCYHGHSDSLLVK AGSGLLTFGNPSSAGVPADFTKHTLVLEYNNIAQLEEAFAQSGNEIACVIVEPFVGNMNLVRPTEAFVKALRGLTE KYGAVLIYDEVMTGFRVALGGAQSLHGITPDLTTMGKVIGGGMPLAAFGGRKDIMECISPLGGVYQAGTLSGNPIA VAAGLKTLEIIQREGFYENLTARTEQLVQGFRTAADAAGIEFTADSVGGMFGLYFAAHAPRNYADMARSNIEGFKQ FFHGMLDRNVAFGPSAYEAGFVSAAHTPELIDETVAVAVEVFKAMAE
180	1903	MTLAEFWPLCLRRLHDMLPQGQFAQWIAPLTVGEEGGVWVVYGKNQFACNMLKSQFAGKIEAVREELAAGRSAFVF KPGEGVRYEMAAVEGAVEPAEPSLHAVSEGMPVQEVLLDELPSEEPVKPAASKTAADILAERMKNLPHEPRQAAGS ASRPESVAVAKARTDVQRDAEEARYEQTNLSPDYTFDTLVEGKGNRLAAAAAQAIAESPGQSYNPFFLYGSTGLGK THLVQAVGNELLKNRPDAKVRYMHSDDYIRSFMKAVRNNTYDVFKQQYKQYDLLIIDDIQFIKGKDRTMEEFFYLY NHFHNEKKQLILTCDVLPAKIEGMDDRLKSRFSWGLTLELEPPELEMRIAILQKKAEAAGISIEDEAALFIANLIR SNVRELEGAFNRVGASSRFMNRPVIDIDLARTALQDIIAEKHKVITADIIIDAVAKYYRIKISDVLGKKRTRNIAR PRQVAMSLTKELTTLSLPSIGDSFGGRDHTTVMHGIRAVAKLREEDPELAQDYEKLLILIQN
181	1920	MTQDKILILDFGSQVTQLIARRVREAHVYCELHSFDMPLDEIKAFNPKGIILSGGPNSVYESDYQADTGIFDLGIP VLGICYGMQFMAHHLGGEVQPGNQREFGYAQVKTIDSELTRGIQDGEPNTLDVWMSHGDKVSKLPDGFAVIGNTPS CPIAMMENAEKQFYGIQFHPEVTHTKQGRALLNRFVLDICGAQPGWTMPNYIEEAVAKIREQVGSDEVILGLSGGV DSSVAAALIHRAIGDQLTCVFVDHGLLRLNESKMVMDMFARNLGVKVIHVDAEGQFMAKLAGVTDPEKKRKIIGAE FIEVFDAEEKKLTNAKWLAQGTIYPDVIESAGAKTKKAHAIKSHHNVGGLPENMKLKLLEPLRDLFKDEVRELGVA LGLPREMVYRHPFPGPGLGVRILGEVKKEYADLLRQADDIFIQELRNTTDENGTSWYDLTSQAFAVFLPVKSVGVM GDGRTYDYVIALRAVITSDFMTAHWAELPYSLLGKVSNRIINEVKGINRVVYDVSGKPPATIEWE
182	1921	MSTQDLNGKIALVTGASRGIGAAIADTLAAAGAKVIGTATSESGAAAISERLAQWGGEGRVLNSAEPETIESLIAD IEKAFGKLDILVNNAGITRDNLLMRMKEEEWDDIMQVNLKSVFRASKAVLRGMMKQRSGRIINITSVVGVMGNAGQ TNYAAAKAGLIGFSKSMAREVGSRGITVNCVAPGFIDTDMTRALPEETRQTFTAQTALGRFGDAQDIADAVLFLAS DQAKYITGQTLHVNGGMLMP
183	1930	MMTQTLLIELLTEELPPKALNNLGNHFAASVAEGLEKAQLVDGAAEFTAYASPRRLAVQVKNVKAVQADQKIVKKG PAVANAMKDGAPTKALEGFARGAGAKIEDLTIVHDGKQDVYAYEYVQIGKPLGGLLEDIINQAVKKLPIPKVMRWG SSTFTFEVRPVHGLVVLHGGDIVNVSVLGLQSGNKTLGHRFLSDGEITIENADSYAAQMREQGKVVASFAERKAAIQ TVLEGQARRLNATAAADEALLDEVTALVEWPVVLEAGFEEHFLAVPQECLILTMQQNQKYFPLLDQNGKLMNRFLL VSNLQTEDPSHIIQGNERVLRARLSDAEFFYKQDQKATLESRLPKLTNVVYHNKIGSQAERIERLQSIAAHIAKAL GADAAAAERAARLAKADLVTEMVGEFPELQGTMGKYYARLDGETEEITEAVEQHYQPRFAGDNLPEGKIAAAVALA DKLETLVGIWGIGLIPTGDKDPYALRRAALGILRMLMQYGLDVNELIQTAFNSFPQGLLNEKTPSETADFMQARLA VLLQNDYPQDIVAAVLAKQPRRLDDLTAKLQAVAAFKQLPEAAALAAANKRVQNLLKKADAELGAVNESLLQQDEE KALFAAAQGLQPKIAAAVAEGNFQTALSELASVKPQVDAFFDGVMVMAEDAAVKQNRLNLLNRLAEQMNAVADIAL LGE
184	1934	MSQGKIVQIIGAVVDVEFPRDMIPRVYDALKLDENGLTLEVQQLLGDGVVRAIAMGSSDGLKRGMTVSNTGAPITV PVGKGTLGRIVDVLGTPVDEAGPIDTDKSRAIHQAAPKFDELSSTTELLETGIKVIDLLCPFAKGGKVGLFGGAGV GKTVNMMELINNIAKAHSGLSVFAGVGERTREGNDFYHEMKDSNVLDKVAMVYGQMNEPPGNRLRVALTGLTMAEY FRDEKDENGKGRDVLFFVDNIYRYTLAGTEVSALLGRMPSAVGYQPTLAEEMGRLQERITSTQTGSITSIQAVYVP ADDLTDPSPATTFAHLDATVVLSRDIASLGIYPAVDPLDSTSRQLDPMVLGQEHYDVARGVQSTLQKYKELRDIIA ILGMDELSDEDKLTVMRARKIQRFLSQPFHVAEVFTGSPGKYVALRDTIAGFKAILNGEYDHLPEQAFYMVGSIEE AVEKAKTLN
185	1936	MQLNPAEISDLIKAKIENLSVNAEVRTCGTVISVTDGIVRIHGLSDAMQGEMLEFPGNTFGLAMNLERDSVGAVVL GEYEHIKEGDTVTCTGRILEVPVGRELVGRVVDALGRPIDGKGPINTTLTAPIEKIAPGVIARKSVDQPMQTGLKA IDSMVPVGRGQRELIIGDRQTGKTAVALDAIVNQKGTGVICIYVAIGQKASSIANVVRKLEEHGAMEHTIVVAATA SEAAALQYIAPYSGCTMGEFFRDRGEDALIVYDDLSKQAVAYRQISLLLRRPPGREAYPGDVFYLHSRLLERAARV NEHEVEKLTNGEVKGKTGSLTALPIIETQAGDVSAFVPTNVISITDGQIFLETDLFNAGIRPAINAGISVSRVGGA AQTKVIKKLGGGIRLALAQYRELAAFSQFASDLDEATRKQLEHGEVVTELMKQKQFSTLNTAEMALTLWAINNGSY SDVPVAKALAFESEFLSFVRTQHPEVLEAVNASGAMSDESEKTLEAAMKSFKSSYAYQA
186	1937	MAEFATIARPYAKALFGLAQEKNQIESWLGGLEKLAAVVQEGKVASLIDRPETNASEKADILIDLVGLKDKELKNF VIVLAGQKRLSILPEVYAQYQDLTLSFNHIKSAVIYSAYPLTDKQVGELVQMLNKRFDSELKISVEIEPELIGGIK VEVGDQVLDLSVQGKLSALYTTMTN
187	1938	MNINATLFAQIIVFFGLVWFTMKFVWPPIAKALDERAAKVAEGLAAAERGKSDFEQAEKKVAELLAEGRNQVSEMV ANAEKRAAKIVEEAKEQASSEAARIAAQAKADVEQELFRARESLREQVAVLAVKGAESILRSEVDASKHAKLLDTL KQEL
188	1953	MMTLYSGITCPFSHRCRFVLYEKGMDFEIKDVDIYNKPEDLAVMNPYNQVPVLVERDLVLHESNIINEYIDERFPH PQLMPGDPVMRGRGRLVLYRMEKELFNHVQVLENPAATNKEQAKAREAIGNGLTMLAPSFSKSKYILGEDFSMIDV ALAPLLWRLDHYDVKLGKSAAPLLKYAERIFQREAFIEALTPAEKAMRK
189	1966	MSPSPFIEMKDVAFAYGDRPILKNINFSIPQGNFAAVMGGSGSGKTTLMRLITGQIRPQSGQVLIEGRDLAGFSAD ELYEHRRRMGVLFQHGALFTDLSVFDNIAFPMRELTRLPEAVIRDLVLLKLNAVGLRGVENLMPSELSGGMSRRVA

		LARTIALDPEIMLYDEPFTGLDPISLGVIAHLISRVNKALRSTSIMVTHDIEKSLEIVDQVIFLAHGEIMFSGSPQ EMRELDSPWVRQFVGGLADGPVAYRYPAQTSLQQDLLG
190	1968	MKQLAMYINGRFENDFNGEWRDVLNPSTEEAIAREPKGGKADVDRAVAAARAAQPAWERLPAVERGAYLRKIAQGI RERADELTDTIVAEGGKTKDLARVEVMFTADYLDYQAEWARRYEGEIIQSDRPRENILLFKRPLGVIAGILPWNFP FFLIARKMGPALVTGNTIVVKPSSVTPINCHIFAEIVDAVGLPAGVFNVVNGPGAEIGNALSAHPQVDMVSLTGSV EAGRQVMEAASANITKVSLELGGKAPAIVLKDADLDLAVKSILASRVGNTGQICNCAERVYVHSSLKDAFIEKMTA AMKGVRYGNPAEAEAGALEMGPLIEERAVKAVAEKVERAVKQGAKLVCGGKRAEGRGYFFEPTLLTDTDNSMDIMK EETFGPVLPVSAFDTLDQVIALANDCEFGLTSSVYTTNLNEAFYVTRRLQFGETYINRENFEAMQGFHAGWKKSGI GGADGKHGLEEYLQTQVVYLETDI
191	1982	MSNRPTLLLVDGSSYLYRAYHAMGQNLTAPDGAPTGALYGVLNMLRRLRSEYPHDYCAVVFDAKGKNFRHQMFEEY KATRPPMPDDLRPQAEALPDLVRLTGWPVLVIGQVEADDVIGTLAKQGAEHGLRVIVSTGDKDMAQLVDERVTLVN TMSSETLDIEGVKAKFGVRPDQIRDYLALMGDKVDNVPGVEKCGPKTAVKWLEAYGSLAGVMEHASEIKGKVGENL QAALPQLPLSYDLVTIKTDVDLHAELSDGIESLRRTTPKWAQLVVDFKRWGFRTWLKEAESNMNTGSTDDLFGSDS IGEQAALNAEMPFEKQAEKATAPEKLDYQAVTTEAQFAALLDKLSRADTIGIDTETTSLDAMNASLVGISIAFQAG EAVYIPVGHSLTAAPEQLDLQDVLGRLKPHLGNPALKKIGQNLKYDQHVFANYGIALNGIAGDAMLASYIIESHLG HGLDELSERWLGLETITYESLCGKGAKQIGFADVAIGQATEYAAQDADFALRLEAHLRAQMDEKQLEMYEKMELPV AQVLFEMERNGVQIDRAELARQSAELGAELMKLEQEAYAAAGQPFNLNSPKQLQEILFDKMGIPTKGLKKTAKGGI STNEAVLEQLAPDYPLPKIILQNRSLAKLKSTYTDKLPEMISPKDGRVHTTYAQAVAITGRLASNNPNLQNIPIRT EEGRKVRRAFTAPQGSVIVSADYSQIELRIMAHLSGDKTLIAAFQNGEDVHRRTAAEVFGTAPENVSSEQRRYAKS INFGLIYGMGQYGLAKSLGIDNLSAKNFIDRYFARYPGVAEYMQRTKEQAAAQGYVETLFGRRLYLPDIRNKNANA RAGAERAAINAPMQGTASDLIKRAMIDVSRWLSECEASPWDELLQSKLIMQVHDELVLEVVETELDFVKEKLPQIM AKVDGGLLDVPLVAEVGVGENWEEAH
192	1996	MSVVLPLRGVTALSDFRVEKLLQKAAALGLPEVKLSSEFWYFVGSEKALDAATVEKLQALLAAQSVEQTPKAREGL HLFLVTPRLGTISPWASKATNIAENCGLAGIERIERGMAVWLEGRLNDEQKQQWAALLHDRMTESVLPDFQTASKL FHHLESETFSGVDVLGGGKEALVKANTEMGLALSADEIDYLVENYQALQRNPSDVELMMFAQANSEHCRHKIFNAD FILNGEKQPKSLFGMIRDTHNAHPEGTVVAYKDNSSVIEGAKIERFYPNAAENQGYRFHEEDTHIIMKVETHNHPT AIAPFAGAATGAGGEIRDEGATGKGSRPKAGLTGFTVSNLNIPDLKQPWEQDYGKPEHISSPLDIMIEGPIGGAAF NNEFGRPNLLGYFRTFEEKFDGQVRGYHKPIMIAGGLGSIQAQQTHKDEIPEGALLIQLGGPGMLIGLGGGAASSM DTGTNDASLDFNSVQRGNPEIERRAQEVIDRCWQLGGKNPIISIHDVGAGGLSNAFPELVNDARRGAVFKLREVPL EEHGLNPLQIWCNESQERYVLSILEKDLDAFRAICERERCPFAVVGTATDDGHLKVRDDLFANNPVDLPLNVLLGK LPKTTRTDKTVAPSKKPFHAGDIDITEAAYRVLRLPAVAAKNFLITIGDRSVGGLTHRDQMVGKYQTPVADCAVTM MGFNTYRGEAMSMGEKPTVALFDAPASGRMCVGEAITNIAAVNIGDIGNIKLSANWMAACGNEGEDEKLYRTVEAV SKACQALDLSIPVGKDSLSMKTVWQDGEEKKSVVSPLSLIISAFAPVKDVRKTVTPELKNVEDSVLLFVDLGFGKA RMGGSAFGQVYNNMSGDAPDLDDTGRLKAFYSVIQQLVAENKLLAYHDRSDGGLFAVLVEMAFAGRCGLDIDLNLL LAQTFITNHTALSQSLRTEEVKALAEWQETIARTLFNEELGAVIQVRKQDVADIINLFYQQQLHHNVFEIGTLTDE NTLIIRDGQTHLISDNLIKLQQTWQETSHQIQRLRDNPACADSEFALIGDNERSALFADVKFDVNEDIAAPFINSG AKPKIAILREQGVNGQIEMAAAFTRAGFDAYDVHMSDLMAGRIHLADFKMLAACGGFSYGDVLGAGEGWAKSILFH PALRDQFAAFFADPDTLTLGVCNGCQMVSNLAEIIPGTAGWPKFKRNLSEQFEARLSMVHVPKSASLILNEMQGSS LPVVVSHGEGRADFALHGGNISADLGIALQYIDGQNQVTQTYPLNPNGSPQGIAGVTNADGRITIMMPHPERVYRA AQMSWKPEGWTELSGWYRLFAGARKALG
193	2000	MNQTAINRADVRTRFIFDDMPVRGLHVRLENVWQHIVKQKNYPAAIRRALGELLAAGVLLSGNLKNEGTLIVQVQG RGRLKMLVAEAASDRTVRATARWDETAEIADDESLGDLLGEGGVFVLTLQPKDGEPWQGVVPLEGGGIAQMLVNYM KRSEQLDTHIVLSASDEAAGGLLVQRLPEEVLDEEAWEHVSTLARTLTAEELAGLDAQHVLYRLFHETPPRVFEPE TFEFSCTCSRGKVSDMLLMLGGEEVGGVVVEQGSIEVDCDFCHSKYVFDETDVNALFGEDVVGVAKGLPRHTVQ
194	2039	MKKSLIALTLAALPVAAMADVTLYGTIKAGVETSRSVFHQNGQVTEVTTATGIVDLGSKIGFKGQEDLGNGLKAIW QVEQKASIAGTDSGWGNRQSFIGLKGGFGKLRVGRLNSVLKDTGDINPWDSKSDYLGVNKIAEPEARLISVRYDSP EFAGLSGSVQYALNDNAGRHNSESYHAGFNYKNGGFFVQYGGAYKRHHQVQEGLNIEKYQIHRLVSGYDNDALYAS VAVQQQDAKLTDASNSHNSQTEVAATLAYRFGNVTPRVSYAHGFKGLVDDADIGNEYDQVVVGAEYDFSKRTSALV SAGWLQEGKGENKFVATAGGVGLRHKF
195	2057	MKTFSAKPHEVKREWFVIDAQDKVLGRVAAEVASRLRGKHKPEYTPHVDTGDYIIVINADKLRVTGAKFEDKKYFR HSGFPGGIYERTFREMQEQFPGRALEQAVKGMLPKGPLGYAMIKKLKVYAGAEHAHAAQQPKVLELK
196	2079	MKVGFVGWRGMVGSVLMQRMKEENDFAHIPEAFFFTTSNVGGAAPDFGQAAKTLLDANNVAELAKMDIIVTCQGGD YTKSVFQALRDSGWNGYWIDAASSLRMKDDAIIVLDPVNRDVLDNGLKNGVKNYIGGNCTVSLMLMALGGLFQNDL VEWATSMTYQAASGAGAKNMRELISGMGAVHAQVADALADPAGSILDIDRKVSDFLRSEDYPKANFGVPLAGSLIP WIDVDLGNGQSKEEWKGGVETNKILGRSDNPTVIDGLCVRVGAMRCHSQAITLKLKKDLPVSEIETILAGANDWVK VIPNEKEASIHELTPAKVTGTLSVPVGRIRKLGMGGEYISAFTVGDQLLWGAAEPLRRVLRIVLGSL
197	2086	MKFIDEAKIEVAAGKGGNGATSFRREKFVPRGGPDGGDGGKGGSVWAEADENTNTLVEYRFVKRYQAKNGEKGHGS DRYGAGADDIVLKMPVGTLIRDLDTGETVADLTYHGQRVCLAKGGKGGLGNIHFKSSVNRAPKQSTPGEEGEARSL QLELKVLADVGLLGMPNAGKSTLITAVSAARPKIANYPFTTLHPNLGVVRIDENHSFVMADIPGLIEGAAEGAGLG HRFLKHLSRTGLLLHVVDLAPFDETVNPAEEALAIINELRKYDEELYGKPRWLVLNKLDMLDEEEAQTRTAAFLEA VGWDYPKPDDRFQFDMETPRLFQISALTHQGTQELVHQINQYLTEKKRIEAEKAEAEKAAANVEIIEQQPKTDTGV FKPE

| 198	2101	MSQITMRQMIEAGVHFGHQTRFWNPKMAQYIFGARNKIHIVNLEKTLPMFQDAQEAVRRLVANKGTVLFVGTKRQA RDIIREEATRAGMPFVDYRWLGGMLTNYKTVKQSIKRLEEKTAALENAAESGFSKKEILEMQRDVEKLERSLGGIK NMKGLPDAIFVIDTGYQKGTLVEAEKLGIPVIAVVDTNNSPDGVKYVIPGNDDSAKAIRLYCRGIADAVLEGKNQA LQETVAAAQEAAAE
199	2102	MAEITAKMVADLRAATGLGMMECKKALVEAEGNFDKAEEILRIKSGAKAGKLAGRTAAEGVLAYAINGNVGALVEV NCETDFVAKDAGFVEFANFVAKTAAEKKPASVEELSELVEAERKAIIAKLGENMSVRRFQVIDTANQLVAYIHGAL ATEGVLVEYKGSEDVARKIGMHIVAAKPQCVSEAEVDAETVEKERHIYTEQAIASGKPADIAAKMVEGRIRKFLAE ITLNGQAFVMNPDQTVAQFSKENGTEVISFVRYKVGDGIEKKAVDYAAEVAAAAKV
200	2103	MTQQIKYKRVLLKLSGESLMGSDPFGINHDTIVQTVGEIAEVVKMGVQVGIVVGGGNIFRGVSAQAGSMDRATADY MGMMATVMNALALKDAFETLGIKARVQSALSMQQIAETYARPKAIQYLEEGKVVIFAAGTGNPFFTTDTAAALRGA EMNCDVMLKATNVDGVYTADPKKDPSATRYETITFDEALLKNLKVMDATAFALCRERKLNIVVFGIAKEGSLKRVI TGEDEGTLVHC
201	2129	MSQNHTILQSLPVGQKVGIAFSGGLDTSAALLWMKLKGALPYAYTANLGQPDEDDYNAIPKKAMEYGAENARLIDC RAQLAHEGIAAIQCGAFHVSTGGIAYFNTTPLGRAVTGTMLVSAMKEDDVNIWGDGSTYKGNDIERFYRYGLLTNP ALKIYKPWLDQQFIDELGGRHEMSEFLIANGFNYKMSVEKAYSTDSNMLGATHEAKDLEFLNSGIKIVKPIMGVAF WDENVEVSPEEVSVRFEEGVPVALNGKEYADPVELFLEANRIGGRHGLGMSDQIENRIIEAKSRGIYEAPGMALFH IAYERLVTGIHNEDTIEQYRINGLRLRGRLLYQGRWFDSQALMLRETAQRWVAKAVTGEVTLELRRGNDYSILNTES PNLTYQPERLSMEKVEDAAFTPLDRIGQLTMRNLDITDTRVKLGIYSQSGLLSLGEGSVLPQLGNKQ
202	2138	MEAEVINQLNNTLNDLEKRSEDIRVYMDYQGKKDRLEEVIGLSEDPELWNDPKRAQEIGKERKILEGIVLTLDNIA SGIEDNRMLIEMTVEENDEEGFAAVQEDVAGLEKQMADLEFKRMFNQPADPNNCFIDITAGAGGTEAEDWAGMLFR MYSRYAERKGFRIEILEEDDGEIAGINRATIRVEGEYAYGLLRTETGVHRLVRYSPFDSNNKRHTSFASVFVYPEI DDSIEIEINPADLRIDTYRASGAGGQHINKTDSAVRITHEPTGIVVQCQNDRSQHANKAAAMEMLKSKLYELEMRK RNEEKQALEEGKSDVGWGSQIRSYVLDSSRIKDLRTGYEVGNTKAVLDGDLDGFIEASLKQGV
203	2154	MSVLIIVEHDNKQLNPTTLHAVTAAAKLGKVDLLVAGNGASAVVEFAKQVAGVKKVLVADAAHYAEGLAEELAPLV VKLAADYRYVAATATTFGKNLLPRVAALLDVPQISDLTEIVDNTTFVRPIYAGNAFETVQADSEKLVLTFRATVFD AVAAQGGNAEVINVEATPAQNLSRFVNRQLSHSDRPELTQAKVIVSGGRALGSAEKFNEVLTPLADVLGAAIGASR AAVDAEYAPNDAQVGQTGKVVAPQLYFAIGISGAIQHVAGMQDSKVIVAINKDADAPIFNVADYGLVGDLFEIVPQ LTEVLKN
204	2155	MKALVAVKRVVDYNVKVRVKADGSDVDIGNVKMSMNPFDEIAVEEAVRLKEAGKVSEIVAVSLGEKKCEETLRTAL AMGADRAIHVETDTKLESLAVAKLLKAVADKENPQIFFLGKQAIDDDANQVAQMLAALLNAAQGTFASKVQIEGDE VQIVREIDGGEETIALKLPAVISADLRLNEPRFVKLPNIMAAKKKPLEKLTPDDLVADISPRLKTVKFAEPKARQA GVKVASVAELVEKLKNEAKVI
205	2159	MSIKVAINGFGRIGRLALRQIEKAHDIEVVAVNDLTPAEMLLHLFKYDSTQGRFQGTAELKDDAIVVNGKEIKVFA NPNPEELPWGELGVDVILECTGFFTNKTKAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCT TNCLAPMAAVLQKEFGVVEGLMTTIHAYTGDQNTLDAPHRKGDLRRARAAALNIVPNSTGAAKAIGLVIPELNGKL DGSAQRVPVASGSLTELVSILERPVTKEEINAAMKAAASESYGYNEDQIVSSDVVGIEYGSLFDATQTRVMTVGGK QLVKTVAWYDNEMSYTCQLVRTLEYFAGKI

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5

Entrez-Protein - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back ... Stop Refresh Home Search History Print   Address http://www.ncbi.nlm.nih.gov/entrez/query.fcg?CMD=&DB=protein

NCBI   Protein

PubMed | Nucleotide | Protein | Genome | Structure | PopSet | Taxonomy | OMIM | Book

Search Protein for NMB1506   Go Clear

About Entrez

Entrez Protein
Help | FAQ

Batch Entrez Upload a
file of GI or accession
numbers to retrieve
sequences

Check sequence
revision history

How to create WWW
links to Entrez

LinkOut

Cubby

Related resources
BLAST

Reference sequence
project

Display Summary   Save Text Clip Add

Show 20

☐ 1: Q9JYM8   Links
    Arginyl-tRNA synthetase (Arginine--tRNA ligase) (ArgRS)
    gi|23822209|sp|Q9JYM8|SYR_NEIMB[23822209]

☐ 2: NP_274514   Links
    arginyl-tRNA synthetase [Neisseria meningitidis MC58]
    gi|15677359|ref|NP_274514.1|[15677359]

☐ 3: F81075   Links
    arginyl-tRNA synthetase NMB1506 [imported] - Neisseria meningitidis (group B strain MD58)
    gi|11271722|pir||F81075[11271722]

☐ 4: AAF41862   Links
    arginyl-tRNA synthetase [Neisseria meningitidis MC58]
    gi|7226749|gb|AAF41862.1|[7226749]

PCT/IB2003/006281